<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003769.pub3" GROUP_ID="COLOCA" ID="725901071020132945" MERGED_FROM="" MODIFIED="2012-01-04 13:39:20 +0100" MODIFIED_BY="Henning Keinke Andersen" REVIEW_NO="010" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2012-01-04 13:22:33 +0100" MODIFIED_BY="Henning Keinke Andersen">
<TITLE>Antibiotic prophylaxis for hernia repair.</TITLE>
<CONTACT>
<PERSON ID="12877" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Francisco Javier</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sanchez-Manuel</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>frajasama@telefonica.net</EMAIL_1>
<EMAIL_2>jsanchezmanuel@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>General and Digestive Surgery</DEPARTMENT>
<ORGANISATION>Complejo Asistencial Universitario de Burgos-General Yagüe Hospital</ORGANISATION>
<ADDRESS_1>Avda. del Cid, s/n</ADDRESS_1>
<ADDRESS_2/>
<CITY>Burgos</CITY>
<ZIP>09005</ZIP>
<REGION>Castilla y León</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 947225921</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-01-04 13:21:02 +0100" MODIFIED_BY="Henning Keinke Andersen">
<PERSON ID="12877" MODIFIED="2012-01-04 13:15:53 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Francisco Javier</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sanchez-Manuel</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>frajasama@telefonica.net</EMAIL_1>
<EMAIL_2>jsanchezmanuel@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>General and Digestive Surgery</DEPARTMENT>
<ORGANISATION>Complejo Asistencial Universitario de Burgos. Hospital General Yagüe</ORGANISATION>
<ADDRESS_1>Avda. del Cid, s/n</ADDRESS_1>
<ADDRESS_2/>
<CITY>Burgos</CITY>
<ZIP>09005</ZIP>
<REGION>Castilla y León</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 947225921</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="EAB2E14A82E26AA200CD32E54C146336" MODIFIED="2012-01-04 13:19:13 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Javier</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lozano-García</LAST_NAME>
<SUFFIX/>
<POSITION>Doctor</POSITION>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Preventive Medicine</DEPARTMENT>
<ORGANISATION>Complejo Asistencial Universitario de Burgos. Hospital General Yagüe</ORGANISATION>
<ADDRESS_1>Avda. del Cid, s/n</ADDRESS_1>
<ADDRESS_2/>
<CITY>Burgos</CITY>
<ZIP>09002</ZIP>
<REGION>Castilla y Leon</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 699340604</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12880" MODIFIED="2012-01-04 13:21:02 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Juan Luis</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Seco-Gil</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jlseco@ozu.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>General and Digestive Surgery</DEPARTMENT>
<ORGANISATION>Complejo Asistencial Universitario de Burgos. Hospital General Yagüe</ORGANISATION>
<ADDRESS_1>Avda. del Cid, s/n</ADDRESS_1>
<ADDRESS_2/>
<CITY>Burgos</CITY>
<ZIP>09006</ZIP>
<REGION>Castilla-León</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 947235450</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-01-04 13:21:43 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="25" MONTH="10" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="25" MONTH="10" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="12" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2012-01-04 13:22:33 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-01-04 13:22:33 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>Four new trials added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-12-04 20:12:33 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>Four new trials included. Conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-12-02 10:51:49 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2011-12-02 10:38:00 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="6" YEAR="2009"/>
<DESCRIPTION>
<P>One new trial included. Conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-12-02 10:51:49 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="8" YEAR="2006"/>
<DESCRIPTION>
<P>Administration of antibiotic prophylaxis for elective inguinal hernia repair cannot be universally recommended. Nevertheless, its administration cannot either be recommended against when high rates of wound infection are observed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-11-17 19:01:37 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="3" YEAR="2004"/>
<DESCRIPTION>
<P>Administration of antibiotic prophylaxis for elective inguinal hernia repair cannot be firmly recommended or discarded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-01-04 13:37:27 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-01-04 13:24:51 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-10-29 20:16:16 +0200" MODIFIED_BY="[Empty name]">
<I>Administration of antibiotic prophylaxis for elective inguinal hernia repair cannot be universally recommended</I>.</TITLE>
<SUMMARY_BODY MODIFIED="2012-01-04 13:24:51 +0100" MODIFIED_BY="[Empty name]">
<P>The use of antibiotic prophylaxis for elective hernia repair is currently a controversial issue. Although elective hernia repair is considered a clean procedure, the rate of postoperative wound infection in many countries exceeds the one expected for clean surgery, increasing discomfort in patients and health care expenses. In addition, antibiotics administration is not exempt of potential risks.<BR/>Controlled clinical trials on the use of antibiotic prophylaxis for hernia repair are scarce, the number of patients studied is low and the results are diverse. Based on the results of this meta-analysis of randomised clinical trials, administration of antibiotic prophylaxis for elective inguinal hernia repair cannot be universally recommended. Neither can the administration be recommended when high rates of wound infection are observed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-01-04 13:25:47 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-12-02 15:19:53 +0100" MODIFIED_BY="[Empty name]">
<P>The use of antibiotic prophylaxis for hernia repair is currently a controversial issue given the disparity among study results in this area.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of this systematic review was to clarify the effectiveness of antibiotic prophylaxis in reducing postoperative wound infection rates in elective open inguinal hernia repair.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-01-04 13:23:22 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Colorectal Cancer Group specialized register, by crossing the terms herni* and inguinal or groin and the terms antimicr* or antibiot* , as free text and MeSH terms. A similar search were performed in Medline using the following terms: #1 antibiotic* OR antimicrob* OR anti infecti* OR antiinfecti*; #2 prophyla* OR prevent*; #3 #1 AND #2; #4 clean AND (surgery OR tech* OR proced*); #5 herni*; #6 (wound infection) AND #4; #7 #3 AND (#4 or #5 or #6).<B> </B>National Research<B> </B>Register, ISI-Web, DARE, Scirus, TRIPDATABASE, NHS EED, reference list of the included studies and web of clinical trials register (www.controlled-trials.com and clinicaltrials.gov) were checked to identify further studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-01-04 13:25:47 +0100" MODIFIED_BY="[Empty name]">
<P>Only randomised clinical trials were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-01-04 13:23:30 +0100" MODIFIED_BY="[Empty name]">
<P>In the present review, we searched for eligible trials in October 2011. This revealed four new included trials, so seventeen trials are included in the meta-analysis. Eleven of them used prosthetic material for hernia repair (hernioplasty) whereas the remaining studies did not (herniorrhaphy). Pooled and subgroup analysis were conducted depending on whether prosthetic material was or not used. A fixed effects model was used in the analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-01-04 13:24:19 +0100" MODIFIED_BY="[Empty name]">
<P>The total number of patients included was 7843 (prophylaxis group: 4703, control group: 3140). Overall infection rates were 3.1% and 4.5% in the prophylaxis and control groups, respectively (OR 0.64, 95% CI 0.50 - 0.82).<BR/>The subgroup of patients with herniorrhaphy had infection rates of 3.5<B>%</B> and 4.9<B>%</B> in the prophylaxis and control groups, respectively (OR 0.71, 95% CI 0.51 - 1.00).<BR/>The subgroup of patients with hernioplasty had infection rates of 2.4% and 4.2% in the prophylaxis and control groups, respectively (OR 0.56, 95% CI 0.38 - 0.81).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-01-04 13:24:45 +0100" MODIFIED_BY="[Empty name]">
<P>Based on the results of this systematic review the administration of antibiotic prophylaxis for elective inguinal hernia repair cannot be universally recommended. Neither can the administration be recommended against when high rates of wound infection are observed.<I>
<BR/>
</I>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-01-04 13:37:27 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Wound infection is one of the most commonly occurring surgical complications. Infection of a wound may result from a number of factors both intrinsic and extrinsic to the patient. Although many of the intrinsic factors cannot be modified, the external ones can certainly be influenced. In particular those related to aseptic conditions, surgical technique and peri-operative care. However even under the most scrupulous aseptic conditions and with a careful technique, post-operative wound infection still presents a very serious problem. </P>
<P>The use of antibiotic prophylaxis to avoid infectious complications of surgery is very common in surgical practice. However, indiscriminate use of antibiotics can lead to problems including an increase in costs and the emergence of resistant micro-organisms. The benefits of antibiotic prophylaxis either in clean-contaminated, contaminated and dirty surgery are universally accepted. Antibiotic prophylaxis is generally accepted in clean surgery (i.e. surgery with no inflammation, no contact with septic material, or interruption of aseptic technique where hollow viscera is not opened) when the placement of prosthetic materials, or the presence of infection poses a significant risk to the patient. Nonetheless, controversy remains about the use of antibiotics in some types of clean surgery.</P>
<P>Surgery for inguinal hernia is one of the most common techniques performed in a general surgical service making up approximately a third of total interventions (<LINK REF="REF-Cainzos-1990" TYPE="REFERENCE">Cainzos 1990</LINK>; <LINK REF="REF-Rodriguez-2005" TYPE="REFERENCE">Rodriguez 2005</LINK>). This type of surgery is considered clean and it has been estimated that the rate of postoperative infection should not be greater than 2% (<LINK REF="REF-Condon-1991" TYPE="REFERENCE">Condon 1991</LINK>; <LINK REF="REF-Page-1993" TYPE="REFERENCE">Page 1993</LINK>; <LINK REF="REF-Dellinger-1994" TYPE="REFERENCE">Dellinger 1994</LINK>; <LINK REF="REF-Woods-1998" TYPE="REFERENCE">Woods 1998</LINK>).</P>
<P>Currently, the use of antibiotic prophylaxis is recommended for elective open mesh inguinal hernia repair (<LINK REF="REF-Condon-1991" TYPE="REFERENCE">Condon 1991</LINK>; <LINK REF="REF-Page-1993" TYPE="REFERENCE">Page 1993</LINK>; <LINK REF="REF-Woods-1998" TYPE="REFERENCE">Woods 1998</LINK>). However, this treatment is not universally accepted. For hernia repair not involving prosthetic material, the antibiotic prophylaxis is not recommended in the absence of risk factors, but the controversy arises when wound infection rates exceed the expected figures (<LINK REF="REF-Bailey-1992" TYPE="REFERENCE">Bailey 1992</LINK>; <LINK REF="REF-Ranaboldo-1993" TYPE="REFERENCE">Ranaboldo 1993</LINK>; <LINK REF="REF-Holmes-1994" TYPE="REFERENCE">Holmes 1994</LINK>). Contradictory results from clinical trials investigating the effectiveness of antibiotic prophylaxis have complicated this situation (<LINK REF="REF-Wittmann-1995" TYPE="REFERENCE">Wittmann 1995</LINK>; <LINK REF="REF-Leaper-1998" TYPE="REFERENCE">Leaper 1998</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of this systematic review was to clarify the effectiveness of antibiotic prophylaxis in reducing postoperative wound infection rates in elective open inguinal hernia repair.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-01-04 13:33:47 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-11-13 19:11:52 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-11-13 19:11:52 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trials on antibiotic prophylaxis for hernia repair were included. Randomised clinical trials of antibiotic prophylaxis in patients subject to clean surgical techniques were also included in the review when the report allowed the extraction of data on hernia repair.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adult patients undergoing open elective inguinal or femoral hernia repair, with or without the use of prosthetic material. Laparoscopic repairs were excluded from this review. We performed an overall analysis of the studies, stratified by whether herniorrhaphies (non-mesh repair) or hernioplasties (mesh repair) was used.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Treatment group: administration of prophylactic antibiotics, irrespective of the type of administered antibiotic or the route of administration.<BR/>Control group: placebo or no treatment. <BR/>Studies using antiseptics for prophylaxis were not included in the review. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-11-01 19:28:51 +0100" MODIFIED_BY="[Empty name]">
<P>Wound infection rate assessed at least at 30 days after the prophylactic antibiotic treatment was given. The criteria of infection were as defined by the authors of each primary study: discharge of pus from the wound; a wound that was opened and not closed; spreading erythema indicative of cellulitis or definitions established by associations as Centers for Disease Control (CDC) (<LINK REF="REF-Horan-1992" TYPE="REFERENCE">Horan 1992</LINK>). </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-01-04 13:33:47 +0100" MODIFIED_BY="[Empty name]">
<P>A search in the Cochrane Colorectal Cancer Group specialised register was conducted crossing the terms herni* and inguinal or groin and the terms antimicr* or antibiot* as free text and MeSH terms.</P>
<P>A similar search was conducted in Medline with the following search strategy:</P>
<P>#1 antibiotic* or antimicrob* or anti infecti* or antiinfecti*<BR/>#2 prophyla* or prevent*<BR/>#3 #1 and #2<BR/>#4 clean and (surgery or tech* or proced*)<BR/>#5 herni*<BR/>#6 (wound infection) and #4<BR/>#7 #3 and (#4 or #5 or #6)</P>
<P>National Research Register, ISI-Web, DARE, Scirus, TRIPDATABASE, NHS EED, reference list of the included studies and web of clinical trials register (www.controlled-trials.com and clinicaltrials.gov) were checked to identify further studies.</P>
<P>Controlled clinical trials were sought as a source of supplementary evidence.</P>
<P>In the previous update, the searches were performed until June 2009. In this update, the searches were performed October 2011.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-12-04 20:06:32 +0100" MODIFIED_BY="[Empty name]">
<P>Data extraction</P>
<P>Authors independently performed the selection of studies and data extraction. Disagreements were resolved through consensus, or by the input of a third party. The following data were extracted from each study: study design; type of allocation and allocation concealment; number of patients included; mesh or non-mesh hernia repair; antibiotics used; dose, mode and timing of antibiotic administration; wound infection rates in prophylaxis and control groups, respectively. When the paper was considered eligible and data in the publication were incomplete, we contacted with the author to obtain the necessary information.</P>
<P>Assessment of methodological quality</P>
<P>The methodological quality of the included studies was assessed as recommended by the Cochrane Collaboration.</P>
<P>Statistical analysis</P>
<P>Odds ratios and 95% confidence intervals were computed for included studies. Since heterogeneity between studies due to differences in study design and populations was expected, the analysis was initially performed with a random effects model. Nevertheless, chi-square and I<SUP>2 </SUP>tests for heterogeneity were conducted to test whether significant heterogeneity precluded a meta-analysis. Heterogeneity assessment was performed according to <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>. If significant heterogeneity was found to be present, the use of meta-regression techniques was considered to assess the impact of prophylaxis on the following factors:<BR/>
<B>
<BR/>
</B>* Number and type of antibiotics used.<BR/>* Quality of study design<BR/>* Use of mesh.</P>
<P>We expected that a small number of events would be observed in the included studies. Therefore, a fixed-effect meta-analysis using Peto odds ratios was performed as a sensitivity analysis, as a tool to reduce bias in the analysis of scarce data (<LINK REF="REF-Deeks-1999" TYPE="REFERENCE">Deeks 1999</LINK>). Sensitivity analyses were also conducted excluding highly influential studies, as well as poor quality studies.</P>
<P>Numbers needed to treat (NNT) with 95% confidence intervals were estimated for each study, for the herniorrhaphies and hernioplasties sub-groups, and for the pooled results, if there was a statistically significant benefit with the use of antibiotic prophylaxis. Numbers needed to treat were computed as the inverse of risk differences. In the studies where statistical signification was not reached, numbers needed to treat and their confidence intervals were computed according to<B> </B>
<LINK REF="REF-Altman-1998" TYPE="REFERENCE">Altman 1998</LINK>.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-01-04 13:37:27 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-01-04 13:37:27 +0100" MODIFIED_BY="[Empty name]">
<P>From the initial search strategy we identified 39 potentially eligible studies, and after further analyses 7 studies met the inclusion criteria of the first published version of this review. After updating the search strategy, one additional study was identified, so eight studies met the above criteria and were included.</P>
<P>The first update of this review (August 2006) identified 159 additional studies. After reading the abstract, eight studies were selected for a more detailed revision. Four studies were excluded for different reasons. Finally, four additional studies were included in the meta analysis, making a total of twelve studies.</P>
<P>The second update (June 2009) the search revealed additional 99 studies, of which one was selected for inclusion in the meta analysis (<LINK REF="STD-Jain-2008" TYPE="STUDY">Jain 2008</LINK>). So, thirteen studies composed the meta-analysis.</P>
<P>The present update (October 2011) identified 213 additional studies, of which 23 studies were selected for a more detailed revision. One study was excluded (<LINK REF="STD-Praveen-2009" TYPE="STUDY">Praveen 2009</LINK>). Four studies met inclusion criteria and were included (<LINK REF="STD-Ergul-2011" TYPE="STUDY">Ergul 2011</LINK>; <LINK REF="STD-Othman-2011" TYPE="STUDY">Othman 2011</LINK>; <LINK REF="STD-Shankar-2010" TYPE="STUDY">Shankar 2010</LINK>; <LINK REF="STD-Tzovaras-2007" TYPE="STUDY">Tzovaras 2007</LINK>). <BR/>In total, seventeen studies are included in this update.<I>
<BR/>
</I>
<BR/>Studies were described according to the antibiotic used, timing and route of administration, number of doses given, technique of hernia repair, criteria for the diagnosis of infection and follow-up time.</P>
<P>In one study on the use of different surgical techniques including hernia repair, <LINK REF="STD-Evans-1973" TYPE="STUDY">Evans 1973</LINK> used intra-muscular (IM) cephaloridine 1 gr in the anaesthesia induction and two further intra-muscular doses in the postoperative period. Definition of infection was: purulent exudates at the wound site or need for pus drainage from the wound. Follow-up was 4 weeks.</P>
<P>
<LINK REF="STD-Andersen-1980" TYPE="STUDY">Andersen 1980</LINK> used a single dose of 1 gr topical subfascial ampicillin before closure of non-mesh hernia repair and cholecystectomy. The criteria for wound infection considered in this study was the collection of pus in the wound site requiring revision. Patients in the study were followed for one year.</P>
<P>In the study on antimicrobial prophylaxis for mastectomy and non-mesh hernia repair, <LINK REF="STD-Platt-1990" TYPE="STUDY">Platt 1990</LINK> used a single dose of 1g cefonicid, administered intra-venously 90 minutes before surgery. Wound infection was defined as the presence of erythema and drainage, purulent exudates, or non-closing open wound. Probable infection was considered when erythema extending at least 2 cm to any direction was present, or when wound infection was diagnosed even if established infection criteria were not met.</P>
<P>
<LINK REF="STD-Lazorthes-1992" TYPE="STUDY">Lazorthes 1992</LINK> combined cefamandole 750 mg to local anaesthesia for patients undergoing non-mesh hernia repair. Wound abscess was defined as all wounds with discharge in which pathogens grew regardless of whether or not the discharge was purulent or serohematic. Discharge of pus, even when germs were not found, was also considered a wound abscess. Patients were assessed one month after the intervention.</P>
<P>
<LINK REF="STD-Taylor-1997" TYPE="STUDY">Taylor 1997</LINK> administered amoxicillin-clavulanic acid 1.2 gr intra-venously before the incision in patients undergoing non-mesh hernia repair. Infection was defined as purulent wound discharge or spreading erythema indicative of cellulites; wound breakdown; or dehiscence with clinical evidence of infection. Patients were assessed 4 and 6 weeks after surgery.</P>
<P>
<LINK REF="STD-Pessaux-2006" TYPE="STUDY">Pessaux 2006</LINK> analysed patients undergoing elective hernia inguinal repair from 3 previous clinical trials on antibiotics in clean surgical techniques. The intervention groups were homogenous. Several antibiotics were administered by endovenous route during anaesthetic induction : cefotaxime, cefazolin, ceftriaxone and amoxacillin-clavulanic acid. The surgical technique was Shouldice herniorrhaphy. Since the publication didn't report enough information to include the study in the meta analysis, we contacted the principal author to complete them. The minimum follow-up was of 6 weeks.<I>
<BR/>
</I>
<BR/>
<LINK REF="STD-Morales-2000" TYPE="STUDY">Morales 2000</LINK> is a multicenter study that assessed the efficacy of a single dose of cefazolin 2 gr administered intra-venously during anaesthetic induction for patients undergoing mesh hernia repair. The authors defined the following criteria for wound infection:<BR/>a) cutaneous erythema greater than 2 cm on both sides of the incision,<BR/>b) purulent exudates through the wound,<BR/>c) organism isolated from culture of non- purulent exudates, and<BR/>d) an open wound that was not closed afterwards.</P>
<P>The wound was assessed 30 days after the surgery.</P>
<P>
<LINK REF="STD-Yerdel-2001" TYPE="STUDY">Yerdel 2001</LINK> used ampicillin-sulbactam 1.5 gr IV before the incision in patients undergoing mesh hernia repair. The criteria of the CDC (1992) for wound infection were applied. One year follow-up period was considered.</P>
<P>
<LINK REF="STD-Oteiza-2004" TYPE="STUDY">Oteiza 2004</LINK> used amoxacillin-clavulanic acid 2 gr IV 15-30 minutes before the incision in patients undergoing elective mesh hernia repair, Lichtenstein or plug-mesh technique. Wound infection was defined as the purulent exudate or non purulent exudate with positive culture or the surgeon declares that incisional infection is present. A month follow-up period was considered.</P>
<P>
<LINK REF="STD-Aufenacker-2004" TYPE="STUDY">Aufenacker 2004</LINK> used cefuroxime 1,5 gr IV during anaesthetic induction in patients undergoing mesh hernia repair (Lichtenstein technique). The patients were assessed at one, two and twelve weeks. The criteria of the CDC for wound infection were applied.<BR/>
<B>
<I>
<BR/>
</I>
</B>
<LINK REF="STD-Celdran-2004" TYPE="STUDY">Celdran 2004</LINK> used cefazolin 1 gr IV 30 minutes before the surgery. Lichtenstein technique was carried out. Assessment was performed at two year follow-up after surgery. The authors used the CDC criteria for wound infection.<I>
<BR/>
</I>
<BR/>
<LINK REF="STD-Perez-2005" TYPE="STUDY">Perez 2005</LINK> administered cefazolin 1 gr IV before the incision in patients undergoing Lichtentein technique. The authors used the CDC criteria for wound infection.</P>
<P>
<LINK REF="STD-Tzovaras-2007" TYPE="STUDY">Tzovaras 2007</LINK> administered 1.2 gr IV amoxicillin-clavulanic acid or placebo to patients underwent tension-free hernioplasty between January 2000 to June 2004. CDC criteria were applied. They were followed 1 month after the operation.</P>
<P>
<LINK REF="STD-Jain-2008" TYPE="STUDY">Jain 2008</LINK> administered placebo or 1.2 gr IV amoxicillin-clavulanic acid before incision. PHS mesh repair was carried out. The patients were assessed at 7-9 days, two weeks and four weeks after discharge. CDC criteria was used for wound infection.</P>
<P>
<LINK REF="STD-Shankar-2010" TYPE="STUDY">Shankar 2010</LINK> between November 2006 and June 2008 performed a study with 334 patients underwent to tension free mesh repair using a polypropylene mesh to receive cefazolin 1 gr IV at the time of induction. Patients were followed for 30 days. CDC criteria were applied.</P>
<P>
<LINK REF="STD-Ergul-2011" TYPE="STUDY">Ergul 2011</LINK> between July 2008 and October 2010 administered cefazolin 1 gr IV before induction to 200 patients underwent to Lichtenstein repair. The wound was assessed at 3, 5, 7 and 30 days after discharge. The authors used the CDC criteria for wound infection.</P>
<P>
<LINK REF="STD-Othman-2011" TYPE="STUDY">Othman 2011</LINK> during a period from July 2006 to April 2010 administered 1.2 gr IV amoxicillin and clavulanic acid 30 minutes or placebo before incision to 98 patients underwent to Lichtenstein hernioplasty. Follow-up was 30 days. CDC criteria were applied.</P>
<P>The remaining studies were excluded for several reasons:</P>
<UL>
<LI>studies focused on clean surgical techniques including hernia pathology, but data for this subgroup of patients could not be collected (<LINK REF="STD-Houck-1989" TYPE="STUDY">Houck 1989</LINK>; <LINK REF="STD-Lewis-1995" TYPE="STUDY">Lewis 1995</LINK>; <LINK REF="STD-Nundy-1983" TYPE="STUDY">Nundy 1983</LINK>; <LINK REF="STD-Dixon-2006" TYPE="STUDY">Dixon 2006</LINK>; <LINK REF="STD-Karran-1992" TYPE="STUDY">Karran 1992</LINK>; <LINK REF="STD-Esposito-2006" TYPE="STUDY">Esposito 2006</LINK>).</LI>
<LI>studies reported results of patients series having no antibiotic prophylaxis (<LINK REF="STD-Hedawoo-1995" TYPE="STUDY">Hedawoo 1995</LINK>; <LINK REF="STD-Wantz-1996" TYPE="STUDY">Wantz 1996</LINK>), otherwise, they were non-controlled studies of antibiotic prophylaxis (<LINK REF="STD-Angio-2001" TYPE="STUDY">Angio 2001</LINK>; <LINK REF="STD-Dazzi-1994" TYPE="STUDY">Dazzi 1994</LINK>; <LINK REF="STD-Gervino-2000" TYPE="STUDY">Gervino 2000</LINK>; <LINK REF="STD-Massaioli-1995" TYPE="STUDY">Massaioli 1995</LINK>; <LINK REF="STD-Spallitta-1999" TYPE="STUDY">Spallitta 1999</LINK>; <LINK REF="STD-Van_x002d_Damme-1981" TYPE="STUDY">Van-Damme 1981</LINK>; <LINK REF="STD-Sultan-1989" TYPE="STUDY">Sultan 1989</LINK>; <LINK REF="STD-Deysine-2005" TYPE="STUDY">Deysine 2005</LINK>).</LI>
<LI>both study arms received antibiotic prophylaxis (<LINK REF="STD-Musella-2001" TYPE="STUDY">Musella 2001</LINK>; <LINK REF="STD-Shwed-1991" TYPE="STUDY">Shwed 1991</LINK>; <LINK REF="STD-Reggiori-1996" TYPE="STUDY">Reggiori 1996</LINK>; <LINK REF="STD-Kuzu-2005" TYPE="STUDY">Kuzu 2005</LINK>; <LINK REF="STD-Terzi-2005" TYPE="STUDY">Terzi 2005</LINK>; <LINK REF="STD-Praveen-2009" TYPE="STUDY">Praveen 2009</LINK>).</LI>
<LI>studies used historical controls (<LINK REF="STD-Abo_x002d_Rahmy-1998" TYPE="STUDY">Abo-Rahmy 1998</LINK>), they were comparative retrospective or non-randomised studies, or mis balances in patients and techniques used in both treatment groups were present (<LINK REF="STD-Barreca-2000" TYPE="STUDY">Barreca 2000</LINK>; <LINK REF="STD-Escart_x00ed_n-1999" TYPE="STUDY">Escartín 1999</LINK>; <LINK REF="STD-Gilbert-1993" TYPE="STUDY">Gilbert 1993</LINK>; <LINK REF="STD-Hair-2000" TYPE="STUDY">Hair 2000</LINK>; <LINK REF="STD-Platt-1992" TYPE="STUDY">Platt 1992</LINK>; <LINK REF="STD-Ryan-1967" TYPE="STUDY">Ryan 1967</LINK>; <LINK REF="STD-Vara-1993" TYPE="STUDY">Vara 1993</LINK>).</LI>
<LI>studies did not use antibiotic but local antiseptic treatment (<LINK REF="STD-Gilmore-1977" TYPE="STUDY">Gilmore 1977</LINK>).</LI>
</UL>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-12-04 20:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>Assessment of methodological quality is presented in<B> </B>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.<B> </B>
</P>
<P>Three studies did not provide information on the random allocation concealment procedures (<LINK REF="STD-Andersen-1980" TYPE="STUDY">Andersen 1980</LINK>; <LINK REF="STD-Lazorthes-1992" TYPE="STUDY">Lazorthes 1992</LINK>; <LINK REF="STD-Pessaux-2006" TYPE="STUDY">Pessaux 2006</LINK>). Consequently, they are considered as "unclear". The concealment procedure of <LINK REF="STD-Evans-1973" TYPE="STUDY">Evans 1973</LINK> (coin tossing) and<B> </B>
<LINK REF="STD-Celdran-2004" TYPE="STUDY">Celdran 2004</LINK> (number list) was inappropriate. The remaining studies used appropriated concealment methods (sealed envelopes: <LINK REF="STD-Morales-2000" TYPE="STUDY">Morales 2000</LINK>; <LINK REF="STD-Ergul-2011" TYPE="STUDY">Ergul 2011</LINK>; <LINK REF="STD-Shankar-2010" TYPE="STUDY">Shankar 2010</LINK>, computer programs: <LINK REF="STD-Platt-1990" TYPE="STUDY">Platt 1990</LINK>; <LINK REF="STD-Taylor-1997" TYPE="STUDY">Taylor 1997</LINK>; <LINK REF="STD-Yerdel-2001" TYPE="STUDY">Yerdel 2001</LINK>;<LINK REF="STD-Oteiza-2004" TYPE="STUDY">Oteiza 2004</LINK>, <LINK REF="STD-Aufenacker-2004" TYPE="STUDY">Aufenacker 2004</LINK>, <LINK REF="STD-Perez-2005" TYPE="STUDY">Perez 2005</LINK>; <LINK REF="STD-Tzovaras-2007" TYPE="STUDY">Tzovaras 2007</LINK>; <LINK REF="STD-Jain-2008" TYPE="STUDY">Jain 2008</LINK>; <LINK REF="STD-Othman-2011" TYPE="STUDY">Othman 2011</LINK>).</P>
<P>Eleven of the trials were blinded (<LINK REF="STD-Morales-2000" TYPE="STUDY">Morales 2000</LINK>; <LINK REF="STD-Platt-1990" TYPE="STUDY">Platt 1990</LINK>; <LINK REF="STD-Taylor-1997" TYPE="STUDY">Taylor 1997</LINK>; <LINK REF="STD-Yerdel-2001" TYPE="STUDY">Yerdel 2001</LINK>; <LINK REF="STD-Aufenacker-2004" TYPE="STUDY">Aufenacker 2004</LINK>; <LINK REF="STD-Perez-2005" TYPE="STUDY">Perez 2005</LINK>;<LINK REF="STD-Celdran-2004" TYPE="STUDY">Celdran 2004</LINK>; <LINK REF="STD-Tzovaras-2007" TYPE="STUDY">Tzovaras 2007</LINK>; <LINK REF="STD-Jain-2008" TYPE="STUDY">Jain 2008</LINK>; <LINK REF="STD-Ergul-2011" TYPE="STUDY">Ergul 2011</LINK>; <LINK REF="STD-Othman-2011" TYPE="STUDY">Othman 2011</LINK>). <LINK REF="STD-Andersen-1980" TYPE="STUDY">Andersen 1980</LINK> was described by the author as a triple-blinded trial despite the fact that the control group received no intervention, and the remaining trials were open (<LINK REF="STD-Evans-1973" TYPE="STUDY">Evans 1973</LINK>,<LINK REF="STD-Lazorthes-1992" TYPE="STUDY">Lazorthes 1992</LINK>, <LINK REF="STD-Pessaux-2006" TYPE="STUDY">Pessaux 2006</LINK>; <LINK REF="STD-Oteiza-2004" TYPE="STUDY">Oteiza 2004</LINK>; <LINK REF="STD-Shankar-2010" TYPE="STUDY">Shankar 2010</LINK>).</P>
<P>The two comparison groups were homogeneous in the majority of included studies, with respect to epidemiological characteristics, techniques used in the hernia repair, and associated co-morbilities. However, the two groups in <LINK REF="STD-Andersen-1980" TYPE="STUDY">Andersen 1980</LINK> differed with regard to one factor, and in <LINK REF="STD-Evans-1973" TYPE="STUDY">Evans 1973</LINK> they differed by more than one factor. In the study of <LINK REF="STD-Jain-2008" TYPE="STUDY">Jain 2008</LINK> the surgery was significantly longer in the placebo group.</P>
<P>Apart from <LINK REF="STD-Evans-1973" TYPE="STUDY">Evans 1973</LINK> and <LINK REF="STD-Lazorthes-1992" TYPE="STUDY">Lazorthes 1992</LINK>, the statistical methods were clearly reported in the studies.</P>
<P>All studies except <LINK REF="STD-Lazorthes-1992" TYPE="STUDY">Lazorthes 1992</LINK>, clearly described a set of wound infection criteria.</P>
<P>All studies used a penicillin derivative antibiotic. The route of administration was intravenous in fourteen studies, subcutaneous/subfascial in two studies (<LINK REF="STD-Andersen-1980" TYPE="STUDY">Andersen 1980</LINK>; <LINK REF="STD-Lazorthes-1992" TYPE="STUDY">Lazorthes 1992</LINK>) and intramuscularly in one study (<LINK REF="STD-Evans-1973" TYPE="STUDY">Evans 1973</LINK>). <LINK REF="STD-Lazorthes-1992" TYPE="STUDY">Lazorthes 1992</LINK>; <LINK REF="STD-Morales-2000" TYPE="STUDY">Morales 2000</LINK>; <LINK REF="STD-Platt-1990" TYPE="STUDY">Platt 1990</LINK>; <LINK REF="STD-Taylor-1997" TYPE="STUDY">Taylor 1997</LINK>; <LINK REF="STD-Yerdel-2001" TYPE="STUDY">Yerdel 2001</LINK>; <LINK REF="STD-Oteiza-2004" TYPE="STUDY">Oteiza 2004</LINK>; <LINK REF="STD-Aufenacker-2004" TYPE="STUDY">Aufenacker 2004</LINK>; <LINK REF="STD-Celdran-2004" TYPE="STUDY">Celdran 2004</LINK>, <LINK REF="STD-Pessaux-2006" TYPE="STUDY">Pessaux 2006</LINK>,<B> </B>
<LINK REF="STD-Perez-2005" TYPE="STUDY">Perez 2005</LINK>; <LINK REF="STD-Tzovaras-2007" TYPE="STUDY">Tzovaras 2007</LINK>; <LINK REF="STD-Jain-2008" TYPE="STUDY">Jain 2008</LINK>; <LINK REF="STD-Ergul-2011" TYPE="STUDY">Ergul 2011</LINK>; <LINK REF="STD-Othman-2011" TYPE="STUDY">Othman 2011</LINK>; <LINK REF="STD-Shankar-2010" TYPE="STUDY">Shankar 2010</LINK> used a single preoperative dose. <LINK REF="STD-Andersen-1980" TYPE="STUDY">Andersen 1980</LINK> administered subfascial antibiotic before closing the aponeurosis. <LINK REF="STD-Evans-1973" TYPE="STUDY">Evans 1973</LINK> used one preoperative and two postoperative intramuscularly doses.</P>
<P>Five trials included patients with no drug intervention as the control group (<LINK REF="STD-Andersen-1980" TYPE="STUDY">Andersen 1980</LINK>; <LINK REF="STD-Evans-1973" TYPE="STUDY">Evans 1973</LINK>; <LINK REF="STD-Lazorthes-1992" TYPE="STUDY">Lazorthes 1992</LINK>, <LINK REF="STD-Pessaux-2006" TYPE="STUDY">Pessaux 2006</LINK> and <LINK REF="STD-Oteiza-2004" TYPE="STUDY">Oteiza 2004</LINK>). The remaining studies used placebo.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-01-04 13:26:18 +0100" MODIFIED_BY="[Empty name]">
<P>The heterogeneity analysis did not reach statistical significance neither for the overall analysis nor in the sub-groups analysis, considering separately trials with herniorrhaphy and hernioplasty <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. For this reason, the main analysis was performed with the fixed effects model and a sensitivity analysis was performed with the random effects model .</P>
<P>The total number of patients included in the meta-analysis was 7843 (prophylaxis group: 4703, control group: 3140). The overall infection rates were 3.1% in the prophylaxis group, and 4.5% in the control group (OR 0.64, 95% CI 0.5 - 0.82).<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>
</P>
<P>Analysis of the group of patients with herniorrhaphy showed no evidence of heterogeneity (P=0.51, I<SUP>2</SUP>=0%). The number of patients treated with prophylaxis was 2932 and the infection rate for this group was 3.5%. The number of patients in the control group was 1337 and the infection rate was 4.9% (OR 0.71, 95% CI 0.51 - 1.00).</P>
<P>Analysis of the group of patients with hernioplasty showed no evidence of heterogeneity (P=0.66, I<SUP>2</SUP>=0%). The number of patients treated with prophylaxis was 1771<B> </B>and the infection rate for this group was 2.4%. The number of patients in the control group was 1803 and the infection rate was 4.2<B>% </B>(OR 0.56, 95% CI 0.38 - 0.81).</P>
<P>In <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> the NNT of the studies including in the meta analysis are exposed.</P>
<P>Sensitivity analyses<BR/>In the sensitivity analysis performed with the random effects model, the overall analysis still shows statistical significance but the herniorrhaphy subgroup estimation become non significant. Similarly, sensitivity analysis performed with risk differences present borderline signification. These results require cautiousness in interpretation, because they could be congruent both with benefit and no effect from antibiotic prophylaxis administration.</P>
<P>Sensitivity analysis performed excluding any of the trials did not show any qualitative differences with respect to the main analysis. See results in <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>.</P>
<P>Metaregression<BR/>Factors like number and type of antibiotics administered, methodological quality and use of mesh for hernia repair are not related to differences in the treatment effect between the included studies, as shown by the non significant results of the meta regression model (details can be sought from the authors).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-11-13 19:18:32 +0100" MODIFIED_BY="[Empty name]">
<P>A systematic review is important, considering that hernia repair is a commonly used technique in any general hospital. As a clean procedure, the wound infection rate should not exceed 2%. However, follow-up studies have shown figures as low as 0.1% (<LINK REF="STD-Wantz-1996" TYPE="STUDY">Wantz 1996</LINK>; <LINK REF="REF-Rutkow-1993" TYPE="REFERENCE">Rutkow 1993</LINK>), and close to 10% (<LINK REF="REF-Bailey-1992" TYPE="REFERENCE">Bailey 1992</LINK>). The mean wound infection rate in general hospitals has been estimated around 4% (<LINK REF="REF-Cainzos-1990" TYPE="REFERENCE">Cainzos 1990</LINK>; <LINK REF="REF-Holmes-1994" TYPE="REFERENCE">Holmes 1994</LINK>). Surgeons do not usually assess wound infection after hernia repair because in most cases, the patient is discharged from the hospital under an outpatient-based major surgical regimen, or in the first 48 hours after the procedure. Therefore, wound abscess drainage is usually performed in emergency rooms several days after discharge, without attaining any control. This gives the impression that infection rates are lower than the actual values. It has been calculated that 72% of patients are diagnosed after discharge during a 4-6 week follow-up period, once the intervention has taken place (<LINK REF="REF-Ranaboldo-1993" TYPE="REFERENCE">Ranaboldo 1993</LINK>).</P>
<P>Wound infection after hernia repair is not a devastating event as in other types of clean surgery (i.e. Neurosurgery), where antibiotic prophylaxis is given to avoid case fatality. In general, simple drainage with or without antibiotic therapy is enough to resolve the problem in such a way that vital risk is not a major problem for the patient. Nonetheless, wound infection can lead to significant discomfort and inconvenience, and leading to use of more potent antibiotics, to a higher risk of hernia relapse and even to re-intervention, raising significantly the costs. Therefore, even though wound infection is not a severe condition, it is a common event that constitutes an important health problem. A study conducted to assess the postoperative infection-related costs, found that annual expenses for infections after hernia repair (a very often performed procedure) were similar to those for colon surgery (a less frequent technique) (<LINK REF="REF-Davey-1998" TYPE="REFERENCE">Davey 1998</LINK>).</P>
<P>Several factors that may increase the infection rate after hernia repair have been analysed (<LINK REF="REF-NRC-1964" TYPE="REFERENCE">NRC 1964</LINK>; <LINK REF="REF-Haley-1985" TYPE="REFERENCE">Haley 1985</LINK>; <LINK REF="REF-Wittmann-1995" TYPE="REFERENCE">Wittmann 1995</LINK>; <LINK REF="REF-Porcu-1996" TYPE="REFERENCE">Porcu 1996</LINK>; <LINK REF="STD-Pessaux-2006" TYPE="STUDY">Pessaux 2006</LINK>). Although it may not be possible to modify the patient-related factors, it could be possible to modify factors related to the environment and the surgical technique, in such a way that the administration of antibiotic prophylaxis does not involve the detriment of either sanitary conditions or the surgical technique. Current recommendations suggest the administration of antibiotic prophylaxis when prosthetic material is being used or when risk factors are present (<LINK REF="REF-Condon-1991" TYPE="REFERENCE">Condon 1991</LINK>; <LINK REF="REF-Page-1993" TYPE="REFERENCE">Page 1993</LINK>; <LINK REF="REF-Woods-1998" TYPE="REFERENCE">Woods 1998</LINK>; <LINK REF="REF-Mangram-1999" TYPE="REFERENCE">Mangram 1999</LINK>,<LINK REF="REF-Simons-2009" TYPE="REFERENCE">Simons 2009</LINK>). Controversy arises when greater series using synthetic material show up infection rates around 0% (<LINK REF="STD-Gilbert-1993" TYPE="STUDY">Gilbert 1993</LINK>; <LINK REF="STD-Wantz-1996" TYPE="STUDY">Wantz 1996</LINK>) whereas series without prosthetic material provide rates around 10% (<LINK REF="REF-Bailey-1992" TYPE="REFERENCE">Bailey 1992</LINK>; <LINK REF="REF-Ranaboldo-1993" TYPE="REFERENCE">Ranaboldo 1993</LINK>; <LINK REF="STD-Taylor-1997" TYPE="STUDY">Taylor 1997</LINK>). Alternatively, benefits of antibiotic prophylaxis to prevent infections after the first week from the intervention have been questioned, as it would not be covered by the prophylaxis administration of antibiotics (<LINK REF="REF-Sanderson-1999" TYPE="REFERENCE">Sanderson 1999</LINK>). Surveys conducted among surgeons have reported that about half of them use antibiotic prophylaxis for hernia repair (<LINK REF="REF-Mozillo-1988" TYPE="REFERENCE">Mozillo 1988</LINK>; <LINK REF="REF-Codina-1999" TYPE="REFERENCE">Codina 1999</LINK>; <LINK REF="REF-Heineck-1999" TYPE="REFERENCE">Heineck 1999</LINK>).</P>
<P>There are several studies on the use of antibiotics for hernia repair, but most of them compare new antibiotics versus antibiotics whose efficacy has already been established. Other studies are conducted with too few patients and insufficient statistical power to draw firm conclusions. Many of them are retrospective series and in some instances there is a lack of control groups. In order to detect a 50% difference between both groups (reduction of the actual rate from 4% to an appropriate rate of 2% in clean surgical procedures) and to have sufficient statistical power, a prospective, randomised blinded study should include at least 800 patients in each treatment arm. This involves performing multicenter studies or studies with longer recruitment periods.</P>
<P>From those studies considered for further analysis after reading the abstracts, there were only seventeen studies that met the criteria to be included in the review. They were well-designed comparative, randomised and often blinded studies. However, conclusions cannot be drawn due to disparity of results. <LINK REF="STD-Evans-1973" TYPE="STUDY">Evans 1973</LINK>; <LINK REF="STD-Andersen-1980" TYPE="STUDY">Andersen 1980</LINK>; <LINK REF="STD-Platt-1990" TYPE="STUDY">Platt 1990</LINK>; <LINK REF="STD-Taylor-1997" TYPE="STUDY">Taylor 1997</LINK>; <LINK REF="STD-Morales-2000" TYPE="STUDY">Morales 2000</LINK>; <LINK REF="STD-Aufenacker-2004" TYPE="STUDY">Aufenacker 2004</LINK>; <LINK REF="STD-Oteiza-2004" TYPE="STUDY">Oteiza 2004</LINK>; <LINK REF="STD-Perez-2005" TYPE="STUDY">Perez 2005</LINK>; <LINK REF="STD-Tzovaras-2007" TYPE="STUDY">Tzovaras 2007</LINK>; <LINK REF="STD-Jain-2008" TYPE="STUDY">Jain 2008</LINK>; <LINK REF="STD-Ergul-2011" TYPE="STUDY">Ergul 2011</LINK>; <LINK REF="STD-Othman-2011" TYPE="STUDY">Othman 2011</LINK> and <LINK REF="STD-Shankar-2010" TYPE="STUDY">Shankar 2010</LINK> concluded that antibiotic prophylaxis is not efficacious, whereas <LINK REF="STD-Lazorthes-1992" TYPE="STUDY">Lazorthes 1992</LINK>; <LINK REF="STD-Yerdel-2001" TYPE="STUDY">Yerdel 2001</LINK> (this study was finished early due to the incidence of high infection rates in the control group); <LINK REF="STD-Celdran-2004" TYPE="STUDY">Celdran 2004</LINK> (finished early for ethical reasons) and <LINK REF="STD-Pessaux-2006" TYPE="STUDY">Pessaux 2006</LINK> (in high risk patients)<I> </I>did so.</P>
<P>Meta-analysis is a non-perfect technique that is no substitute for a large and well-designed randomised controlled study. Nonetheless, the technique is indicated for similar situations where the number of patients in the studies is low, or when results are conflicting, as it provides pooled estimates with narrower confidence intervals and greater statistical power (<LINK REF="REF-DerSimonian-1982" TYPE="REFERENCE">DerSimonian 1982</LINK>; <LINK REF="REF-Sacks-1987" TYPE="REFERENCE">Sacks 1987</LINK>; <LINK REF="REF-Sackett-1997" TYPE="REFERENCE">Sackett 1997</LINK>; <LINK REF="REF-Imperiale-1999" TYPE="REFERENCE">Imperiale 1999</LINK>). Unlike the early version of this review (<LINK REF="REF-Sanchez_x002d_Manuel-2001" TYPE="REFERENCE">Sanchez-Manuel 2001</LINK>) where studies should be only controlled trials to meet the inclusion criteria, the current review has been restricted to randomised prospective trials to improve the quality of the review, reducing biases produced by lack of randomisation, as well as the level of heterogeneity.</P>
<P>When the analysis included all the comparative and controlled studies, the observed trend in the confidence intervals of the randomised clinical trials becomes more evident, with a higher statistical significance at the expense of greater heterogeneity. That is to say, a greater benefit from antibiotic prophylaxis is detected, particularly when mesh repair is used. Heterogeneity in the set of comparative studies came from the herniorrhaphy group. Variations in the results among the studies were statistically significant, whereas they were absent in the hernioplasty group. However, caution should be exercised when interpreting these results since non-randomised and unblinded studies tend to overestimate the effects of treatment or prophylaxis.</P>
<P>Meta-analysis is only as strong as the primary data on which it is based (<LINK REF="REF-Imperiale-1999" TYPE="REFERENCE">Imperiale 1999</LINK>). Therefore, non-randomised studies, even not included in a statistical analysis, should be taken into account. The current meta-analysis has only addressed the use of antibiotic (whatever the type) for prophylaxis. The antibiotics considered in the included studies were beta lactamic agents, which are commonly used for antibiotic prophylaxis. They are able to attack Gram-positive cocci, commonly responsible for infections after hernia repair. All the included studies used antibiotic prophylaxis according to clinical management norms (<LINK REF="REF-Condon-1991" TYPE="REFERENCE">Condon 1991</LINK>,<LINK REF="REF-Page-1993" TYPE="REFERENCE">Page 1993</LINK>,<LINK REF="REF-Woods-1998" TYPE="REFERENCE">Woods 1998</LINK>,<LINK REF="REF-Mangram-1999" TYPE="REFERENCE">Mangram 1999</LINK>). In every case, patients were followed-up for longer than 30 days, the time required to follow up postoperative infections (<LINK REF="REF-Ranaboldo-1993" TYPE="REFERENCE">Ranaboldo 1993</LINK>).</P>
<P>A separate analysis of subgroups herniorrhaphies and hernioplasties showed that it was possible to combine these (no statistically significant heterogeneity). In the herniorrhaphies subgroup, the results showed that prophylaxis might reduce the postoperative wound infection, although statistical significance is borderline. In the hernioplasties subgroup, the antibiotic prophylaxis show a significant reduction of wound infection rates. The overall analysis show a significant albeit small reduction of wound infection rates with a low level of heterogeneity. However, sensitivity analysis with a random effects model shows marginal significance.There are several reasons, widely known, that explain this phenomenon: under the random effects model, confidence intervals are wider than under a fixed effects one, and smaller studies have more weight. In addition, the incidence of infections in the populations studied is low, thus being more difficult to show a significant reduction caused by the prophylaxis. It is possible that this sum of factors is masking a small, significant benefit of antibiotic prophylaxis, that might be of interest to clinicians in settings of high incidence of infections.</P>
<P>In conclusion, the results of this meta-analysis show that antibiotic prophylaxis may be useful to prevent wound infection in open elective hernia repair. However, the data are not sufficiently strong neither to recommend its universal administration nor to recommend against its use when high rates of wound infections are observed. When assessing this results it is important to take into account the setting of the included studies. Neither individual patient risk factors nor hospital-related risk factors (outpatient surgery, hospitals of different level) that might change the conclusions from this meta-analysis were considered in the included studies. These results should also be considered within their context; that is to say, the applicability of the results is related to the studies included in this meta-analysis. Therefore, to make generalizations of the findings inclusion of studies conducted in other settings should be carefully considered.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Based on the results of this systematic review, administration of antibiotic prophylaxis for elective inguinal hernia repair cannot be universally recommended. Nevertheless, its administration cannot either be recommended against when high rates of wound infection are observed.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Identification of risk factors for infection would be useful to identify those groups of patients that may benefit from antibiotic prophylaxis.<BR/>A cost-effectiveness analysis to evaluate the advantages of antibiotic prophylaxis is needed to appropriately appraise the economic implications.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>My special thanks to the Iberoamerican Cochrane Centre, particularly to Marta Roqué, for providing statistical advice. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-07-23 14:13:36 +0200" MODIFIED_BY="[Empty name]">
<P>None mentioned</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2011-12-02 10:34:59 +0100" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-12-04 20:22:51 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-12-04 20:14:32 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-12-04 20:14:32 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Andersen-1980" NAME="Andersen 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Andersen JR, Burcharth F, Larsen HW, Roder O, Andersen B</AU>
<TI>Polyglycolic acid, silk, and topical ampicillin. Their use in hernia repair and cholecystectomy</TI>
<SO>Arch Surg</SO>
<YR>1980</YR>
<VL>115</VL>
<PG>293-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aufenacker-2004" NAME="Aufenacker 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aufenacker TJ, van Geldere D, van Mesdag T, Bossers AN, Dekker B, Scheije E et al</AU>
<TI>The role of antibiotic prophylaxis in prevention of wound infection after Lichtenstein open mesh repair of primary inguinal hernia. A multicenter double-blind randomized controlled trial</TI>
<SO>Ann Surg</SO>
<YR>2004</YR>
<VL>240</VL>
<NO>6</NO>
<PG>955-961</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Celdran-2004" MODIFIED="2009-07-30 15:28:17 +0200" MODIFIED_BY="[Empty name]" NAME="Celdran 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-07-30 15:28:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Celdran A, Frieyro O, de la Pinta JC, Souto JL, Esteban J, Rubio JM et al.</AU>
<TI>The role of antibiotic prophylaxis on wound infection after mesh hernia repair under local anaesthesia on an ambulatory basis</TI>
<SO>Hernia</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>1</NO>
<PG>20-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ergul-2011" MODIFIED="2011-12-04 20:14:32 +0100" MODIFIED_BY="[Empty name]" NAME="Ergul 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-12-04 20:14:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ergul Z, Akinci M, Urgulu C, Kulacoglu H, Yilmaz KB</AU>
<TI>Prophylactic antibiotic use in elective inguinal hernioplasty in a trauma center</TI>
<SO>Hernia</SO>
<YR>September 2011</YR>
<VL>Epub ahead of print</VL>
<IDENTIFIERS MODIFIED="2011-10-29 22:11:48 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1973" NAME="Evans 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans C, Pollock AV</AU>
<TI>The reduction of surgical wound infections by prophylactic parenteral cephaloridine. A controlled clinical trial</TI>
<SO>Br J Surg</SO>
<YR>1973</YR>
<VL>60</VL>
<NO>6</NO>
<PG>434-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jain-2008" MODIFIED="2009-07-01 21:15:20 +0200" MODIFIED_BY="[Empty name]" NAME="Jain 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-01 21:15:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jain SK, Jayant M, Norbu C</AU>
<TI>The role of antibiotic prophylaxis in mesh repair of primary inguinal hernias using prolene hernia system: a randomized prospective double-blind control trial</TI>
<SO>Tropical Doctor</SO>
<YR>2008</YR>
<VL>38</VL>
<PG>80-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lazorthes-1992" NAME="Lazorthes 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lazorthes F, Chiotasso P, Massip P, Materre JP, Sarkissian M</AU>
<TI>Local antibiotic prophylaxis in inguinal hernia repair</TI>
<SO>Surg Gynecol Obstet</SO>
<YR>1992</YR>
<VL>175</VL>
<PG>569-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morales-2000" NAME="Morales 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morales R, Carmona A, Pagán A, García Menéndez C, Bravo R, Hernández MJ et al.</AU>
<TI>Utility of antibiotic propyhylaxis in reducing wound infection in inguinal or femoral hernia repair using propypropylene mesh</TI>
<TO>Utilidad de la profilaxis antibiótica en la reducción de la infección de herida en la reparación de la hernia inguinal o crural mediante malla de prolipropileno</TO>
<SO>Cir Esp</SO>
<YR>2000</YR>
<VL>67</VL>
<NO>1</NO>
<PG>51-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oteiza-2004" NAME="Oteiza 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oteiza F, Ciga MA, Ortiz H</AU>
<TI>Antibiotic prophylaxis in inguinal hernioplasty</TI>
<TO>Profilaxis antibiótica en la hernioplastia inguinal</TO>
<SO>Cir Esp</SO>
<YR>2004</YR>
<VL>75</VL>
<NO>2</NO>
<PG>69-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Othman-2011" MODIFIED="2011-10-29 22:15:51 +0200" MODIFIED_BY="[Empty name]" NAME="Othman 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-10-29 22:15:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Othman I</AU>
<TI>Prospective randomized evaluation of prophylactic antibiotic usage in patients undergoing tension free inguinal hernioplasty</TI>
<SO>Hernia</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>3</NO>
<PG>309-313</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perez-2005" NAME="Perez 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perez AR, Roxas MF, Hilvano SS</AU>
<TI>A randomized, double-blind, placebo-controlled trial to determine effectiveness of antibiotic prophylaxis for tension-free mesh herniorraphy</TI>
<SO>J Am Coll Surg</SO>
<YR>2005</YR>
<VL>200</VL>
<NO>3</NO>
<PG>393-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pessaux-2006" MODIFIED="2011-11-12 12:45:40 +0100" MODIFIED_BY="[Empty name]" NAME="Pessaux 2006" YEAR="">
<REFERENCE MODIFIED="2011-11-12 12:45:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pessaux P, Lermite E, Blezel E, Msika S, Hay J-M, Flamant Y et al</AU>
<TI>Predictive risk score for infection after inguinal hernia repair</TI>
<SO>Am J Surg</SO>
<YR>2006</YR>
<VL>192</VL>
<PG>165-171</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Platt-1990" NAME="Platt 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Platt R, Zaleznik DF, Hopkins CC, Dellinger EP, Karchmer AW, Bryan CS et al.</AU>
<TI>Perioperative antibiotic prophylaxis for herniorrhaphy and breast surgery</TI>
<SO>N Engl J Med</SO>
<YR>1990</YR>
<VL>322</VL>
<NO>3</NO>
<PG>153-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shankar-2010" MODIFIED="2011-11-01 13:35:23 +0100" MODIFIED_BY="[Empty name]" NAME="Shankar 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-01 13:35:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shankar VG, Srinivasan K, Sistla SC, Jagdish S</AU>
<TI>Prophylactic antibiotics in open mesh repair of inguinal hernia. A randomized controlled trial</TI>
<SO>Int J Surg</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>6</NO>
<PG>444-447</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-1997" NAME="Taylor 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor EW, Byrne DJ, Leaper DJ, Karran SJ, Kennedy Browne M, Mitchell KJ</AU>
<TI>Antibiotic prophylaxis and open groin hernia repair</TI>
<SO>World J Surg</SO>
<YR>1997</YR>
<VL>21</VL>
<NO>8</NO>
<PG>811-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tzovaras-2007" MODIFIED="2011-11-01 13:36:39 +0100" MODIFIED_BY="[Empty name]" NAME="Tzovaras 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-11-01 13:36:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tzovaras G, Delikoukos S, Christodoulides G, Spyridakis M, Mantzos F, Tepetes K, Athanassiou E, Hatzitheofilou C</AU>
<TI>The role of antibiotic prophylaxis in elective tension-free mesh inguinal hernia repair: results of a single-centre prospective randomised trial</TI>
<SO>Int J Clin Pract</SO>
<YR>2007</YR>
<VL>61</VL>
<NO>2</NO>
<PG>236-239</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yerdel-2001" MODIFIED="2009-07-30 15:29:44 +0200" MODIFIED_BY="[Empty name]" NAME="Yerdel 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-30 15:29:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yerdel MA, Akin EB, Dolalan S, Turkcapar AG, Pehlivan M, Gecim IE et al.</AU>
<TI>Effect of single-dose prophylactic ampicillin and sulbactam on wound infection after tension-free inguinal hernia repair with polypropylene mesh. The randomized, double-blind, prospective trial</TI>
<SO>Ann Surg</SO>
<YR>2001</YR>
<VL>233</VL>
<NO>1</NO>
<PG>26-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-11-12 19:50:03 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abo_x002d_Rahmy-1998" NAME="Abo-Rahmy 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abo-Rahmy E</AU>
<TI>Perioperative antibiotic prophylaxis in abdominal surgery for hernia repair: retrospective study of 1524 consecutive patients</TI>
<SO>J Chemother</SO>
<YR>1998</YR>
<VL>10</VL>
<NO>3</NO>
<PG>248-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angio-2001" NAME="Angio 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angio LG, Versaci A, Rivoli G, Santagati C, De Caridi G, Pacile V</AU>
<TI>The switch prophylaxis with levofloxacin in surgical procedures for prosthetic inguinal hernia repair in one day surgery.</TI>
<TO>La switch prophylaxis con levofloxacina negli interventi di ernioplastica inguinale con protesi in regime di one day surgery.</TO>
<SO>G Chir</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>8-9</NO>
<PG>299-302</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21540039"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barreca-2000" NAME="Barreca 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barreca M, Stipa F, Cardi E, Bianchini L, Lucandri G, Randone B</AU>
<TI>Antibiotic prophylaxis in the surgical treatment of inguinal hernia: need or habit?</TI>
<TO>La profilassi antibiotica nel trattamento chirurgico dell'ernia inguinale: necessità o abitudine?</TO>
<SO>Minerva Chir</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>9</NO>
<PG>599-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dazzi-1994" NAME="Dazzi 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dazzi C, Licheri S, Sias F, Secci L, Daniele GM</AU>
<TI>Wound infection's prophylaxis with teicoplanin in major ambulatory surgery</TI>
<TO>La teicoplanina nella profilassi delle infezioni della ferita in chirurgia ambulatoriale maggiore</TO>
<SO>Ann Ital Chir</SO>
<YR>1994</YR>
<VL>65</VL>
<NO>1</NO>
<PG>121-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deysine-2005" NAME="Deysine 2005" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deysine M</AU>
<TI>Postmesh herniorrhaphy wound infections: can they be eliminated?</TI>
<SO>Int Surg</SO>
<YR>2005</YR>
<VL>90</VL>
<NO>3 Suppl</NO>
<PG>S40-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dixon-2006" NAME="Dixon 2006" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dixon AJ, Dixon MP, Dixon JB</AU>
<TI>Randomized clinical trial of the effect of applying ointment to surgical wounds before occlusive dressing.</TI>
<SO>Br J Surg</SO>
<YR>2006</YR>
<VL>93</VL>
<PG>937-943</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Escart_x00ed_n-1999" NAME="Escartín 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Escartín A, Pellicer MM, Elía M, Jiménez A, Arribas MD, Lagunas E et al.</AU>
<TI>Antibiotic prophylaxis in inguinal hernia repair</TI>
<TO>Profilaxis antibiótica en la cirugía de la hernia inguinal</TO>
<SO>Cir Esp</SO>
<YR>1999</YR>
<VL>65</VL>
<NO>1</NO>
<PG>24-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Esposito-2006" MODIFIED="2011-11-12 19:50:03 +0100" MODIFIED_BY="[Empty name]" NAME="Esposito 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-11-12 19:49:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Esposito S, Leone S, Noviello S, Ianniello F, Marvaso A, Cuniato V, Bellitti F</AU>
<TI>Antibiotic prophylaxis in hernia repair and breast surgery: A prospective randomized study comparing piperacillin/tazobactam versus placebo</TI>
<SO>J Chemother</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>3</NO>
<PG>278-289</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gervino-2000" NAME="Gervino 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gervino L, Cangioni G, Renzi F</AU>
<TI>A retrospective study on the efficacy of short-term perioperative prophylaxis in abdominal surgery for hernia repair in 1254 patients</TI>
<SO>J Chemother</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>Suppl 3</NO>
<PG>34-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilbert-1993" NAME="Gilbert 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert AI, Felton LL</AU>
<TI>Infection in inguinal hernia repair considering biomaterials and antibiotics</TI>
<SO>Surg Gynecol Obstet</SO>
<YR>1993</YR>
<VL>177</VL>
<PG>126-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilmore-1977" NAME="Gilmore 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilmore OJA, Reid C, Strokon A</AU>
<TI>A study of the effect of povidone-iodine on wound healing</TI>
<SO>Postgrad Med J</SO>
<YR>1967</YR>
<VL>53</VL>
<NO>617</NO>
<PG>122-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hair-2000" NAME="Hair 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hair A, Duffy K, McLean J, Taylor S, Smith H, Walker A et al</AU>
<TI>Groin hernia repair in Scotland</TI>
<SO>Br J Surg</SO>
<YR>2000</YR>
<VL>87</VL>
<NO>12</NO>
<PG>1722-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hedawoo-1995" NAME="Hedawoo 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hedawoo JB, Kulkarni VM, Gundeti MS</AU>
<TI>Role of antibiotics in clean wounds</TI>
<SO>J Indian Med Assoc</SO>
<YR>1985</YR>
<VL>93</VL>
<NO>8</NO>
<PG>293-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Houck-1989" NAME="Houck 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Houck JP, Rypins EB, Sarfeh IJ, Juler GL, Shimoda KJ</AU>
<TI>Repair of incisional hernia</TI>
<SO>Surg Gynecol Obstet</SO>
<YR>1989</YR>
<VL>169</VL>
<PG>397-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karran-1992" NAME="Karran 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karran SJ, Karran SE, Toyn K, Brough P</AU>
<TI>Antibiotic prophylaxis in clean surgical cases and the role of community surveillance.</TI>
<SO>Eur J Surg</SO>
<YR>1992</YR>
<VL>567 Suppl</VL>
<PG>31-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuzu-2005" NAME="Kuzu 2005" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuzu M A, Jazinedaroglu S, Dolalan S, Özkan N, Yalçin S, Erkek A B et al.</AU>
<TI>Prevention of surgical site infection after open prosthetic inguinal hernia repair: efficacy of parenteral versus oral prophylaxis with amoxicillin-clavulanic acid in a randomized clinical trial.</TI>
<SO>World J Surg</SO>
<YR>2005</YR>
<VL>29</VL>
<NO>6</NO>
<PG>794-799</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1995" MODIFIED="2009-07-30 15:30:51 +0200" MODIFIED_BY="[Empty name]" NAME="Lewis 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-07-30 15:30:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis RT, Weigand FM, Mamazza J, Lloyd-Smith W, Tataryn D</AU>
<TI>Should antibiotic prophylaxis be used routinely in clean surgical procedures: a tentative yes.</TI>
<SO>Surgery</SO>
<YR>1995</YR>
<VL>118</VL>
<NO>4</NO>
<PG>742-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Massaioli-1995" NAME="Massaioli 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Massaioli N, Marchesa P, Bacino A, Galliano R, Borello G, Bonatti L et al.</AU>
<TI>Antibiotic prophylaxis with vancomycin in reparative surgery using alloplastic material</TI>
<TO>Antibioticoprofilassi con vancomicina nella chirurgia riparativa con materiale alloplastico.</TO>
<SO>Minerva Chir</SO>
<YR>1995</YR>
<VL>50</VL>
<NO>9</NO>
<PG>827-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Musella-2001" NAME="Musella 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Musella M, Guido A, Musella S</AU>
<TI>Collagen tampons as aminoglycoside carriers to reduce postoperative infection rate in prosthetic repair of groin hernias</TI>
<SO>Eur J Surg</SO>
<YR>2001</YR>
<VL>167</VL>
<NO>2</NO>
<PG>130-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nundy-1983" MODIFIED="2009-07-30 15:31:22 +0200" MODIFIED_BY="[Empty name]" NAME="Nundy 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-07-30 15:31:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nundy S, Ramachandran K</AU>
<TI>The place of antibiotics in preventing wound infection after clean operations in an Indian hospital: a prospective, randomised, controlled clinical trial.</TI>
<SO>Ann R Coll Surg Engl</SO>
<YR>1983</YR>
<VL>65</VL>
<PG>400-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Platt-1992" NAME="Platt 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Platt R, Zucker JR, Zaleznik DF, Hopkins CC, Dellinger EP, Karchmer AW et al.</AU>
<TI>Prophylaxis against wound infection following herniorrhaphy or breast surgery.</TI>
<TO>Prophylaxis against wound infection following herniorrhaphy or breast surgery.</TO>
<SO>J Infect Dis</SO>
<YR>1993</YR>
<VL>166</VL>
<NO>3</NO>
<PG>556-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Praveen-2009" MODIFIED="2011-11-01 13:37:27 +0100" MODIFIED_BY="[Empty name]" NAME="Praveen 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-11-01 13:37:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Praveen S, Rohaizak M</AU>
<TI>Local antibiotics are equivalent to intravenous antibiotics in the prevention of superficial wound infection in inguinal hernioplasty</TI>
<SO>Asian J Surg</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>1</NO>
<PG>59-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reggiori-1996" NAME="Reggiori 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reggiori A, Ravera M, Cocozza E, Andreata M, Mukasa F</AU>
<TI>Randomized study of antibiotic prophylaxis for general and gynaecological surgery from a single centre in rural Africa</TI>
<SO>Br J Surg</SO>
<YR>1996</YR>
<VL>83</VL>
<PG>356-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ryan-1967" NAME="Ryan 1967" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ryan EA</AU>
<TI>Wound infection prevention by topical antibiotics</TI>
<SO>Br J Surg</SO>
<YR>1967</YR>
<VL>54</VL>
<NO>5</NO>
<PG>324-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shwed-1991" NAME="Shwed 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shwed JA, Danziger LH, Wojtynek J, Rodwold KA</AU>
<TI>A comparative evaluation of the safety and efficacy of cefotetan and cefoxitin in surgical prophylaxis.</TI>
<SO>DICP</SO>
<YR>1991</YR>
<VL>25</VL>
<PG>10-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spallitta-1999" NAME="Spallitta 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spallitta SI, Temrine G, Zappulla A, Greco V, compagno GM, Lo-lacono I et al</AU>
<TI>Tension-free hernioplasty in the treatment of inguinal hernia in the adult: our experience with local anesthesia and a review of the literature</TI>
<TO>Ernioplastica "tension-free" nel trattamento dell'ernia inguinale dell'adulto: la nostra esperienza in anestesia locale e revisione della letteratura</TO>
<SO>Minerva Chir</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>9</NO>
<PG>573-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sultan-1989" NAME="Sultan 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sultan S, Ahmed R, Mufti T, Mohammad G, Nawaz M</AU>
<TI>Use of prophylactic antibiotic in clean surgical cases. A prospective trial of various regimens.</TI>
<SO>J Pak Med Assoc</SO>
<YR>1989</YR>
<VL>39</VL>
<NO>1</NO>
<PG>9-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terzi-2005" NAME="Terzi 2005" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terzi C, Kilic D, Unek T, Hosgorler F, Fuzun M, Ergor G</AU>
<TI>Single-dose oral ciprofloxacin compared with single-dose intravenous cefazolin for prophylaxis in inguinal hernia repair: a controlled randomized clinical study</TI>
<SO>J Hosp Infect</SO>
<YR>2005</YR>
<VL>60</VL>
<NO>4</NO>
<PG>340-347</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van_x002d_Damme-1981" NAME="Van-Damme 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van-Damme JP, Timmermans TT</AU>
<TI>Wound infections in general surgery. A two-year prospective study in a private hospital</TI>
<SO>Acta Chir Belg</SO>
<YR>1981</YR>
<VL>80</VL>
<NO>4</NO>
<PG>161-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vara-1993" NAME="Vara 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vara R, Ruiz M, Rosell J, Tovar JL, Moreno A, Guerrero JA et al.</AU>
<TI>Chemoprophylaxis in inguinal herniorrhaphy?</TI>
<TO>¿Quimioprofilaxis en cirugía herniaria?</TO>
<SO>Cir Esp</SO>
<YR>1993</YR>
<VL>53</VL>
<NO>3</NO>
<PG>105-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wantz-1996" NAME="Wantz 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wantz GE</AU>
<TI>Experience with tension-free hernioplasty for primary inguinal hernia in men</TI>
<SO>J Am Coll Surg</SO>
<YR>1996</YR>
<VL>183</VL>
<NO>4</NO>
<PG>351-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-12-04 20:22:51 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-11-12 13:05:23 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1998" NAME="Altman 1998" TYPE="JOURNAL_ARTICLE">
<AU>Altman, Douglas G</AU>
<TI>Confidence intervals for the number need to treat</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>317</VL>
<NO>7168</NO>
<PG>1309-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bailey-1992" NAME="Bailey 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bailey IS, Karran SE, Toyn K, Brough P, Ranaboldo C, Karran SJ</AU>
<TI>Community surveillance of complications after hernia surgery</TI>
<SO>BMJ</SO>
<YR>1992</YR>
<VL>304</VL>
<NO>6825</NO>
<PG>469-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cainzos-1990" NAME="Cainzos 1990" TYPE="JOURNAL_ARTICLE">
<AU>Cainzos M, Lozano F, Balibrea JL, Dávila D, Potel J, Gómez Alonso A, et al.</AU>
<TI>Postoperative infection: multicentric, prospective and controlled study.</TI>
<TO>La infección postoperatoria: estudio multicéntrico, prospectivo y controlado.</TO>
<SO>Cir Esp</SO>
<YR>1990</YR>
<VL>48</VL>
<NO>5</NO>
<PG>481-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Codina-1999" NAME="Codina 1999" TYPE="JOURNAL_ARTICLE">
<AU>Codina C, Trilla A, Riera N, Tuset M, Carne X, Ribas J et al.</AU>
<TI>Perioperative antibiotic prophylaxis in Spanish hospitals: results of a questionnaire survey</TI>
<SO>Infect Control Hosp Epidemiol</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>6</NO>
<PG>436-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Condon-1991" NAME="Condon 1991" TYPE="JOURNAL_ARTICLE">
<AU>Condon RE, Wittmann DH</AU>
<TI>The use of antibiotics in general surgery</TI>
<SO>Curr Probl Surg</SO>
<YR>1991</YR>
<VL>28</VL>
<NO>12</NO>
<PG>803-907</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davey-1998" NAME="Davey 1998" TYPE="JOURNAL_ARTICLE">
<AU>Davey PG, Nathwani D</AU>
<TI>What is the value of preventing postoperative infections?</TI>
<SO>New Horiz</SO>
<YR>1998</YR>
<VL>6</VL>
<NO>2 Suppl</NO>
<PG>S64-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-1999" NAME="Deeks 1999" TYPE="CONFERENCE_PROC">
<AU>Deeks J, Bradburn M, Localio R, Berlin J</AU>
<TO>Much Ado About Nothing: Statistical Methods for Meta-analysis with Rare Events.</TO>
<SO>Presentatioon held at the 2nd Symposium on Systematic Reviews: Beyond the basics.</SO>
<YR>1999</YR>
<CY>St. Ctatherine's College, Oxford. UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dellinger-1994" NAME="Dellinger 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dellinger EP, Gross PA, Barrett TL, Krause PJ, Martone WJ, McGowan JE et al.</AU>
<TI>Quality standard for antimicrobial prophylaxis in surgical procedures</TI>
<SO>Clin infect Dis</SO>
<YR>1994</YR>
<VL>18</VL>
<PG>422-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1982" NAME="DerSimonian 1982" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Charette J, McPeek B, Mosteller F</AU>
<TI>Reporting on methods in clinical trials</TI>
<SO>N Engl J Med</SO>
<YR>1982</YR>
<VL>306</VL>
<PG>1332-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haley-1985" NAME="Haley 1985" TYPE="JOURNAL_ARTICLE">
<AU>Haley RW, Culver DH, Morgan WM, White JW, Emori TG, Hooton TM</AU>
<TI>Identifying patients at high risk of surgical wound infection</TI>
<SO>Am J Epidemiol</SO>
<YR>1985</YR>
<VL>121</VL>
<PG>206-215</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heineck-1999" NAME="Heineck 1999" TYPE="JOURNAL_ARTICLE">
<AU>Heineck I, Ferreira MB, Schenkel EP</AU>
<TI>Prescribing practice for antibiotic prophylaxis for 3 commonly performed surgeries in a teaching hospital in Brazil</TI>
<SO>Am J Infect Control</SO>
<YR>1999</YR>
<VL>27</VL>
<NO>3</NO>
<PG>296-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Decks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-560</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holmes-1994" NAME="Holmes 1994" TYPE="JOURNAL_ARTICLE">
<AU>Holmes J, Readman R</AU>
<TI>A study of wound infections following inguinal hernia repair</TI>
<SO>J Hosp Infect</SO>
<YR>1994</YR>
<VL>28</VL>
<PG>153-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horan-1992" NAME="Horan 1992" TYPE="JOURNAL_ARTICLE">
<AU>Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG</AU>
<TI>CDC definitions of nosocomial surgical site infections 1992: a modification of CDC definitions of surgical wound infections</TI>
<SO>Infect Control Hosp Epidemiol</SO>
<YR>1992</YR>
<VL>29</VL>
<NO>Suppl 1</NO>
<PG>26S-31S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imperiale-1999" NAME="Imperiale 1999" TYPE="JOURNAL_ARTICLE">
<AU>Imperiale TE</AU>
<TI>Meta-analysis: When and how</TI>
<SO>Hepatology</SO>
<YR>1999</YR>
<VL>29</VL>
<NO>Suppl 1</NO>
<PG>26S-31S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leaper-1998" NAME="Leaper 1998" TYPE="JOURNAL_ARTICLE">
<AU>Leaper DJ</AU>
<TI>Use of antibiotic prophylaxis in clean non-implant wounds</TI>
<SO>J Antimicrob Chemother</SO>
<YR>1998</YR>
<VL>41</VL>
<PG>501-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mangram-1999" NAME="Mangram 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, The Hospital Infection Control Practices Advisory Committee</AU>
<TI>Guideline for prevention of surgical site infection, 1999</TI>
<SO>Infect Control Hosp Epidemiol</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>4</NO>
<PG>247-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mozillo-1988" NAME="Mozillo 1988" TYPE="JOURNAL_ARTICLE">
<AU>Mozillo N, Greco D, Pescini A, Formato A</AU>
<TI>Chemoprophylaxis in the surgical ward: results of a national survey in Italy</TI>
<SO>Eur J Epidemiol</SO>
<YR>1988</YR>
<VL>4</VL>
<NO>3</NO>
<PG>357-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NRC-1964" NAME="NRC 1964" TYPE="JOURNAL_ARTICLE">
<AU>National Academy of Sciences, National Research Council, Division of Medical Sciences, Ad Hoc Commitee on Trauma</AU>
<TI>Postoperative wound infections: the influence of ultraviolet irradiation on the operating room and of various other factors.</TI>
<SO>Ann Surg</SO>
<YR>1964</YR>
<VL>16</VL>
<NO>Suppl 2</NO>
<PG>1-196</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Page-1993" NAME="Page 1993" TYPE="JOURNAL_ARTICLE">
<AU>Page CP, Bohnen JMA, Fletcher JR, MacManus AT, Solomkin JS, Wittmann DH</AU>
<TI>Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care</TI>
<SO>Arch Surg</SO>
<YR>1993</YR>
<VL>128</VL>
<PG>79-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Porcu-1996" NAME="Porcu 1996" TYPE="JOURNAL_ARTICLE">
<AU>Porcu A, Noya G, Dessanti A, Niolu P, Cottu P, Castiglia P, Dettori G</AU>
<TI>A new approach to the problem of surgical wound infections in clean operations</TI>
<SO>Minerva Chir</SO>
<YR>1996</YR>
<VL>51</VL>
<NO>9</NO>
<PG>691-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ranaboldo-1993" NAME="Ranaboldo 1993" TYPE="JOURNAL_ARTICLE">
<AU>Ranaboldo CJ, Karran SE, Bailey S, Karran SJ</AU>
<TI>Antimicrobial prophylaxis in clean surgery: hernia repair</TI>
<SO>J Antimicrob Chemother</SO>
<YR>1993</YR>
<VL>31</VL>
<NO>Suppl B</NO>
<PG>35-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodriguez-2005" NAME="Rodriguez 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez-Cuellar E, Villeta R, Ruiz P, Alcalde J, Landa JI, Porrero JL et al.</AU>
<TI>National project for the management of clinical processes. Surgical treatment of inguinal hernia</TI>
<TO>Proyecto nacional para la gestión clínica de procesos asistenciales. Tratamiento quirúrgico de la hernia inguinal</TO>
<SO>Cir Esp</SO>
<YR>2005</YR>
<VL>77</VL>
<NO>4</NO>
<PG>194-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rutkow-1993" NAME="Rutkow 1993" TYPE="JOURNAL_ARTICLE">
<AU>Rutkow IM, Robbins AW</AU>
<TI>Tension-free inguinal herniorrhaphy: a preliminary report on the mesh-plug technique</TI>
<SO>Surgery</SO>
<YR>1993</YR>
<VL>114</VL>
<PG>3-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sackett-1997" NAME="Sackett 1997" TYPE="BOOK">
<AU>Sackett DL, Richardson WS, Rosenberg W, Haynes RB</AU>
<SO>Evidence-based Medicine. How to Practice &amp; Teach EBM</SO>
<YR>1997</YR>
<PB>Churchill Livingstone</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sacks-1987" NAME="Sacks 1987" TYPE="JOURNAL_ARTICLE">
<AU>Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers ThC</AU>
<TI>Meta-analyses of randomized controlled trials</TI>
<SO>N Engl J Med</SO>
<YR>1987</YR>
<VL>316</VL>
<NO>8</NO>
<PG>450-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sanderson-1999" NAME="Sanderson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Sanderson PJ</AU>
<TI>Assessing the role of prophylactic antibiotics in clean surgery</TI>
<SO>J Hosp Infect</SO>
<YR>1999</YR>
<VL>42</VL>
<PG>7-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simons-2009" MODIFIED="2011-11-12 13:05:08 +0100" MODIFIED_BY="[Empty name]" NAME="Simons 2009" TYPE="JOURNAL_ARTICLE">
<AU>Simons MP, Aufenacker T, Bay-Nielsen M, Bouillot JL, Campanelli G, Conze J, de Lange D,Fortelny R, Heikkinen T et al</AU>
<TI>European Hernia Society guidelines on the treatment of inguinal hernia in adult patients</TI>
<SO>Hernia</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>4</NO>
<PG>343-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wittmann-1995" NAME="Wittmann 1995" TYPE="JOURNAL_ARTICLE">
<AU>Wittmann DH, Schein M, Condon RE</AU>
<TI>Antibiotic prophylaxis in abdominal wall hernia surgery: never, always, or selectively?</TI>
<SO>Probl Gen Surg</SO>
<YR>1995</YR>
<VL>12</VL>
<NO>1</NO>
<PG>47-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woods-1998" NAME="Woods 1998" TYPE="JOURNAL_ARTICLE">
<AU>Woods RK, Dellinger EP</AU>
<TI>Current guidelines for antibiotic prophylaxis of surgical wounds</TI>
<SO>Am Fam Physysician</SO>
<YR>1998</YR>
<VL>58</VL>
<NO>11</NO>
<PG>2731-40</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-12-04 20:22:51 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Sanchez_x002d_Manuel-2001" NAME="Sanchez-Manuel 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sánchez-Manuel FJ, Seco-Gil JL, Lozano-García J</AU>
<TI>[Antibiotic prophylaxis and hernia repair. Systematic quantitative review results]. [Spanish]</TI>
<TO>Profilaxis antibiótica y reparación herniaria. Resultado de una revisión sistemática cuantitativa.</TO>
<SO>Enferm Infecc Microbiol Clin</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>3</NO>
<PG>107-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sanchez_x002d_Manuel-2003" MODIFIED="2011-12-04 20:22:51 +0100" MODIFIED_BY="[Empty name]" NAME="Sanchez-Manuel 2003" TYPE="COCHRANE_REVIEW">
<AU>Sánchez-Manuel FJ, Seco-Gil JL</AU>
<TI>Antibiotic prophylaxis for hernia repair</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-12-04 20:22:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Sanchez_x002d_Manuel-2004" MODIFIED="2011-12-04 20:22:48 +0100" MODIFIED_BY="[Empty name]" NAME="Sanchez-Manuel 2004" TYPE="COCHRANE_REVIEW">
<AU>Sánchez-Manuel FJ, Seco-Gil JL</AU>
<TI>Antibiotic prophylaxis for hernia repair</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-12-04 20:22:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Sanchez_x002d_Manuel-2007" MODIFIED="2011-12-04 20:22:42 +0100" MODIFIED_BY="[Empty name]" NAME="Sanchez-Manuel 2007" TYPE="COCHRANE_REVIEW">
<AU>Sánchez-Manuel FJ, Lozano-García J, Seco-Gil JL</AU>
<TI>Antibiotic prophylaxis for hernia repair</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-12-04 20:22:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Sanchez_x002d_Manuel-2010" MODIFIED="2011-12-04 20:22:37 +0100" MODIFIED_BY="[Empty name]" NAME="Sanchez-Manuel 2010" TYPE="COCHRANE_REVIEW">
<AU>Sánchez-Manuel FJ, Lozano-García J, Seco Gil JL</AU>
<TI>Antibiotic prophylaxis for hernia repair</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2011-12-04 20:22:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-01-04 13:28:13 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-01-04 13:27:51 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-11-13 19:19:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andersen-1980">
<CHAR_METHODS MODIFIED="2011-11-13 19:18:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: prospective, randomised. <I>Allocation</I>: NM. <I>Blinding</I>: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-30 21:21:21 +0100" MODIFIED_BY="[Empty name]">
<P>287 patients: 137 P / 150 C</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 19:19:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Herniorrhaphy</I>
</P>
<P>
<I>ATB:</I> ampicillin 1 gr subfascial. <I>MA:</I> before closure fascial. <I>Control:</I> no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-30 21:23:12 +0100" MODIFIED_BY="[Empty name]">
<P>IP= 5; IC= 6</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-02 16:09:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aufenacker-2004">
<CHAR_METHODS MODIFIED="2011-12-02 16:09:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study:</I> prospective, randomised, multicenter. <I>Allocalion:</I> computer. <I>Blinding</I>: yes.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1008 patients: 505 P / 503 C</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 19:19:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hernioplasty. </I>
</P>
<P>
<I>ATB:</I> cefuroxime 1.500 mg IV. <I>MA:</I> induction. <I>Control</I>= placebo.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-30 21:25:48 +0100" MODIFIED_BY="[Empty name]">
<P>IP= 9; IC= 8</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-02 16:34:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Celdran-2004">
<CHAR_METHODS MODIFIED="2011-11-13 19:19:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: prospective, randomised. <I>Allocaton</I>: number list. <I>Blinding</I>: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-30 21:27:00 +0100" MODIFIED_BY="[Empty name]">
<P>99 patients: 50 P / 49 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 18:32:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hernioplasty</I>
</P>
<P>
<I>ATB</I>: cephazolin 1 gr. <I>MA:</I> 30 minutes before the incision. <I>Control:</I> placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-30 21:27:47 +0100" MODIFIED_BY="[Empty name]">
<P>IP= 0; IC= 4</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-02 16:34:05 +0100" MODIFIED_BY="[Empty name]">
<P>The interim analysis, performed after the first 91 patients had been included, recommended ending the study due to ethical reasons.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-13 19:20:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ergul-2011">
<CHAR_METHODS MODIFIED="2011-11-13 19:20:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: prospective, randomised. <I>Allocation</I>: sealed envelopes. <I>Blinding</I>: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-30 21:28:32 +0100" MODIFIED_BY="[Empty name]">
<P>200 patients: 100 P / 100 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 19:20:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hernioplasty</I>
</P>
<P>
<I>ATB:</I> cefazolin 1 gr IV. <I>MA:</I> induction. <I>Control:</I> sterile saline.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-30 21:29:49 +0100" MODIFIED_BY="[Empty name]">
<P>IP=5; IC=7</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-04 13:26:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-1973">
<CHAR_METHODS MODIFIED="2012-01-04 13:26:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: prospective, randomised. <I>Allocation</I>: coin. <I>Blinding</I>: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-30 21:30:42 +0100" MODIFIED_BY="[Empty name]">
<P>97 patients: 48 P / 49 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 19:20:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Herniorrhaphy</I>
</P>
<P>
<I>ATB:</I> cefaloridine 1 gr IM. <I>MA:</I> induction and two dosis postoperatives. <I>Control:</I> no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-30 21:31:48 +0100" MODIFIED_BY="[Empty name]">
<P>IP= 1;IC= 2</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-13 19:21:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jain-2008">
<CHAR_METHODS MODIFIED="2011-11-13 19:21:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: prospective, randomised. <I>Allocation</I>: computer. Blinding: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-30 21:32:50 +0100" MODIFIED_BY="[Empty name]">
<P>120 patients: 60 P / 60 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 18:34:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hernioplasty</I>
</P>
<P>
<I>ATB:</I> amoxicillin-clavulanic acid 1.2 gr IV. <I>MA</I>: before incision. <I>Control:</I> placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-30 21:33:55 +0100" MODIFIED_BY="[Empty name]">
<P>IP= 1; IC= 1</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-13 19:21:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lazorthes-1992">
<CHAR_METHODS MODIFIED="2011-11-13 18:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: prospective, randomised. <I>Allocation</I>: NM. <I>Blinding</I>: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-30 21:34:48 +0100" MODIFIED_BY="[Empty name]">
<P>308 patients: 155 P / 153 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 19:21:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Herniorrhaphy</I>
</P>
<P>
<I>ATB:</I> cefamandole 750 mg subcutaneous. <I>MA:</I> added to local anaesthesia. <I>Control:</I> no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-30 21:35:38 +0100" MODIFIED_BY="[Empty name]">
<P>IP= 0; IC= 7</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-13 19:21:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morales-2000">
<CHAR_METHODS MODIFIED="2011-11-13 19:21:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: multicenter, prospective, randomised. <I>Allocation</I>: envelopes. Blinded: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-30 21:36:20 +0100" MODIFIED_BY="[Empty name]">
<P>524 patients: 237 P / 287 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 18:39:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hernioplasty</I>
</P>
<P>
<I>ATB:</I> cefazolin 2 gr IV. <I>MA:</I> induction. <I>Control:</I> placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-30 21:37:02 +0100" MODIFIED_BY="[Empty name]">
<P>IP= 4; IC= 6</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-13 19:21:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oteiza-2004">
<CHAR_METHODS MODIFIED="2011-11-13 19:21:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: prospective, randomised. <I>Allocation</I>: computer. <I>Blinding</I>: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-30 21:37:53 +0100" MODIFIED_BY="[Empty name]">
<P>247 patients: 124 P / 123 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 18:42:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hernioplasty</I>
</P>
<P>
<I>ATB:</I> amoxicillin-clavulanic 2 gr IV. <I>MA:</I> 15-30 minutes before the incision. <I>Control:</I> no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-30 21:38:36 +0100" MODIFIED_BY="[Empty name]">
<P>IP= 1; IC= 0</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-13 19:22:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Othman-2011">
<CHAR_METHODS MODIFIED="2011-11-13 19:22:02 +0100" MODIFIED_BY="[Empty name]">
<P>Study: prospective, randomised. <I>Allocation</I>: computer. <I>Blinding</I>: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-31 19:47:34 +0100" MODIFIED_BY="[Empty name]">
<P>98 patients: 50 P / 48 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 19:22:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hernioplasty</I>
</P>
<P>
<I>ATB</I>: amoxicillin-clavulanic 1.2 gr IV. <I>MA</I>: 30 minutes before induction. <I>Control</I>: sterile saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-31 19:48:12 +0100" MODIFIED_BY="[Empty name]">
<P>IP= 4; IC= 6</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-13 19:22:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perez-2005">
<CHAR_METHODS MODIFIED="2011-11-13 19:22:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: prospective, randomised. <I>Allocation</I>: computer. <I>Blinding</I>: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-31 19:48:53 +0100" MODIFIED_BY="[Empty name]">
<P>350 patients: 174 P / 176 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 18:47:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hernioplasty</I>
</P>
<P>
<I>ATB:</I> cefazolin 1 gr IV. <I>MA:</I> before incision. <I>Control:</I> placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-31 19:50:02 +0100" MODIFIED_BY="[Empty name]">
<P>IP=4; IC=7</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-02 17:43:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pessaux-2006">
<CHAR_METHODS MODIFIED="2011-11-13 19:21:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: prospective, randomised. <I>Allocation</I>: NM. <I>Blinding</I>: No.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-31 19:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>2402 patients: 2008 P / 394 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 19:21:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Herniorrhaphy</I>
</P>
<P>
<I>ATB:</I> several, IV. MA: induction. <I>Control:</I> not treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-31 19:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>IP=68; IC=20</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-02 17:43:10 +0100" MODIFIED_BY="[Empty name]">
<P>Additional information provided by the first author.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-13 19:22:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Platt-1990">
<CHAR_METHODS MODIFIED="2011-11-13 19:22:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: multicenter, prospective, randomised. <I>Allocation</I>: computer. <I>Blinding</I>: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-31 19:52:15 +0100" MODIFIED_BY="[Empty name]">
<P>612 patients: 301 P / 311 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 19:22:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Herniorrhaphy</I>
</P>
<P>
<I>ATB:</I> cefonicid 1 g IV. <I>MA:</I> 90 minutes before surgery. <I>Control:</I> placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-31 19:55:41 +0100" MODIFIED_BY="[Empty name]">
<P>IP= 4; IC= 6</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-13 18:55:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shankar-2010">
<CHAR_METHODS MODIFIED="2011-11-13 18:55:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: prospective randomised. <I>Allocation</I>: sealed envelope. <I>Blinding</I>: No</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-31 19:56:19 +0100" MODIFIED_BY="[Empty name]">
<P>334 patients: 172 P / 162 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 18:54:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hernioplasty</I>
</P>
<P>
<I>ATB:</I> cefazolin 1 gr IV. <I>MA:</I> induction. Control: sterile saline.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-31 19:57:15 +0100" MODIFIED_BY="[Empty name]">
<P>IP=12; IC=17</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-13 19:23:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taylor-1997">
<CHAR_METHODS MODIFIED="2011-11-13 19:22:57 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: multicenter, prospective, randomised. <I>Allocation</I>: computer. <I>Blinding</I>: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-31 20:25:40 +0100" MODIFIED_BY="[Empty name]">
<P>269 patients: 136 P / 133 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 19:23:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Herniorrhaphy</I>
</P>
<P>
<I>ATB:</I> Amoxicillin-clavulanic 1,2 gr IV. MA: before the incision. <I>Control:</I> placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-31 20:26:34 +0100" MODIFIED_BY="[Empty name]">
<P>IP=1; IC= 12</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-13 19:05:12 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-13 19:23:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tzovaras-2007">
<CHAR_METHODS MODIFIED="2011-11-13 19:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: prospective randomised. <I>Allocation</I>: computer. <I>Blinding</I>: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-31 20:27:38 +0100" MODIFIED_BY="[Empty name]">
<P>386 patients: 193 P / 193 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 19:23:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hernioplasty</I>
</P>
<P>
<I>ATB:</I> amoxicillin-clavulanic 1,2 gr. MA: not standardised. <I>Control:</I> sterile saline.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-31 20:28:58 +0100" MODIFIED_BY="[Empty name]">
<P>IP= 5; IC= 9</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-13 19:10:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yerdel-2001">
<CHAR_METHODS MODIFIED="2011-11-13 19:09:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study</I>: prospective, randomised. <I>Allocation</I>: computer. <I>Blinding</I>: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-31 20:29:36 +0100" MODIFIED_BY="[Empty name]">
<P>269 patients: 136 P / 133 C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-13 19:07:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Hernioplasty</I>
</P>
<P>
<I>ATB:</I> Ampicilln-sulbactam 1,5 gr IV. <I>MA:</I> before the incision. <I>Control:</I> placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-31 20:30:18 +0100" MODIFIED_BY="[Empty name]">
<P>IP= 1; IC= 12</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-13 19:10:05 +0100" MODIFIED_BY="[Empty name]">
<P>Because of the high rate of wound infections, the code was broken after the discharge of patient 280 (140 patients in each group).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>P = prophylaxis group, C = control group, IP = infected with prophylaxis, IC = infected without prophylaxis, NM = not mentioned, ATB = antibiotic, MA = timing of prophylaxis administration</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-01-04 13:28:13 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-11-13 19:24:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abo_x002d_Rahmy-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 19:24:34 +0100" MODIFIED_BY="[Empty name]">
<P>NOT RANDOMIZED. A total of 1524 consecutive hernia patients, divided in 3 groups: A) 606 with ceftriaxone, B) 408 with pefloxacine, C) 510 with several cefalosporins or quinolones different from the A and B groups. One single patient with infection was observed (0,06%).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-13 19:24:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Angio-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 19:24:38 +0100" MODIFIED_BY="[Empty name]">
<P>UNCONTROLLED TRIAL. Single arm with antibiotic prophylaxis. 112 patients submitted to prosthetic hernioplasty by anterior approach (94 cases) and by transabdominal preperitoneal laparoscopy (18 cases), received levofloxacin 500 mg IV 30 minutes before the surgical operation and 500 mg os in seven days following. Infection rate was zero.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barreca-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>RETROSPECTIVE. Study developed in two hospitals, one arm by hospital. Administers cefotaxime 2 gr IV 30' before surgery. A total of 147 patients, 63 with prophylaxis and 84 without; 87% with hernioplasty . Both hospitals show an infection rate of zero.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-13 19:24:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dazzi-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 19:24:47 +0100" MODIFIED_BY="[Empty name]">
<P>UNCONTROLLED TRIAL. Single arm with antibiotic prophylaxis. Patients with several pathologies; can be identified 189 hernia patients (100 herniorraphy, 89 hernioplasty), prophylaxis with teicoplanin. Infection rate: zero.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-13 19:25:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deysine-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 19:25:06 +0100" MODIFIED_BY="[Empty name]">
<P>UNCONTROLLED TRIAL. Single arm with antibiotic prophylaxis in ventral and inguinal herniorrhaphies. The patients received cefazolin 1 hour before surgery plus frequent wound irrigations with a solution of 80 mg of gentamycin sulphate dissolved in 250 ml of normal saline solution. Infection rate: 0.11% in over 4.000 herniorrhaphies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dixon-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>DOES NOT INCLUDE HERNIA PATOHOLOGY.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Escart_x00ed_n-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>RETROSPECTIVE. Study with 475 patients. In 277 prosthetic material is used: 144 with antibiotic prophylaxis (3 infected) and 133 with placebo (10 infected). In 198 patients no prosthetic material was used: 14 with antibiotic prophylaxis (0 infected) and 184 with placebo (13 infected). They recommend prophylaxis when using prosthetic material.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-13 19:25:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Esposito-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 19:25:13 +0100" MODIFIED_BY="[Empty name]">
<P>INCOMPLETE DATA. Prospective randomised trial. The objective of the study is prophylaxis in hernia repair and breast surgery. There were 350 patients underwent to hernia repair, 168 y 162 patients in the prophylaxis and placebo group. Data of infected patients undergoing hernia repair are not provided by the author.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-13 19:25:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gervino-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 19:25:18 +0100" MODIFIED_BY="[Empty name]">
<P>UNCONTROLLED TRIAL. Single arm with antibiotic prophylaxis. 1254 patients intervened with prosthetic material, received ceftriaxone IV 2 gr before surgery. Infection rate assessed retrospectively: zero .</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-06 11:45:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gilbert-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-06 11:45:07 +0200" MODIFIED_BY="[Empty name]">
<P>RETROSPECTIVE. Large series, that presents methodologic handicaps. Infection rate: a)primary herniorraphy: 1.1% without prophylaxis and 1.3% with prophylaxis; b) primary hernioplasty: 0.34% without prophylaxis and 0.98% with prophylaxis; c) herniorraphy for recurrent hernia: 0% in both groups; d) hernioplasty for recurrent hernia: 2.2% without prophylaxis and 0.43% with prophylaxis. They do not recommend antibiotic prophylaxis on surgery for hernia repair.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gilmore-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>PROPHYLAXIS WITH ANTISEPTIC TREATMENT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-06 11:45:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hair-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-06 11:45:26 +0200" MODIFIED_BY="[Empty name]">
<P>RETROSPECTIVE. Multicentric trial where 71% of 5.506 patients received antibiotic prophylaxis. Global infection rate: 8%, without significant differences between patients with and without antibiotic prophylaxis (RR 0.9, IC95% 0.7 - 1.1). Individualized infection rate is not provided for each group. They recommend not to administer antibiotic prophylaxis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hedawoo-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>REVIEW. In a study of clean surgical techniques, 134 hydroceles and hernias are included, without antibiotic prophylaxis. Infection rate 3,6%.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Houck-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>INCOMPLETE DATA. The objective of the study is prophylaxis in incisional hernia and patients with inguinal hernia constitute the control group. Data for these patients is not provided.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Karran-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>INCOMPLETE STUDY. No results provided.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-13 19:25:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuzu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 19:25:38 +0100" MODIFIED_BY="[Empty name]">
<P>BOTH STUDY ARMS RECEIVED PROPHYLAXIS. A total of 408 patient were enrolled in a prospective randomised study which compare the efficacy of oral versus parenteral prophylactic amoxicillin-clavulanic acid in open mesh hernia repair. Infections rates: 0,5% and 1,5%, respectively.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-13 19:25:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lewis-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 19:25:44 +0100" MODIFIED_BY="[Empty name]">
<P>INCOMPLETE DATA. Prospective, randomised, well-designed study on clean surgical techniques. A total of 165 patients had hernia repair (86 receiving cefotaxime 2 gr IV prior to surgery and 79 receiving placebo), but there's no information on the number of infections on these patients. INCOMPLETE DATA. Prospective, randomised, well-designed study on clean surgical techniques. A total of 165 patients had hernia repair (86 receiving cefotaxime 2 gr IV prior to surgery and 79 receiving placebo), but there's no information on the number of infections on these patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-13 19:25:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Massaioli-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 19:25:49 +0100" MODIFIED_BY="[Empty name]">
<P>UNCONTROLLED TRIAL. Single arm of antibiotic prophylaxis with vancomycin on patients with incisional hernia or inguinal hernia repair with prosthetic material. Infection rate: 1/40 patients (2,5%).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-13 19:26:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Musella-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 19:26:20 +0100" MODIFIED_BY="[Empty name]">
<P>BOTH STUDY ARMS RECEIVED PROPHYLAXIS. Both groups received prophylaxis with a systemic antibiotic. Intervention group, additionally, is administered a collagen sponge impregnated with gentamicin. Infection rate: 6/284 patients on control group and 1/293 patients on prophylaxis group<BR/>(OR=0.16; IC95% 0.02-1.33).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-13 19:26:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nundy-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 19:26:25 +0100" MODIFIED_BY="[Empty name]">
<P>INCOMPLETE DATA. Study on clean surgical techniques, not possible to obtain data of patients with hernia repair. Prophylaxis is penicillin 2 to 12 hours prior to the surgery.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-04 13:28:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Platt-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-04 13:28:13 +0100" MODIFIED_BY="[Empty name]">
<P>NOT RANDOMISED. Study developed with the patients not included on the published 1990 trial. A total of 1221 patients with herniorraphy. Infection rate: 2/239 patients on prophylaxis, and 15/982 patients without prophylaxis (OR 0.54; IC95% 0,06-2,07; P= 0.4). They recommend prophylaxis only for high risk patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-30 19:39:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Praveen-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-30 19:39:24 +0100" MODIFIED_BY="[Empty name]">
<P>BOTH STUDY ARMS RECEIVED PROPHYLAXIS. A single blinded prospective randomised trial with locally applied gentamicin against systemic gentamicin in 202 patients underwent to Lichtenteins tension free repair. There were seven SSI in each arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-13 19:26:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reggiori-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 19:26:45 +0100" MODIFIED_BY="[Empty name]">
<P>BOTH STUDY ARMS RECEIVED PROPHYLAXIS. Prospective randomised trial, well designed, administering a single dose of ampicillin 2 gr IV at induction of anaesthesia in one arm and fortified procaine 1,2 megaunits/24 hr IM daily for seven days starting about 3 hr after surgery on the other arm. Infection rate: 0/123 patients on ampicillin and 8/106 patients on penicillin (OR = 0,05; IC 95% 0,0 - 0,82).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-13 19:26:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ryan-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 19:26:49 +0100" MODIFIED_BY="[Empty name]">
<P>NOT RANDOMISED. Non homogeneous groups: control group with majority of patients on local anaesthesia, prophylaxis group with majority of patients on general anaesthesia. Children are included on the trial. Control group is sequential in time to the intervention group. Each group is intervened in a different hospital. Infection rate: 82/5335 patients in control group, 2/1183 patients in penicillin group. (OR 0.11; IC95% 0.03-0.44)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-06 11:49:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shwed-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-06 11:49:19 +0200" MODIFIED_BY="[Empty name]">
<P>BOTH STUDY ARMS RECEIVED PROPHYLAXIS. Study of several surgical techniques to evaluate the efficacy of a new antibiotic compared to an already established one. A total of 128 patients, 5 of whom had hernia repair.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spallitta-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>UNCONTROLLED TRIAL. Single arm of 100 patients receiving antibiotic prophylaxis and prosthetic material.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sultan-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>BOTH STUDY ARMS RECEIVED PROPHYLAXIS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-13 19:27:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Terzi-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-13 19:27:00 +0100" MODIFIED_BY="[Empty name]">
<P>BOTH STUDY ARMS RECEIVED PROPHYLAXIS. Prospective randomised study which compare the efficacy of oral ciprofloxacin versus parenteral cefazolin in open mesh hernia repair. Infections rates: 2% in both arms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van_x002d_Damme-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>NOT RANDOMISED. Technical review using different types of antibiotics, both intravenous and topical.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vara-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>MISBALANCES IN TREATMENT BETWEEN GROUPS: Patients with hernioplasty received prophylaxis while patients with herniorraphy received placebo . Patients infected: 2/141 patients on prophylaxis and 9 /137 patients on placebo. They recommend antibiotic prophylaxis to all patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wantz-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>RETROSPECTIVE SERIE. Serie of 1076 patients followed for 6 years. Administers local anaesthesia and prosthetic material (Lichtentein and Gilbert), without antibiotic prophylaxis. One single patient with infection (0,09%).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-01-04 13:27:51 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-01-04 13:27:33 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 19:03:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andersen-1980">
<DESCRIPTION>
<P>Quote: "A triple-blind, random-allocation design was used."</P>
<P>Comment: Information not provided about sequence generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-04 13:26:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aufenacker-2004">
<DESCRIPTION>
<P>Quote: "A pharmacist carried out randomizations according to a computer generated list in blocks of 10 patients with stratification for each hospital."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 16:56:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Celdran-2004">
<DESCRIPTION>
<P>Quote: "A list of random numbers was generated to assign the treatment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 16:37:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ergul-2011">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 15:39:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Evans-1973">
<DESCRIPTION>
<P>Toss of a coin</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 16:46:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jain-2008">
<DESCRIPTION>
<P>Computer generated code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 17:03:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lazorthes-1992">
<DESCRIPTION>
<P>Quote: "Two groups of 162 patients were randomly allotted to receive ..."</P>
<P>Information not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 17:15:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morales-2000">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 17:19:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oteiza-2004">
<DESCRIPTION>
<P>Computer generated list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 17:27:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Othman-2011">
<DESCRIPTION>
<P>Computer generated list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 17:37:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Perez-2005">
<DESCRIPTION>
<P>Computer generated list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-04 13:26:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pessaux-2006">
<DESCRIPTION>
<P>Quote: "A database was established from 3 prospective, randomised, multicenter studies led by the French Associations for Surgical Research on antibiotic prophylaxis in abdominal noncolorectal surgery".</P>
<P>Comment: Probably yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 18:49:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Platt-1990">
<DESCRIPTION>
<P>Computer generated list. in blocks of 10.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-04 13:27:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shankar-2010">
<DESCRIPTION>
<P>Quote: "...were randomised into antibiotic group and control group by sealed envelope method on the day before the surgery."</P>
<P>Comment: Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 19:12:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taylor-1997">
<DESCRIPTION>
<P>Computer generated code in blocks of four.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 19:34:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tzovaras-2007">
<DESCRIPTION>
<P>Code numbers generated by the Arcus Quiqstat randomisation program using numbered sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 19:39:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yerdel-2001">
<DESCRIPTION>
<P>Computer-generated code by a resident who also prepared the sealed antibiotic or placebo syringes. He was unaware of the research in progress and was never involved in surgery, data collection or patient follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-01-04 13:27:51 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 19:04:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andersen-1980">
<DESCRIPTION>
<P>Quote: "...were assigned at the end of the operation to one of the following four regimens:..."</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 16:56:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aufenacker-2004">
<DESCRIPTION>
<P>Quote: "A pharmacist prepared the trial medication under laminar airflow condition and it was packed in nontransparent material to exclude optical differences."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 19:06:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Celdran-2004">
<DESCRIPTION>
<P>Quote: "A prospective, double-blind trial was performed ..."</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-04 13:26:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ergul-2011">
<DESCRIPTION>
<P>Quote: "The anaesthesiologist administered the trial medication (antibiotic or sterile saline in coded syringes..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 16:57:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Evans-1973">
<DESCRIPTION>
<P>Quote: "To avoid bias the details were entered not in the patients' case notes but on punch cards which were kept separately and analysed manually."</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 16:57:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jain-2008">
<DESCRIPTION>
<P>Quote: "Randomization was performed by a computer-generated code by a junior resident who was not involved in the surgery, data compilation or patient follow-up. The same resident also prepared the antibiotic or the placebo syringes containing normal saline."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 17:04:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lazorthes-1992">
<DESCRIPTION>
<P>Not mentioned.</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 17:15:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morales-2000">
<DESCRIPTION>
<P> Comment: Probably yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 17:22:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Oteiza-2004">
<DESCRIPTION>
<P>Information not provided.</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 17:30:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Othman-2011">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 17:34:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Perez-2005">
<DESCRIPTION>
<P>Probably yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 18:25:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pessaux-2006">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 18:47:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Platt-1990">
<DESCRIPTION>
<P>Probably yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 18:58:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shankar-2010">
<DESCRIPTION>
<P>Comment: Randomization on the day before the surgery. Probably not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 19:12:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Taylor-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-04 13:27:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tzovaras-2007">
<DESCRIPTION>
<P>Quote: " The list with code numbers generated by the Arcus Quiqstat randomisation program was kept by a secretary, who was not involved in the treatment of the patients at any stage and was opened at the end of the trial for analysis of the results".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-02 19:37:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yerdel-2001">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-01-04 13:27:33 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 16:02:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andersen-1980">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 16:20:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aufenacker-2004">
<DESCRIPTION>
<P>Probably yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 16:28:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Celdran-2004">
<DESCRIPTION>
<P>Not mentioned.</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 16:44:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ergul-2011">
<DESCRIPTION>
<P>Comment: Probably yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 15:50:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Evans-1973">
<DESCRIPTION>
<P>Concealment not mentioned.</P>
<P>Comment: Probably not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 16:50:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jain-2008">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 17:04:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lazorthes-1992">
<DESCRIPTION>
<P>Not mentioned.</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 17:16:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morales-2000">
<DESCRIPTION>
<P>Quote: "La administración de la solución (antibiótico o placebo) fue realizada por la enfermera circulante, no informando del contenido de la solución a ninguno de los dos cirujanos implicados en la intervención."</P>
<P>Comment: Yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 17:23:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Oteiza-2004">
<DESCRIPTION>
<P>Information not provided.</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 17:30:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Othman-2011">
<DESCRIPTION>
<P>Quote: "Randomization and preparation of drug and placebo were controlled by a surgery clinic nurse without the previous knowledge of the patient or surgeon."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 17:36:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Perez-2005">
<DESCRIPTION>
<P>Quote: "Senior surgical residents or consultants, blinded to the study group, performed all operations.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 17:44:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pessaux-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-04 13:27:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Platt-1990">
<DESCRIPTION>
<P>Quote: "Cefonicid and placebo were supplied in identical numbered vials. The treatment codes were not known by anyone at the participating centres, unless the sealed, opaque label attached to each vial was opened".</P>
<P>Comment: Yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 18:59:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shankar-2010">
<DESCRIPTION>
<P>Not mentioned.</P>
<P>Comment: Probably not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-04 13:27:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Taylor-1997">
<DESCRIPTION>
<P>Quote in abstract: "We have conducted a randomised multicenter, double-blind prospective trial...".</P>
<P>Comment: Information about concealment not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 19:35:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tzovaras-2007">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-02 19:38:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yerdel-2001">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-12-02 19:29:39 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-02 16:04:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andersen-1980">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-02 16:20:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aufenacker-2004">
<DESCRIPTION>
<P>Probably yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-02 16:31:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Celdran-2004">
<DESCRIPTION>
<P>Not mentioned.</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-02 16:45:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ergul-2011">
<DESCRIPTION>
<P>Comment: Probably yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-02 15:51:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Evans-1973">
<DESCRIPTION>
<P>Not mentioned.</P>
<P>Comment: Probably not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-13 18:30:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jain-2008">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-02 17:05:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lazorthes-1992">
<DESCRIPTION>
<P>Not mentioned.</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-02 17:17:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morales-2000">
<DESCRIPTION>
<P>Comment: Yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-02 17:23:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Oteiza-2004">
<DESCRIPTION>
<P>Information not provided.</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-13 18:44:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Othman-2011">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-02 17:36:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Perez-2005">
<DESCRIPTION>
<P>Yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-13 18:49:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pessaux-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-02 18:53:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Platt-1990">
<DESCRIPTION>
<P>Quote: " None of the personnel at the data processing or coordinating center knew the treatment codes, and the codes were not revealed to the patients or medical personnel until the last one completed the evaluation."</P>
<P>Comment: Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-02 18:59:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shankar-2010">
<DESCRIPTION>
<P>Not mentioned.</P>
<P>Comment: Probably not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-02 19:29:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Taylor-1997">
<DESCRIPTION>
<P>Comment: Information about concealment not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-13 19:00:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tzovaras-2007">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-13 19:08:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yerdel-2001">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2011-12-02 19:00:35 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-02 16:04:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andersen-1980">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-02 16:56:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aufenacker-2004">
<DESCRIPTION>
<P>Quote: "In most cases, the surgeon who performed the operation did not perform the follow-up."</P>
<P>Comment: Probably yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-02 16:56:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Celdran-2004">
<DESCRIPTION>
<P>Quote: "All patients were examined 1 week, 1, 3, and 6 months, and 1 and 2 years postoperatively by trained impartial surgeon."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-02 16:57:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ergul-2011">
<DESCRIPTION>
<P>Quote: "The surgeon who performed the follow-up frequently was not the surgeon who performed the operation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-02 15:51:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Evans-1973">
<DESCRIPTION>
<P>Not mentioned.</P>
<P>Comment: Probably not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-02 16:57:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jain-2008">
<DESCRIPTION>
<P>Quote: "The surgeon who performed the operation was not allowed to follow up their patient."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-02 17:05:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lazorthes-1992">
<DESCRIPTION>
<P>Not mentioned.</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-02 17:17:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morales-2000">
<DESCRIPTION>
<P>Quote: "En el seguimiento postoperatorio, los cirujanos, las enfermeras de planta y la de consulta externa desconocían la solución administrada al paciente."</P>
<P>Comment: Yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-02 17:23:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Oteiza-2004">
<DESCRIPTION>
<P>Not mentioned.</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-02 17:31:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Othman-2011">
<DESCRIPTION>
<P>Not mentioned</P>
<P>Comment: Probably not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-02 17:37:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Perez-2005">
<DESCRIPTION>
<P>Quote: " All incisions were carefully reexamined by an independent surgeon blinded to the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-13 18:50:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pessaux-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-13 18:51:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Platt-1990">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-02 19:00:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shankar-2010">
<DESCRIPTION>
<P>Quoted: "Follow was done by residents who where blinded to the drug used."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-13 18:58:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taylor-1997">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-13 19:00:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tzovaras-2007">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-13 19:08:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yerdel-2001">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-11-13 18:28:12 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-11-13 18:28:12 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2012-01-04 13:28:45 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-01-04 13:28:45 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-11-12 12:27:38 +0100" MODIFIED_BY="[Empty name]">Numbers need to treat (NNT) with 95% CI for each study, for the herniorrhaphies and hernioplasties sub-groups, and for pooled results.</TITLE>
<TABLE COLS="8" ROWS="23">
<TR>
<TH ALIGN="CENTER">
<P>AUTHOR</P>
</TH>
<TH ALIGN="CENTER">
<P>INFECTED PROPHYLAXIS</P>
</TH>
<TH ALIGN="CENTER">
<P>TOTAL PROPHYLAXIS</P>
</TH>
<TH ALIGN="CENTER">
<P>%</P>
</TH>
<TH ALIGN="CENTER">
<P>INFECTED CONTROL</P>
</TH>
<TH ALIGN="CENTER">
<P>TOTAL CONTROL</P>
</TH>
<TH ALIGN="CENTER">
<P>%</P>
</TH>
<TH ALIGN="CENTER">
<P>NNT CI 95%</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Andersen-1980" TYPE="STUDY">Andersen 1980</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>5</P>
</TD>
<TD>
<P>137</P>
</TD>
<TD>
<P>3.65</P>
</TD>
<TD ALIGN="RIGHT">
<P>6</P>
</TD>
<TD>
<P>150</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>285 (20 to infinite to NNTH 24)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Evans-1973" TYPE="STUDY">Evans 1973</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>2.08</P>
</TD>
<TD ALIGN="RIGHT">
<P>2</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>4.08</P>
</TD>
<TD>
<P>50 (11 to infinite to NNTH 20)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lazorthes-1992" TYPE="STUDY">Lazorthes 1992</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>0</P>
</TD>
<TD>
<P>155</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD ALIGN="RIGHT">
<P>7</P>
</TD>
<TD>
<P>153</P>
</TD>
<TD>
<P>4.57</P>
</TD>
<TD>
<P>22 (12 , 79)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pessaux-2006" TYPE="STUDY">Pessaux 2006</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>68</P>
</TD>
<TD>
<P>2008</P>
</TD>
<TD>
<P>3.38</P>
</TD>
<TD ALIGN="RIGHT">
<P>20</P>
</TD>
<TD>
<P>394</P>
</TD>
<TD>
<P>5.07</P>
</TD>
<TD>
<P>59 (25 to infinite to NNTH 162)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Platt-1990" TYPE="STUDY">Platt 1990</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>4</P>
</TD>
<TD>
<P>301</P>
</TD>
<TD>
<P>1.32</P>
</TD>
<TD ALIGN="RIGHT">
<P>6</P>
</TD>
<TD>
<P>311</P>
</TD>
<TD>
<P>1.9</P>
</TD>
<TD>
<P>167 (38 to infinite to NNTH 71)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Taylor-1997" TYPE="STUDY">Taylor 1997</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>25</P>
</TD>
<TD>
<P>283</P>
</TD>
<TD>
<P>8.8</P>
</TD>
<TD ALIGN="RIGHT">
<P>25</P>
</TD>
<TD>
<P>280</P>
</TD>
<TD>
<P>8.9</P>
</TD>
<TD>
<P>1057 (20 to infinite to NNTH 21)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>
SUBTOTAL HR
</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>
103
</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>
2932
</I>
</P>
</TD>
<TD>
<P>
<I>
3.5
</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>
66
</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>
1337
</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>
4.9
</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>
70 (36 , 1181)
</I>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="RIGHT">
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="RIGHT">
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Aufenacker-2004" TYPE="STUDY">Aufenacker 2004</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>8</P>
</TD>
<TD>
<P>475</P>
</TD>
<TD>
<P>1.68</P>
</TD>
<TD ALIGN="RIGHT">
<P>9</P>
</TD>
<TD>
<P>472</P>
</TD>
<TD>
<P>1.9</P>
</TD>
<TD>
<P>449 (52 to infinite to NNTH 68)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Celdran-2004" TYPE="STUDY">Celdran 2004</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>0</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD ALIGN="RIGHT">
<P>4</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>8.16</P>
</TD>
<TD>
<P>12 (6 , 201)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ergul-2011" TYPE="STUDY">Ergul 2011</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>5</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD ALIGN="RIGHT">
<P>7</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>50 (12 to infinite to NNTH 22</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jain-2008" TYPE="STUDY">Jain 2008</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>1.6</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>1.6</P>
</TD>
<TD>
<P>infinite</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Morales-2000" TYPE="STUDY">Morales 2000</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>4</P>
</TD>
<TD>
<P>237</P>
</TD>
<TD>
<P>1.68</P>
</TD>
<TD ALIGN="RIGHT">
<P>6</P>
</TD>
<TD>
<P>287</P>
</TD>
<TD>
<P>2.09</P>
</TD>
<TD>
<P>248 (37 to infinite to NNTH 52)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Oteiza-2004" TYPE="STUDY">Oteiza 2004</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD>
<P>124</P>
</TD>
<TD>
<P>0.8</P>
</TD>
<TD ALIGN="RIGHT">
<P>0</P>
</TD>
<TD>
<P>123</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>-124 (130 to infinite to NNTH 42)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Othman-2011" TYPE="STUDY">Othman 2011</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>4</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD ALIGN="RIGHT">
<P>6</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>12.5</P>
</TD>
<TD>
<P>22 (6 to infinite to NNTH 13)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Perez-2005" TYPE="STUDY">Perez 2005</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>3</P>
</TD>
<TD>
<P>174</P>
</TD>
<TD>
<P>1.72</P>
</TD>
<TD ALIGN="RIGHT">
<P>6</P>
</TD>
<TD>
<P>176</P>
</TD>
<TD>
<P>3.4</P>
</TD>
<TD>
<P>59 (20 to infinite to NNTH 61)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Shankar-2010" TYPE="STUDY">Shankar 2010</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>12</P>
</TD>
<TD>
<P>172</P>
</TD>
<TD>
<P>6.9</P>
</TD>
<TD ALIGN="RIGHT">
<P>17</P>
</TD>
<TD>
<P>162</P>
</TD>
<TD>
<P>10.5</P>
</TD>
<TD>
<P>28 (10 to infinite to NNTH 39)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tzovaras-2007" TYPE="STUDY">Tzovaras 2007</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>5</P>
</TD>
<TD>
<P>193</P>
</TD>
<TD>
<P>2.6</P>
</TD>
<TD ALIGN="RIGHT">
<P>9</P>
</TD>
<TD>
<P>193</P>
</TD>
<TD>
<P>4.6</P>
</TD>
<TD>
<P>48 (17 to infinite to NNTH 61)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yerdel-2001" TYPE="STUDY">Yerdel 2001</LINK>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
<TD>
<P>136</P>
</TD>
<TD>
<P>0.7</P>
</TD>
<TD ALIGN="RIGHT">
<P>12</P>
</TD>
<TD>
<P>133</P>
</TD>
<TD>
<P>9.02</P>
</TD>
<TD>
<P>12 (7 , 31)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>
SUBTOTAL HP
</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
44
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>
1771
</I>
</P>
</TD>
<TD>
<P>
<I>
2.48
</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>
77
</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>
1803
</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>
4.2
</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>
56 (34, 165)
</I>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="RIGHT">
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="RIGHT">
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>
<I>
TOTAL
</I>
</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>
<I>
147
</I>
</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>
<I>
4703
</I>
</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>
<I>
3.1
</I>
</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>
<I>
143
</I>
</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>
<I>
3140
</I>
</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>
<I>
4.5
</I>
</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>
<I>
70 (43, 183)
</I>
</B>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>(NNTH= number needed to treat-harm).</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-11-12 13:45:52 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-11-12 13:45:52 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Antibiotic prophylaxis vs Placebo</NAME>
<DICH_OUTCOME CHI2="12.581955917528559" CI_END="0.8179527645211886" CI_START="0.49505984681618365" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6363454803066755" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="143" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.08727177542417222" LOG_CI_START="-0.30534229688268266" LOG_EFFECT_SIZE="-0.19630703615342746" METHOD="MH" MODIFIED="2011-11-12 13:45:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7030425916051384" P_Q="0.3419932925228786" P_Z="4.175773657294408E-4" Q="0.902945390646404" RANDOM="NO" SCALE="448.57070811727135" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4703" TOTAL_2="3140" WEIGHT="100.0" Z="3.528718308180161">
<NAME>Wound infection</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.305086980082965" CI_END="1.0035921685798663" CI_START="0.507724221969217" DF="5" EFFECT_SIZE="0.7138263465063557" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="66" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.0015572636869933024" LOG_CI_START="-0.2943721172401813" LOG_EFFECT_SIZE="-0.14640742677659405" MODIFIED="2011-11-07 20:39:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.506377723978213" P_Z="0.05246041120272935" STUDIES="6" TAU2="0.0" TOTAL_1="2932" TOTAL_2="1337" WEIGHT="50.1942345955617" Z="1.9393362203662092">
<NAME>Herniorraphies</NAME>
<DICH_DATA CI_END="3.0488915728788393" CI_START="0.27106450368498486" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4841419799122116" LOG_CI_START="-0.5669273502286618" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2011-11-07 20:37:11 +0100" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.6174033274018441" STUDY_ID="STD-Andersen-1980" TOTAL_1="137" TOTAL_2="150" VAR="0.3811868686868687" WEIGHT="3.643963901721796"/>
<DICH_DATA CI_END="5.7037255119524755" CI_START="0.0438310012422777" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7561586172097347" LOG_CI_START="-1.358218608537697" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-11-07 20:37:45 +0100" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="1.2419956487401078" STUDY_ID="STD-Evans-1973" TOTAL_1="48" TOTAL_2="49" VAR="1.5425531914893615" WEIGHT="1.2796373287078338"/>
<DICH_DATA CI_END="1.109512773014082" CI_START="0.003555491446835637" EFFECT_SIZE="0.06280814576634512" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.04513230631350004" LOG_CI_START="-2.4491003617703186" LOG_EFFECT_SIZE="-1.2019840277284093" MODIFIED="2011-11-07 20:38:32 +0100" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="1.4651246158832663" STUDY_ID="STD-Lazorthes-1992" TOTAL_1="155" TOTAL_2="153" VAR="2.146590140067089" WEIGHT="4.967761577101393"/>
<DICH_DATA CI_END="1.0923046732713817" CI_START="0.39332702467665065" EFFECT_SIZE="0.6554639175257732" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="20" LOG_CI_END="0.03834379172522745" LOG_CI_START="-0.405246213100209" LOG_EFFECT_SIZE="-0.1834512106874908" MODIFIED="2011-11-07 20:39:11 +0100" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.26056696464039875" STUDY_ID="STD-Pessaux-2006" TOTAL_1="2008" TOTAL_2="394" VAR="0.0678951430619108" WEIGHT="21.329933611727828"/>
<DICH_DATA CI_END="2.450556877653618" CI_START="0.19126674848406397" EFFECT_SIZE="0.6846240179573513" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3892647869810475" LOG_CI_START="-0.718360525033263" LOG_EFFECT_SIZE="-0.16454786902610777" MODIFIED="2011-11-07 20:39:35 +0100" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.6506245911109264" STUDY_ID="STD-Platt-1990" TOTAL_1="301" TOTAL_2="311" VAR="0.42331235855826016" WEIGHT="3.8449177933608656"/>
<DICH_DATA CI_END="1.7665950870868414" CI_START="0.5529730051938893" EFFECT_SIZE="0.9883720930232558" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.24713701832660795" LOG_CI_START="-0.25729606938515803" LOG_EFFECT_SIZE="-0.005079525529274998" MODIFIED="2011-11-07 20:39:57 +0100" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="0.29630649270594633" STUDY_ID="STD-Taylor-1997" TOTAL_1="283" TOTAL_2="280" VAR="0.08779753761969904" WEIGHT="15.128020382941992"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.690800036940436" CI_END="0.8126605978024336" CI_START="0.38349902762126464" DF="10" EFFECT_SIZE="0.5582602878974546" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="77" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.09009079669089565" LOG_CI_START="-0.4162357328864591" LOG_EFFECT_SIZE="-0.25316326478867734" MODIFIED="2011-11-12 12:41:18 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6590101359281069" P_Z="0.0023441683203974605" STUDIES="11" TAU2="0.0" TOTAL_1="1771" TOTAL_2="1803" WEIGHT="49.8057654044383" Z="3.0427630548699267">
<NAME>Hernioplasties</NAME>
<DICH_DATA CI_END="2.3039416815364997" CI_START="0.33709452135503665" EFFECT_SIZE="0.8812752795622175" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.3624714818225989" LOG_CI_START="-0.4722483058136795" LOG_EFFECT_SIZE="-0.05488841199554029" MODIFIED="2011-11-07 20:40:19 +0100" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.49031853518713764" STUDY_ID="STD-Aufenacker-2004" TOTAL_1="475" TOTAL_2="472" VAR="0.24041226594806034" WEIGHT="5.860574515021967"/>
<DICH_DATA CI_END="1.9109378695050416" CI_START="0.005244552668390111" EFFECT_SIZE="0.1001100110011001" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.28124656702897266" LOG_CI_START="-2.2802915488307205" LOG_EFFECT_SIZE="-0.9995224909008739" MODIFIED="2011-11-07 20:40:39 +0100" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="1.5046601690741548" STUDY_ID="STD-Celdran-2004" TOTAL_1="50" TOTAL_2="49" VAR="2.264002224398264" WEIGHT="2.9710728403243056"/>
<DICH_DATA CI_END="2.281801002308425" CI_START="0.21428158426150298" EFFECT_SIZE="0.6992481203007519" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3582777665643218" LOG_CI_START="-0.6690151513906232" LOG_EFFECT_SIZE="-0.15536869241315066" MODIFIED="2011-11-07 20:41:30 +0100" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.6034369451886913" STUDY_ID="STD-Ergul-2011" TOTAL_1="100" TOTAL_2="100" VAR="0.3641361468186596" WEIGHT="4.390585419590363"/>
<DICH_DATA CI_END="16.365882707597123" CI_START="0.06110272313853228" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2139394343125285" LOG_CI_START="-1.2139394343125285" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-07 20:42:09 +0100" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="1.426148065624585" STUDY_ID="STD-Jain-2008" TOTAL_1="60" TOTAL_2="60" VAR="2.0338983050847457" WEIGHT="0.6492344354782741"/>
<DICH_DATA CI_END="2.883097923373615" CI_START="0.22421201739588498" EFFECT_SIZE="0.804005722460658" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.45985939329302405" LOG_CI_START="-0.6493411136462647" LOG_EFFECT_SIZE="-0.09474086017662034" MODIFIED="2011-11-07 20:42:31 +0100" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.6515498684071993" STUDY_ID="STD-Morales-2000" TOTAL_1="237" TOTAL_2="287" VAR="0.4245172310214388" WEIGHT="3.5229515104099907"/>
<DICH_DATA CI_END="74.36041973731885" CI_START="0.12103213015462883" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.871341832539976" LOG_CI_START="-0.9170993231006508" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-07 20:42:52 +0100" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="1.6379441378296367" STUDY_ID="STD-Oteiza-2004" TOTAL_1="124" TOTAL_2="123" VAR="2.682860998650472" WEIGHT="0.32746764460513317"/>
<DICH_DATA CI_END="2.3072871635507433" CI_START="0.16058269764966637" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.36310164991090005" LOG_CI_START="-0.7943012505896098" LOG_EFFECT_SIZE="-0.21559980033935483" MODIFIED="2011-11-07 20:43:45 +0100" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.6798641929907568" STUDY_ID="STD-Othman-2011" TOTAL_1="50" TOTAL_2="48" VAR="0.46221532091097306" WEIGHT="3.7188938953719197"/>
<DICH_DATA CI_END="2.0199128211060557" CI_START="0.12232437481916691" EFFECT_SIZE="0.49707602339181284" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3053326258181046" LOG_CI_START="-0.9124869951738269" LOG_EFFECT_SIZE="-0.3035771846778611" MODIFIED="2011-11-07 20:44:30 +0100" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.7153532736750078" STUDY_ID="STD-Perez-2005" TOTAL_1="174" TOTAL_2="176" VAR="0.5117303061575507" WEIGHT="3.8708834719653806"/>
<DICH_DATA CI_END="1.3849259911312686" CI_START="0.29548410423194027" EFFECT_SIZE="0.6397058823529411" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.14142656581772867" LOG_CI_START="-0.5294658773209268" LOG_EFFECT_SIZE="-0.19401965575159902" MODIFIED="2011-11-07 20:45:13 +0100" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.3940855420707996" STUDY_ID="STD-Shankar-2010" TOTAL_1="172" TOTAL_2="162" VAR="0.15530341446923596" WEIGHT="10.753583666908996"/>
<DICH_DATA CI_END="1.6531068511471088" CI_START="0.17884385044484463" EFFECT_SIZE="0.5437352245862884" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.21830092578186283" LOG_CI_START="-0.7475259884967617" LOG_EFFECT_SIZE="-0.26461253135744944" MODIFIED="2011-11-07 20:46:15 +0100" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.5673315103675954" STUDY_ID="STD-Tzovaras-2007" TOTAL_1="193" TOTAL_2="193" VAR="0.32186504265597704" WEIGHT="5.788204082704346"/>
<DICH_DATA CI_END="0.5829271614635403" CI_START="0.009570319127978316" EFFECT_SIZE="0.07469135802469136" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.234385708278234" LOG_CI_START="-2.019073580174128" LOG_EFFECT_SIZE="-1.126729644226181" MODIFIED="2011-11-12 12:41:18 +0100" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="1.0483344902990923" STUDY_ID="STD-Yerdel-2001" TOTAL_1="136" TOTAL_2="133" VAR="1.099005203550658" WEIGHT="7.952313922057621"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-01-04 13:27:52 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-01-04 13:27:52 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-01-04 13:27:52 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-12-02 12:48:46 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2011-12-02 12:48:46 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Antibiotic prophylaxis vs Placebo, outcome: 1.1 Wound infection.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Analisis sensibilidad.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2011-12-02 12:29:53 +0100" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Sensitivity analysis excluding each of the studies and their relationship to main analysis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtAAAAPACAYAAAAc9k6zAACAAElEQVR42uydB5RdxZWuWbOMPTPOhmdjG2cbbMKMbWyMweQMj/jIGR4555yxTQ4mh0cONozSSEhEgUAIBMIYEEIPSWAjD2BAAoPEwEtTb301q9pHVx1Pt472bX3fWmdJvfv2vedW1an6a9feVYslERERERHpNYtZBCIiIiIiCmgREREREQW0iIiIiIgCWkREREREAS0iIiIiooAWEREREVFAWwQiIiIiIgpoEREREREFtIiIiIiIAlpERERERAEtIiIiIqKAFhERERFRQFsEIiIiIiIKaBERERERBbSIiIiIiAJaREREREQBLSIiIiKigBYRERERUUBbBCIiIiIiCmgREREREQW0iIiIiIgCWkREREREAS0iIiIiooAWEREREVFAWwQiIiIiIgpoEREREREFtIiIiIiIAlpERERERAEtIiIiIqKAFhERERFRQFsEIiIiIiIKaBERERERBbSIiIiIiAJaREREREQBLSIiIiKigBYRERERUUBbBCIiIiIiCmgREREREQW0iIiIiIgCWkREREREAS0iIiIiooAWEREREVFAWwQiIiIiIgpoEREREREFtIiIiIiIAlpERERERAEtIiIiIqKAFhERERFRQFsEIiIiIiIKaBERERERBbSIiIiIiAJaREREREQBLSIiIiKigBYRERERUUBbBCIiIiIiCmgREREREQW0iIiIiIgCWkREREREAS0iIiIiooAWEREREVFAWwQiIiIiIgpoEREREREFtIiIiIiIAlpERERERAEtIiIiIqKAFhERERFRQFsEIiIiIiIKaBERERERBbSIiIiIiAJaREREREQBLSIiIiKigBYRERERUUBbBCIiIiIiCmgREREREQW0iIiIiIgCWkREREREAS0iIiIiooAWEREREVFAWwQiIiIiIgpoEREREREFtIiIiIiIAlpERERERAEtIiIiIqKAFhERERFRQFsEIiIiIiIKaBERERERBbSIiIiIiAJaREREREQBLSIiIiKigBYRERERUUBbBCIiIiIiCmgREREREQW0iIiIiIgCWkREREREAS0iIiIiooAWEREREVFAWwQiIiIiIgpoEREREREFtIiIiIiIAlpERERERAEtIiIiIqKAFhERERFRQFsEIiIiIiIKaBERERERBbSIiIiIiAJaREREREQBLSIiIiKigBYRERERUUBbBCIiIiIiCmgREREREQW0iIiIiIgCWkREREREAS0iIiIiooAWEREREVFAWwQiIiIiIgpoEREREREFtLQf/+///b/0f//v//Xy8vLy8vLyCnOhTxTQEor/+I//SBMnTky33npruummm9Ltt9/uFfS67bbb8mVZWEde1tFgvxiTrCfriOuOO+5IN9xwQxo5cmT6t3/7NwW0xOD//J//kzbffPP0mc98Jq211lppzz33THvssUfafffdvYJdu+yyS76sn9h1tOuuu1pHQa/ddtst7bzzztZRG1w77bST/V3Qq9QJdbSgnyXee6+99korrLBCWmmlldKoUaNqeaMV0DLg/K//9b/SJptskrbaaqs0derU7JH2inl99NFH6X//7/9tWVhHXv24Pvzww+w4sCxiX3Pnzs3Pk2UR80LEUkdoiCY+76677soOvhEjRuTnVwEtIQT0f/2v/zVts802adq0aRZIYKZPn157+Uqa4X/+z/+Z/vKXv1gQgfM8XnzxxTRr1iwLI3ho4fjx43OfJzHBUTBu3Lj05z//uZHPGzp0aNp7773Tv/7rvyqgJZaA/m//7b/lwV/i8swzz1hHwcXZU089lf74xz9aGIH7O3I+nIjGBoGEp/EPf/iDhRGUf//3f0//8i//0tiYxGf99//+3xXQooCWvvPCCy+kV155xYIILKCfe+65xjwy0nfwmiHK3njjDQsjuIC+//7705QpUyyMoBAKNWbMmPTyyy8roEUBrYCOzXvvvZc++OADCyIoLDtTR3hmJO4k5913382Dv8R+lt588830/vvvWxhBYWs5wtWIg1ZAiwJaAR1+xk99SdxBH/GMl1Pi1hGT0DoDsDQ/GXWiE3sySh2R6KmAFgW0Ajo0JD8ZXxt7QJk8ebLxtYFhckOYDd5NiQsCaezYsbnPk5gwubnvvvsaCytUQIsCWmrz+9//3joKLqCffPJJ49SD93dPPPGEceptIKCHDx+eE6clJqy2sbWcSYSigFZAh4d9uv/0pz9ZEIEFNImer732moURFDzQzz//vB7o4BBf+9BDDzkmBQYP9AMPPNDYqqgCWhTQUhtiN5uKN5P6dWScelzKAR3GqcevJ5I9TciN7TBoMiFXAS0KaKnNnDlzHFCCD/rsGmDiU+w6IvHJSU78euKwG/o8iSug33777cZ2hlJAiwJaakN4QFN7bkq9AeXZZ581vjYweJ6Jq3Uf6NggkEhQo8+TmOAoGD16tPtAiwJaAR0fkwjjC2iTCOP3dyYRtoeAHjZsmEmEgcHzbBKhKKAV0G3BSy+9lGbOnGlBBBbQJHrq3YwLHmhOt3vrrbcsjMCQRDh+/Pg0bdo0CyMo5OM8/PDD6dVXX1VAiwJaAR2/wzL5KX4deUhHXIitZenZOopfTybkxncYNJmQq4AWBbTUhoxnj7aNPejPnj27saNtpd6gT3KaybjxnyUOJHrnnXcsjKCwSkAoVFNjkgJaFNBSG/avnTFjhgURWJwRs9nUkqb0HbxlTz/9dHr99dctjMAgkMaMGZNP9pSYMAkdNWpUY2OSAloU0FIbkwjjC2iTCOP3dyYRtoeA9iTC+ALaJEJRQCug2wK2C/KUu7iw7Dx9+nRPuQsuzOjnCOOQuBAeMHHiRCejgSHfY8KECTnURgEtCmgFdPjBn4FFYtcRnmiJO8khjMM6ag+BZrJn7GeJOmpqTFJAiwJaasPWWyQSStwB5S9/+Us+6U5ignBmm0ETPePXEytubjcY21nAiltTiZ4KaFFAS22ee+653GFJ3EGfOHWTCGP3d5MmTTKJsA3EGafckTgtMSEGGjHb1JikgBYFtNSGhBrrKLaAfuqpp9If//hHCyNwf0dsbVNxm1JfQI8YMSL94Q9/sDACC+ghQ4aYRCgKaAV0fP70pz/lEAGJCSEciOe3337bwggszAgNcH/h2BBX65aQ8bUDW0I2dfKqAloU0NKvQcXkJ+tIrKNFAZI9TZqO7TBoMiFXAS0KaKkNW9jp3YwLAwn7C+vdjC2e8Wqa6Bn/WZoyZYrbdgaf4HDQTVOJngpoUUBLbZ599tk0bdo0CyLwoM+SJqE2Ere/I05dYRYbBBKn3JE4LTEhBprDbpoakxTQooCW2pBQ89JLL1kQgQU0OzyYRBi7v+O0SJMI4wtohBJOA4kroIcOHdrYmKSAFgW01IZB3xCOuBATaAhHbAzhaJ/JqCEcsSGEg20GDeEQBbQCui0Gf5OfrCOxjhYVgWYSYWyHgUmEooBWQLcFxNY2tWWQ9B0GkldeecVVgsAw8M6YMcNVgjaY5HAokfkEsbUD+QRNHUqkgBYFtNTGGOj4AtoY6Pj9HTHQhgbEn+iMHDnSGOjAEAM9bNgwY6BFAa2Ajo9HeccX0HrN4vd3THIU0PEF9N133+1R3sEFNKdFuguHKKAV0OF58803XXoODDGBnBRpglpcCA1gyXnOnDkWRvDJKKE2TSWoSd8h/hnx3NSYpIAWBbTUhk7DpJr4dWSCmnUkAzM21RFK0pzD4KOPPmpsTFJAiwJaaoNHxv1r44IoIx4QL7TEFc9Tp05Ns2bNsjACgyh7/PHHc58nMUE8jx8/Pm/dqYAWBbQCOjQmEcYX0GSlm0QYu7+bOHGiE9E2mOgglOjzJCbEQA8ZMsQkQlFAK6DjQ0KNHpnYApoBf+bMmRZG4P6ORM+mtt6S+gL6nnvuSZMnT7YwAgtojltvakxSQIsCWmoze/bs9P7771sQQSEmkDqaO3euhRF4ksM+3R988IGFEbyePNUz/iQHZ0FTSdMKaFFAS7/qyqQa60j6N8lpMvFJ6tcTHk6eJ4lbR0xE2Y1DAS0KaAV0aIg1e/XVVy2IoOA1mzJliuEBgWGwJyzA7dFiwwTnkUceMecjMB9++GEaO3ZsY/veK6BFAS21eeaZZ6yj4AKaJEKO85a4/Z1JhPFBIA0fPtwkwsCwQoCobWpMUkCLAlpqg3dTcRZbQHNaZFPbOknfwQONKHOrwfgC+oEHHkgvvviihREUPNAkejY1JimgRQEttSGB0OSnuBATSEINA4vEneT89a9/zXHQEvtZIszGpOm4EGbD6bhNjUkKaFFAS21YMnPgjz3oM5iY+BS/jppKfJL+TUbp88TJqAJaFNDSL1jO9JCO2AMKe3UbXxsXhPOzzz5rCEdwEEgPPvigIRyBYaXt3nvvNYRDFNAK6PhwAIR1FFtAP/nkk8apB+/vnnjiCePU20BAk0RI4rTEhNWBu+66yyRCUUAroOMzderUxrYMknoC+oUXXkivvfaahREUPNCsEhC7KXEhvvbhhx92TAoMHmhWCdzGThTQCui2mPEbAx2/joyBjosx0O1TT8TXGgMd22FgDLQooBXQbYG7cMQf9N2Foz3qyIlo/HpyF47YuAtHGz5U7Dt43HHHpaOOOipfJ510Uj68oDN+97vf5b0k+zqrIo7xoosuSscee2y+fvOb3+T40864++670+mnn95xP+U65phjsv3WW29NM2bM6PYzOU/+8ssvzzFfXc24Wc66/fbbcxkooBdNCA94+eWXLYig0HeQoMbzPFig3yv932A4ohzPM3G1b7zxhg02MLQ1EtTo87oDkc24SBv1BNBmQauMHj26R32jgA7A3Llz0znnnJN+9rOfpa222iodcMAB+dpggw3SWmutlW655Zb5xOVKK62U9txzz15/BoklZ599dtpmm23Sfvvtlw4++OB87b///mnbbbdN559//nwP6frrr5++/vWvd9xPufi7ww47LO2www75/8SvMmPrrBFedtll+T34Ho899lin93bggQemFVdcMQ/SCuhFE5MI4wvowZZESJ+32GKLpTPOOCPNmTOn7b/PQCQRMs6wOwRjxYknnpgdJdXr1FNPTSeccEIaNWqUHtR+COhhw4b1mETI8/bNb34zt9EJEyZYcA2C59kkwjYA0YoIRRAjNqsi8t13382dFb+jk581a1bH79Zdd910yCGH9OozWNZD8CLO77zzznk8wYj3O+64IwtNvMv8XNhwww3T4Ycf3uX7cnrcaaedlg466KBOO208IZtuumn69a9/nXbeeefsUe8MPNqrr766AnoRZtq0aYPKuzkYBTQT5cHk3WRl7FOf+lQ688wzB4UYxANNn/z222/3q8+8+eab0xJLLJE22mijdPzxx6dDDz00X4wP++yzT/rqV7+adt111/TSSy/5YNQAZxPOpOnTp3f7OiZD3/3ud9NnP/vZLleiZcFAGNS4ceMaG5MU0DUgxmavvfZKa6+9dhoxYkSnryHm8OKLL85e4pEjR3Z4onsroBHLt912W/YWs2zUFUOGDMlCk4osFbjxxhtnb3V3PP744+mHP/zhfLNpOnMaIPc5adKk7NGg0+0sQ3xBCWhg0oDXvamlGKk/+A+GZfTBLqIHE1dccUX69Kc/nUPa5G8wzmy99dZ5UtsZv/zlL9PJJ5/snuALGJw+P/jBDxTQC4kmE6YV0DWYPHlyWmqppdJNN93UY0XyMLG01lcBTSe33XbbpSuvvLLbrF+WMC+88MK00047ZY814IHAc90Vf/jDH/KSHkt9rZ4pPNJ4dvg9W1899NBD2VONt7s1HKUvApr3YcBjUnHJJZd0eRE3dsEFF6Tll18+bbLJJjm+nAGB+8IDwMSELWooU8qWcsJOGXGgR9XOfbGkU7WzcoAdjz3L2sVOOfD9KM+qncMNsOPpQswXOxOKkvxDDHCxE/9WsrWrr8e7hJ3VCTwYxT579uxu7fzL98eO54jXYWdVg5+Lnc+r2vE68i/3V5Jfip334/sUO5+Hnc/n+1M+fL+qnfLCTnlg5+L7Uc7cU/X1lAf1Qb1Q3tiKnfqjo6Ftce/YKW88B9h5v6qdZwiRXrVTn9i48DQUO+0CG+9Vtb/66qv5vbHz/2LnNdhb21Rpa/1tUz21Neqg2nYGqk3RBoqdumZJ+bnnnutoO121KezdtaliX1BtqtgpX+yUU7XtlH6QPmTxxRdPP//5z3NoWvG0tutFX33EEUfkVcO670E4HY6T733ve3nVkPfiPcvFmEN5/eQnP8m/b/cyW1j1dOSRR/ZYT9tvv3363Oc+l6+nn366Y1xt7afo26r23vRTxd7aT7WOiZ31U/S5xd6ffqqrMbH0U/QPndnpT7rqpzob+9555515+il+7qn/orweffTRnPdR+iP6yWo/Ve2/Sr+DnX4Ke2s/Vfqvaj/F96MOCRfZfffdFdB9gSQClmgQd32ltwKaisNDTAX1BLHWhIsULzFe729/+9vZM916bb755mmNNdZIRx99dKd7JbJEteaaa2avNw8njRChTKfQHwF93nnnpZ/+9Kf5WmWVVbq8VltttdzJ0/kgoPGwI/h5AGigNGaWO1kmQxjQ8LFzn9RLsVN+3D8PCxOeYqcjwM7DXLXTcfA9eBjZk7XYKSPsPJyIEOx4FejIsNMJ8LAWO51aeWi574kTJ2Y7nVp5aPH6FzudF3Yezqq9dFJ0YsQZY6czLiKLv+PnYi+dFJ0kP3Pv/Mv9cZ/cFysK2Hk/vg92Omc+Dzufz/fHzver2ikvyo3ywMZ78f1oL6UzL6+nPKgn6oXyxlZEHJ00HQ8dEPeOnfIux01Tb8VO/TBoMKBQz8VOPWPnol2UuqJd8FoGFO6p2Olo+Uw+g/8XO6/B3tqmqm2tqzZVtfe1TTGoYWdAWJBtCjttgIk+3skyYNG2SpuiHktb66lNFfuCalNcfD+eZeyUX7GXNgWXXnppji/18op8MYbRnoE+pfRfpZ+i/2rtp+gD6acQaa39VGv/1d2YWMbuaj9Fn9vVmNjbfqq7MZHnvky4q/1U6b/oT6p2+pUiWLsaE7vqp6pjYumneB9izs8999y8+QHfn/uknyxjIn9X7b9Kf4S9N/1UdYzDhj7bbbfdFNB1BDSDUqvXmMLcYostOi68yHhzy7JCbwU0D8cyyyyTkxZ6Au/wcsst1+FNJvwBMYpobb0IycCjTIw2DbC69ygPNHF0xD9X47bZtWOzzTbLD3JVLPdFQPOQIra4aORdXYSWEEKy6qqr5uVIGmoRUTwkfBb/pzPhKvbinW618/qqnXro7PWlfsqMvjN79fWl3Hhoqq8fKHt5GPl9sfNvsVdfX7W3vr4kiZYOuNVeOuzevJ5yK6/HxkXHRmfP51dfT7lXX89F+fVkr9ZtT/au2kJnr++sLfTUprp7/YJsU62vr9t2eB8mLI888kgeeEvd9rWtdWcfyDbVXdsp9hLC8YlPfCL3c6zQ3XDDDW19XXvttTnPhJXEuu9x9dVX58TylVdeOZ111lnZqUK/zcX/r7/++uxAwSnBCmO7l9nCuK677rqc90RSZnevI0yGFWpCOIoHuqv+qDf2vvZH/emnBsK+sMZE7gdRT+gruqE4/Po6JvamnyrbghLCQTivArqGgB4zZsw8dmZqdIYlHAFPCZ3W0ksvnX/XFwHNbBFPLMmDPYHoRTAzE+tNCAczLd73lFNOmSceDoG8yy67pCWXXDKts846ubPl+qd/+qf0rW99K4dXVMNJFmQM9JZbbpnLrqt4PokBXkJPuYsNk9f+JKhFgyRCYqARnIOFsrLUH3C2sILH6mFZleOiz8Zrt/fee+dwDp/X+uAsKGN5d68xBnrhQLvHMdjU9oHGQNcU0GQ0Iyh7Ao8vYpuZUV8ENMsV++67b96yqbsjXnkdu2XgfShLnL1JIuTBRnSXJaYixBHtxCoz28arwXXjjTfmWMP11ltvnobpLhxCp9HZVogSq44GUyIhAvqTn/xk3uFoMOzCgXDubx3xDDKYs/UoInqPPfZIO+64Y75IAmc1jzGLWGmWqKX+2NSTUCKk4Tvf+U6e5Cmgm3+WqKOmxiQFdA2IIUK0EndMwltnp3wRN4OHt2xzV5YleiugeT0HleABZvmtKxC4iE1eWzrg3gho9gMlFppYKGBWzf3ige4MQi/YHm/s2LEdDaUIaA9SWXRhcteTR0YW7oBCaFdJMB4M4Hn++Mc/Pt+KWLtCv41jor97WrPKQLgOHmgO63rwwQfzxf/vv//+dN999+X+1GPd69cTeRDdObSAOGImMcRA4w2VZp0FhL8Wh6UCOijEFl511VVZICOIS/gEMMMnFpoDVog/qx7RytZ3LKP1BkQ0YSAIV+Kuqns2E+CP4MUrTLhINZaZ1xPn3JWnghihssNH8eBweg/7hRJ835kgZtkPbzj7RxcPBq8n4XBBzPIV0O0BSSQ97YsqC3fQJ0FmMHkdSeZhIl92D2h36O/IJfDUuvjijFN+EcjdQYws/SKTGRxp0hxMqNlauKnQTwV0PwcnEgnx+LLtGtsEcS277LJ5yYzZfyu8ls3uy2tbLzzbrQ8jsdaIdJL7mNn+4he/yAITkYwnuXqIChA//PnPf36+9+ZveQ8qnGSH6sNNEgthGl2dIc93pZNHnI8fPz7bEPV4grr6Lkwi6iyxKqDbB7KUraPYfRTLyEy4Ja6AxlPp/szxBTTirBr2KPEENDt3NXVYkAJ6ACDhD5GLmOXi/12dhIPYQFiX17ZezFw7g1hnhCszYC5CKro6XYzGg4em9b35O+x4DFsrm+9AslFPHX3ZTxbwShM60tV3YQZe9YwroAcfeDZpmxITVpMQz9VddSSeMKPvLf2qxITVW8SzJ6/Gnoyy4tbUyasKaAn5ECig22dQGWwn3VlHYh1JZ+AQMmk6tsOAOmrqWVJAiwJaasOyczX+X2JRDjZpKqlG6oln4rqNl43/LJF0b6hN7AkOq+RNjUkKaFFAS23YsN69umMP+hzm0NmpoxKnvysns0lcEEjdhVnKwocYaDZCMIlQFNAK6PCUY9YlroAm+VcBHbu/43hgBXR8Ac2mATgNJK6A5kAhkwhFAa2ADg+D/mA65W6wQUwgS84mqMWFEA7CbAbTXt2DdTL64osvut1gYAjh4KC7psYkBbQooKVfg7/JT9aRWEeLikAziTC2w8AkQlFAK6DbAkIDmtoySPoOAwlbpJnoGRcGXrYW9UTP+JMc8wniawfCoZpaJVBAiwJaamMMdHwBTQy0B6nEH/SNgY4/0UEoGQMdF2Kghw4dagy0KKAV0PHxKO/4AnqwHeU9GPs7JjkK6PgCujdHecvCFdCcFtnUmKSAFgW01IbQABPU4kJM4Jtvvpnef/99CyMohAYQBjVnzhwLI/hklHAok6ZjT3KaDIdSQIsCWvrVYZlUYx1J/2gy8Unq89FHH9USStKcw4A6aqq/U0CLAlpqw2z/z3/+swURFEQZz9Bf/vIXCyPwBIft0WbNmmVhBAZRNmHChDRjxgwLI/AE59FHH21sTFJAiwJaavPMM8+YRBhcQHPKnUmEsfu7iRMnekR0G0x0iK8lcVpiQgz0kCFDTCIUBbQCOj6TJ0/WIxNcQDPgc1CHxO3vSPR0O8j4Avree+/NB3VIXAFNomdTY5ICWhTQUhuSNUxQiwsxgdTRBx98YGEEnuQQvsHgL7GfJU/1jD/JIXyjqTFJAS0KaOlXXZEAJXEx8Sm+MGsy8Unq1xMTUfo8iVtHc+fObWxMUkCLAlpqQ/24x3Bc8G5OmTLFPYYDw2BPKJSnRcaGCc64ceMckwLz4YcfpgcffLCx0yIV0KKAltqQRGgdxRbQnHL3yiuvWBiB+7snnnjCJMLgIJCGDx9uEmFgCINC1DY1JimgRQEttcG7qTiLLaA5OU1xFhc80BwP7VaD8QX0Aw88kLcclJjggSbRs6kxSQEtCmipDckaJj/FhZhA6oiBReJOct57770cBy2xnyVOIfTEyLgQZkMoVFNJ0wpoUUBLbRDPDvyxB30Tn+LXUZOJT1K/nv7617/qMAg+GWWXlKbGJAW0KKClNoRweEhH7AHFEI7YGMLRHhjCER9DOEQBrYBuGzgAwjqKLaBNIozf35FE2NTxw1JfQA8bNiwnTktMWG276667TCIUBbQCOj5Tp05tbMsgqSeg3cYuNnigWSV48803LYzAEF/78MMPN3ZMtPQdt7FbxGF5iMrgZKquIJFh5MiRWbwsaDgWc/To0X3+u+eeey7dfPPNtYL5FdDtA/GAxtfGryPja/8T4lgJlZg2bVqOZ41yT/ST1lH8tkOyZzsm5NK+WIUilGswt7OmE3IV0MFgj8lDDz00nX766Z1m+5JRf8opp6RDDjmkkf0oN9poo7TJJpv0+e8uuuii9JWvfCW9/vrrCuhBDO3RY6JjD/omPv0NxM+RRx6Z1l9//XTrrbeGqqOIybiMQYiu6dOnZ4cNF30yF//HG/vGG28sEqcoUk+sEiDQ2o1HHnkkj+U77LBDmjlz5qCtI9ohE2SSchXQiygTJkxIW2+9dQ6Grw58/P+ee+7JwpLXNMGOO+6Ytt9++z7/3VVXXZWWX375WokxCuj2gRPUXn75ZQsiKHhkmGgP5kGzrxM++qXFFlssHX300SHuCY8guQQI0WgMGTIk98Obb755dtocfPDB6aCDDsrX4Ycfnu38uyiEnyCQGJNfeOGFtrt3VoNp8x/72Mdynz1YQSOxaj5jxgwF9KIKs346rp122ik99dRTHXb+zwxy6NCh882w8ARceOGF6cADD8wellGjRs231HTTTTelESNG5ONIDzvssHTJJZek2bNnd8yuSWTB8817nHbaaWn8+PFp4403Trvssst8gxD3R8fJay+99NL5Yo76I6C5FzpmBXR8TCKML6BNIpy3b/3pT3+axcRJJ50U4p6iJhHSD5955plp5ZVXTkcccUROoGPsoe/nQjTQR1Oei0L7auckwjvuuCO3+c997nM5J2KwYhKhZN55553caZ199tl5Y3CE6K9+9assWvldlYceeih3ZHvssUc69thjs2dlyy23zGK4Gue36qqrpq9//ev5PXndWWedld+bZY+rr746e5qPP/74fO21115pww03TF/4whfS/vvv3/EexF+X9+dejjvuuPy5eKqrYr9VQDNw8bdcxHd3dbGHI2EfG2ywQb4ft0iLDTN9dw+IDZNbniv5T28vghAxQX8aBfrFiFxxxRXp1FNP7dIRgjDD2dGOYQ11wFEVJXa+L+BQKwK6idyphQk6BF3TlIDee++9FdDRYPbPwIcwvfLKK9Pll1+etttuu2zjdwWWZxG4XFUhc8stt2RRff3113fEpxED9aMf/ahjCYf3wUPFkgfebjzSBTzcxFp/5jOfSfvuu2+HCMbbTHgJM/EC8XEI7qOOOion51QFdEmGvOCCC9Jqq62Wr1/84hddXmussUYW+gh3RDRxio8++mjOUmfwo6PGAzB27NjsSee7YKdTwxta7MyyadAIh0mTJnXYSdKkPPC8V+3MWLFzv3jsip3vQxnxQE6cOLHDjnAsCUl4j5jEYCecATvLsY8//niHnYkAdiYHxU5c2quvvprt7JJAWA52vi91iZ1/H3vssQ47r8PO37FCUOy8b2kz/Iyd37O0yv3jISp23o/vg5375T7ILufz+f6UA3XKfWPnfpm0Yac8qnbeh5UOBhZsXJQH9US90FkXO+XK6gUeN+qBe8FOh0fbIgaU5dFip37wKPD+1HMpS+qZpTou2kWx0y54LX9DEmupK54RPpPP4P/Fzmuwc0/VNlVta9U2xb2VNvX000/P16Yoo760KURT1U6ZY6fOOmtTrW2tt22KZWd+N1BtivvobZvC3tc2RflSzrSpYud784xTL5RrT20Ke2lT9AXYeW9+V0I4VlhhhdzvRbi22Wab7DCIcj/lYrxYdtll89jR2e9XWmml9OUvfzltscUW4e59QVyMfdtuu23b3TfjLm1+iSWWyM8sz0rpd+ijSz9FX1zsPH/Yu+qnyphYt58qWqY69mEn3Aw7sffVfoqfsfP7qr30U/Rf/MymB/yO+8DO51f7qTImtvZTfE++L2N7dUxEK7T2X3y/4u3eddddFdBRYYZDPDAXldXKeeedlz0AnSVy/Y//8T9ysgwDDKyzzjo5dq1VqCPS8Tq3JhoxYK277rpp55137hDKCFwaSys01vXWWy8Ld8CjXRXQLPkRWsKFZ72rC884SZTf+ta3cqdNyAmHDNDYaaB8TwZchA1iiEGcxo3g54Evdh4a7AyiDLjFzkNbMnXpOIqdhw8735nOpdgRG+V0IwbiYi8PMyKgai9ihIcOwVXsCGrslAdiEHs5PKEcEVu10zmVpBUEHQIPwcfrSifFz8XO+xbhXrVzf9w/nQzvi5334/tg536Lnc+nXLDz/bjvYqcNYac8ip3vR7nxGXRq2LgoD+qD+qK8i51ypf6wUz/FTj2UnSKqduoNAYQ4op5LWVLP2LloF8VOu+C1iGg6wWKn3fLefAb/L3Ze01mb4j370qawUzaUUWdtijKttinKqrO2Rplj722bKgNHd22Kur7//vvzQEBbwk7bKm2K1y/INoWd79mXNkX5Us6UU7GXNoWdcu2sTbW2tdY2xXszwVlxxRWzmKAvI0RhYV+sFBJfTB8c4X7KdcYZZ2QnxiqrrJL222+/Tl9Dgvl3v/vd3HdHuvcFVU94G1l5bbd7Z4JGm8cxhYjlWelpTOyqn+pqTCz9FP1DV/1UsdM/lDGxdezrqp/qakws/RT9F7bhw4fniT79ZWv/xd+V/qu7fqqzMbG1n2KcQZPttttuCujInuhNN900X1XPc4FlSGaVeJu32mqrHFrBxc94WL7xjW90COi11147d3RVGJDw/J588smdfj4x11xFQBMCwut5//JZfO5mm22WH1CEc1VA142B5v2Y6RvCERs6kqYSNqQeDH7uMfyfMMGKGMKBiKkzADcRwsFKZFcJjrfffvsiFcKBhzZisqchHH/TDjgMmgorNISjDWBpr6udMM4555zsUSG04je/+U0Ow+Di/yQNshTB7KkIaJIHWwX0Wmut1WVCDZ9bFdCIYjKx+bzyWVx0tHiZy7Z1/UkipCEioE0ijI9JhLExiXBeIicRRjxuHe/l9773vZxMjpDG0UK5cZFoTlkSxrEoODoYl/BuNrF97ECzqCQRsuqEqDWJUDog9pmrM2644Ya05557dtr5slyJsC37i3YmoJmxYSN+ufU9WOJYffXVO3bhYFbH/2k0nQ0CxGozWPdXQLuNXfuAMKuz17c055FhhaCppJroVLexO+aYY8IIM0KIyo5IkWApnCRCQu9IOucqYQG//OUvc0I5q43tmFjXV3A24YFux8kCoZW0+cUXX3xQb2OH1mEy2tTJqwroNoBQBq7OYDmJDg7BWcQr/Pa3v82hFXioS8XiaSa+uBXif3bfffe8JV0ZaHlfEhP//u//vmMXDuIJSTjEG8FBKSU5kThR/hYhX7b4QUAvt9xyCuhFwCuzKByi0O51VFahFnXoW6699tocb0xSVJRJTtQ64p7o94n3JAa99SonKHYWXjhY20/EUJueQDSzeoAeGMyTadohddTUmKSAbgOIMePqCkIrTjjhhJx0h8d4zTXXzCEQeAZK/DOQDFLdkq4KiQXERxNrTYwz74Eg5jTB6j7QzPDYlB2POEk4vJZERbzYxFqWQYAQDxIB68SLKaDbByZIET1n8rcBhRWCRcFD2JcJBUu9USZ+3Aces85OnpVYkwlWCuo4hSLcO2P3YJ/slF16mhqTFNBtMnvsadmFAZKtWohDLpu9t+6qQbwq3uLuxNADDzyQGwUnHpadFVpPXuJhRCzTaHgt28O0CmXCQVhKQQwroAcvZDczgZO4AyfPfetBRxIH+jvC7Zpadpb6Ey9WYOnzJCZoHnbuKtvpKqBlkRxQFNDtAROs7iZlsvAFdLvGbS5K/R376UZMIpR5BTTirB2TCBclAY0TsakxSQEtCmipDasUbpEWl3IQStmPXWIKM5JxPS0y/mSU/YE9eTW2dsCp01SYjQJaFNBSG+I3TVCzjsQ6WlQmOyZNx3YYEAfd1LOkgBYFtNQGb4xbpMWFgYST+0z0jC2eCbEx0TP+s8SOVXqgY2uHcpqhAloU0Aro0NBZNZWwIfUG/aefftokwuD9HXHqJhHGBoHEiX4mEcaFGGgOuzGJUBTQCmgFtCigFdASRECPHDlSAR1cQLMLmQJaFNAK6PCwx7AJanEhJhBhZoJaXAjhICzgvffeszCCT0anTp1a62wDaQbinzmq/O2331ZAiwJaAR1/8Df5yTqS/uFpke0j0EwijO0waLKOFNCigJbakPyEF1pigiibMWOGiZ7BxTNLzu+8846FEXwiyoE37qkeWzuwp3pT4VAKaFFAS204VMCDVGILaAf9+P3dk08+6UEqbTDRQSiR9yExIQZ66NChHqQiCmgFdHw8yju+gOYob7ayk7j9HZMcV3LiC+jRo0fnrewkroBGzDY1JimgRQEttSE0wAS1uBATyJ6o77//voURFEIDODlt7ty5FkbwySgnRjaVoCb1Jjkvv/xyY2OSAloU0FIbk2qsI+n/JKfJ09OkPh999FGuK4n7LH344Ye1xKwCWhTQ0igslXkyV1wQZTxDbr0VFwbeF198Uc9mcJiEPvbYY4asBZ/gPPLII2nmzJkKaFFAK6Bj88wzz5hEGFxAc0iHSYSx+zt2DjCJMP5EZ8SIETlxWmJCDPSQIUNMIhQFtAI6PpMnT84xZxJXQLNrQFMeGanX35Ho6SpBfAF97733phdeeMHCCCyg77777rx1pwJaFNAK6NCQrDFnzhwLIijEBLK/8AcffGBhBJ7kzJ49Ow/+EvtZYqeUv/71rxZGUAizYSWnqaRpBbQooKU2JtW0Rx01lVQj9YRZk4lPUr+e2CmF50ni1hEOnabGJAW0KKClNtTPn/70JwsiKHg3WXJu6mQu6TsM9uwtzHaDEhe8mw8//LBjUmCYiD7wwAONjUkKaFFAS21IIrSOYgtoTrlj/1qJ29898cQTJhEGB4E0fPhwkwgDQxgUorapMUkBLQpoqc2UKVPc4SG4gMa7qTiLCx5oEj05TEViC+gHH3wwbzkoMcEDfd999zXmMFBAiwJaakO8mclP8evIuM3YkxySnuj3JC7E186aNcsTIwNDmA37qTc1JimgRQEttWF3B2b9EnfQN/GpPerIZNz49cSuQ+5oE3syyq5DTY1JCmhRQEttCOEwvjb2gPLcc895WmRgEM7E1RrCERsEEglq9HkSE4TzPffcYwiHKKAV0PHhAAjrKLaANokwfn9HEqGTnPgCetiwYTlxWmLC6sBdd91lEmFkWCI477zz0kknndRxnXXWWenCCy9Mp5566jz2O+64w1atgB60UD+vvvqqBRFYQOMx4wCIwQIJd1dffXX+dzDsnYwHmhM933rrLRtsYIivHTduXO1jolkJuu2228wZWYDggR47dqzb2EWGju7II49Me+yxR8e18sorp8UWWyxtvfXW89gvu+wyW7UCelB3WCY/xa+jwRRfe/755+e+9swzzxwUp2ASW4uo6s9kgPeYNm1auuSSS7Iz59xzz53nOvvss7OdHQo8ObR+GZPsWTe+9oILLkhLL720+30vYIcBddRUzocCeoCgAJdbbrnGjpBUQEsE3nvvPbPSgw/6HD08mLxel19+efrUpz6VBfRg6G8Z9ElO60/iE33mzTffnL7whS+k9dZbLx1xxBFp//33z9chhxySnTlLLbVU2nXXXWt7UH2W/iPHqdPn1eGKK65IK664Yt4lQhYMrBK88cYbjY1JCugBgqWZZZdddr6lA+Kl9ttvv/mugw46KB199NHpxhtv7Hggy0lHJ554YjrggAPyAPH00093vNfUqVPTVVddlUNIWpk9e3a64YYbOpbTGVio1JNPPjm/14EHHphnwLxHgYH10ksvTePHj09DhgzJr7n99ts7fs934T3xtnPPdMo33XRT3sqnCiednXDCCR0dNvd/77339sujsuWWW2YBjVdF4kLdv/zyyxZEYFg6Hkz7QCOgP/3pT6eLLrpo0HwnYtT7u0owatSotNVWW3UpkPFAMx64J3h9Hn/88dqnejLBQUC3jp8ycDCRHDNmjEmEg0VAc4jBUUcdNc917LHHZk/AWmutlQUsYpeLAWGzzTbLHoNjjjkmC99NN920Q9QidDfeeOOcyFDdSgfv0ujRo7PgLBvys2y3/fbbp+OOOy6/FyJ42223Tfvuu28W6UBH+sUvfjGtueaa+fWHHXZYji2kEfI+hx56aNptt92yOOa+EdiEqJxyyikdwhaBv/nmm+f7PPzww/Ok4OCDD873cvrpp3d4VUg2u/POO/NFkH9XFw2S7/vjH/84DwZPPfVUFvosO+KpoZFSVkwYuLDjGcDORKQnOzNT7AxWXdn5vGKnnLFTJsXOBKZqx3tU7NRFd3aWlqp2ygc7/3Zl5+di5++7s/M5VTv30Wrnc4qd71G18/17spf3xk6CGpOy6v1gp9ypL8q1lCXl15mdemDyiJ16662dq2qnXfBa7NU20pN9YbWpqn1BtClej42dA9jloQi0vra13rSpqr1um6q2nbK1W6u9ePI+/vGPp9VXXz33OfSn7XzRZzIe0L/WfQ/6d/rh73//+2nPPfdMxx9/fO63y8VnUF6rrLJK2muvvdq+zBbGxThaQjTr/P3666+fVlhhhQ4nV1/7qVZ7dUwcqH5qQY6Jrf3UQI+JfC6TG5x+jEuUTV/GxN70U8XO9wY0C8+bAnoBCeiuQFDi9aWSAU/0RhttNI9XhYaCN3eHHXZIjz76aG7Qt956a9p5551z0kmBwRHRWoT1aaedloU2wfRVqHz+dpdddsk/I7SXWWaZLKzLrJj7oREiXvEmT58+fb4JAZ3wNddck3++/vrrszfooYcemud1999/fxbCJRaJWHCWFrk22GCDLq9NNtkkrbvuumnJJZfMA0I5VQixTwOlTGbOnJlFG54W7NwzDwMdU7HzHYqdOil2lnewU05VO2XBQ0Lnw+cVO/FqJfat2Jk8EAePnQ4HD2yxszzXmZ3yLcvpM2bM6LBTJ2V/0aqdn7Hze+qAe+Ff/r47O59TtXPf2Lkv3hc7n1PsfI+qvXS+rXbKi3KjPLDxO74f7YFy53Oxc2GnnqgvyrvYKb/O7NQD7YSOinqr2unssFPPpU74POxcVTvtgtdiZ0eDqp3P5DOqbYfXdNemsHfVpqr2um2qaq+2KeqmN22q2LtqU9hpA2zrhOeshDuUtlbqsae21tqmuI/WNlVta3XbVGk7lC92yq+1TcGVV16ZY6C9vNrtQkCXkww766fov+inqvbST7X2X9UxsT/9FPbSHy3IMZH+pM6Y2Nt+in9JmEaL4Wwsgru3Y2Jv+qliLx5uBDQTKgV0gwJ66NCh6Zxzzul4LZWG5xkR3BqrSGNE9PI7ICZ4nXXWyRVXxDefjfDk4SritWy1Ux4ghOjFF1+cPRTMooHMfH5GvLd+JmKchkSjoBGxDIzgZwlwiSWWyF4gICsZzwaebkR+uYdWaHQIei7EdlcX3nHuFZGOiGeiUU67o5yYhdOguUeuqp0JRm/tfK+qvQzO2Pm8VjsdW7FXkxT6ay8JePzblZ2fi714Ebuy8zk92fmcruylE+jMXmb/5b1LvfBexV5eT7mXWX5PduqBtlw6/br20tGVQaJq5zO7si+sNlW1L4g2hb14rIonpU5b602b6q6t9bZNtbaRzuzFA/2JT3wi95n0aQjqdr4Iy8Mhwepf3ff4zW9+k5eSWbnD6cJ78Z7lfXFgUF44KejD273MFlY9XXfddblM6/w9jjBCOEoITWf9UV/6r4Hqp4rmGAxjIjaEcXXFaiD7qaq9hHCwoqOAbkhAI0LZ3g6PUIGGvuqqq+Zlns5AQBOOUWKbiY3mtQjbP/7xj3mJjvi2algHAniLLbbI3mXEN50q2es8wIRXVAV0Z1vt0VgQ+Xiy8VgT/8zn8lmEfRQBTUO6++67s4D/53/+59yB00nTYfcnps8Y6PaghFRI7DoaTKenlRhotg0dLJTJQX8YOXJkXrWrrk5WIfSOccAY6Pr0J2nVGOgFD0IXp2FTycXGQDckoKlYYhEJi6DQWztP4pARp10J6B133LHjffDmrr322lmM81AS+sHSCL8DZskIUN6P1+DZZdmIGSxx1YjiqoDm3ltDPRDo2223XU48pGN+7LHH8lISYuknP/lJFuPV7zZx4sQcssHrEezERLeK+t7iLhztAyEcrWE+EgeeeVajBtNe3QjoT37yk+mMM84YFLtw0N+RS9KfvbpxVhDe9/nPfz6ttNJKeczYZptt8oXnk/70c5/7XM5p8XmtBwKJXCP6vDq4C8eCB286eqWpNq6AbkBAl9PAdtpppxwu0drpI0D32WefnLRHPFIVYm3oAEkKqQpuEk7YyYPlA/6uCuKV9+ts9oxXmt93J6Dx+vJdfve73833HsQYETfdnfeH70NSItv61dnzUgHdPiDOrKPYAnqwnUTIJP1jH/tYDt8YDJ71chJhfzzD9Lk4OBjQ2SmJPr163XLLLdnZQlK2B3nUF9DDhw/POUd1IL/pm9/8pgfmLGABzTPgSYRtKKARlp0JaLzDzD6J/y1xy60QP4y4ZQeOEl9Dh4onAeHdenwoISB4rUm4o1OsgnjGKz1p0qQOGzMyBDeeGzzLRUAjlFsFNN4q4prJ7K526tw/n7f44ot3JBHiOeF1eNer4P3+zne+kxMRFNCDF0KIBtMpd4MNhBX9z2AatPk+JEYiGLvqT9tNmOG0INRG4oLjijG17il3TGIZQz14asFB/DKr4XW3GlRALyTwLHPKUKunh9AJ4pC/9KUvpTXWWCMnACJOy0XMGoKVh5OlB+KN2e6GLe4QwYhhMkpbYcmOcBC2l2utOEI8ELCrrbZax2eSOIgXG49zCeGgkX3ta1+bL4mQB5xkPrZW+vnPf57vk3vafffds8D/7Gc/m70/RYQzsybhj3vmtZzKyN+VLfEU0IPbKzMQ8ZuyYAf+wSA0B/tzZB3Fh3HX/i62wwD90FQdKaAHCITkhAkT5jtNCq8CO1VQwBR22Qu5XNirIR0IcJLyeC27aXQ3k2LHi65+j8fpwQcfzLt1EAf9yCOP5OQFDr4o3mxma9xzVx5EvNbcC/fJ0hV/R3w0M7zqLJwGyzIxiYu8lntnSbJuEqECun1ghUHPWewBhT6i7FsqMSc4rPR5im1smOCUbd8k7gSHXceaStRUQEs4FNDtA9sbmpQUe9BnK8i6y87STH9HGF5Ty85SDwQSDiX6PIkJMdAjRoxobPcuBbQooKU2rEp0dXSwxBDQiDNi1SVuf8eqntvLxRfQCCVO6ZW4ApoV96bGJAW0KKClNoQR1dlpRZqh7ItqmE1sYcYEh8MfJPZkFO8zyasSVzuwS0qdzQsU0KKAlkYxQc06EutoUcEkwvgOA+qoqWdJAS0KaKkN3hg90HFhICH+2dPPYotnksdN9Iz/LOmBjq8dCCvUAy0KaAV0eIgH9Lj12IM+e7WbRBi7vzOJMD4IJLaaNYkwLsRAsxuYSYSigFZAK6BFAa2AliACetSoUQro4AKaLXcV0KKAVkCHhz1RTVCLi/tAx8d9oNtnMsp41FR4gPQd4p85vM59oEUBrYBui8Hf5CfrSPqHJxG2j0AziTC2w6DJOlJAiwJaakPyU1cnWcrCB1HGQTcmesYWzyw5u5ITfyJKqA19nsSE05U5BbmpcCgFtCigpTbsuelBKrEF9KRJkzxIJXh/9+STT3qQShtMdDxIJTbEQA8dOtSDVEQBrYCOj0d5xxfQbOvEYSoSt78j0dOVnPgCevTo0Wny5MkWRmABzU4pTY1JCmhRQEtt3n77bRPUAkNM4FtvvZXmzJljYQSF0ABCbObOnWthBJ+Muqd6/EkOITZNneqpgBYFtNSGhI06HYc0W0cmPsWe5FhH7cGHH36Y60riPkvUUVNjkgJaFNBSG5KfPJkrLnjNpk6dmrcblJgw8E6ZMiWv5khcmOCMHz/efe8DQxLhuHHj0syZMxXQooBWQMeG+FrrKLaAZucAkwhj93cTJ040ibANJjojRozIidMSE2KghwwZYhKhKKAV0PEhoebll1+2IAILaHYNaMojI/X6OyairhLEF9D33XdfeuGFFyyMoBC+QaJnU2OSAloU0FIbEghNUIsLMYEk1HzwwQcWRuBJzjvvvJMHf4n9LDHJMWk6LoTZsAd0U2OSAloU0FIbYs6oL4mLiU/xhVmTiU9Sv54QZvR5Ency+v777zc2JimgRQEttSFBja2dJO6AwpJzUydzSd9hcsN+6p4WGRu8mw899FDu8ySus+CBBx5oLOdDAS0KaKmNSYTxBTSn3Hn8cOz+juOHTSKMDQJp+PDhJhEGhiRCRG1TY5ICWhTQUpsXX3zRHR6CC2gSPRVnccEDTaLnX/7yFwsjuIAeO3asHujA4IEm0bMph4ECWhTQUhtOTzP5KX4dGbcZF2Jrm4zblPr1NHv2bE+MDO4woI7wRCugRQGtgFZAS78GfROf2qOOFNDx64ndUhTQCmgFdHDee++9dPnll6df/vKXHdd5552XrrjiinT22WfPY//d7343oJ/NNj2//e1vF1rcpAK6feAENeNrYw8oJKjVPS1y1qxZOQmRPgEBIQMPIRzE1RrCMXBQlpMmTRrQ7cwQSPfff3/u8yQmOHPGjBnjPtCLOgxchx12WNpxxx07rp/+9KdpscUWSxtvvPE8doT1QEKM15JLLpluv/12BbR0y+9//3vrKLiA7k8SIQPDuuuum/uCprw60WEiQVm8/vrracaMGWn69OnzXa+++mo+mrs3XuWSRFh3kiPzQ7LfmmuumR599NEBm/ghkIYNG5YTpyUm7Hd/1113mUQo88Ps9wc/+EHumBckDADf/e5385GYCmjpDuoHsSBxBTSJnoi9Olx33XXpYx/7WDr22GPz8rX853ZmEyZMSDvttFPaeeed05FHHpkOOeSQfOH0OPDAA7OT47jjjutVwhkeaLz8b731loU7QNx4443ZCcTqLPU1UPX+yCOPpGnTplnAQcEDzVaDTY1JCug2AkG7zDLLdPsA42m66aab0vHHH5878xNPPDFXMnFbZQnq4Ycf7vRvJ06cmEaOHJmXqBDqrQIab8tll12WjjjiiHTCCSfkpZJWrxQdFu/x+OOP53u49NJLsze9rx3VZpttpoBukw7L2M34dVT3IJUbbrghffrTn04nn3xyPtFQ/nOCT4jb97///XT00UfnfpKfufB+3XLLLVlAc7EnbU8Uj7YHqQwc1MFXv/rVXDcDJaDNJ2gPh4EHqUifBTQD5NNPP50OOuigtNtuu6Wjjjoq/3/PPfdMW221VQ7zYFaGJ4nft1Y2MWOIYrwmxEyusMIKHQKaDoiBYPvtt89/e+ihh2Yvy+abb55OPfXUeQbWtddeOy299NLpV7/6VRbwvGdfD3Hg3vBAb7vttlm0S1zorEyqiQ2Dfl0Bff3116fPfOYz6de//rUFWeHBBx9Mu+yyS5ehMTgXcCAQmiHNQwjH1772tbyl2UDCOEl+ksSFlZymJjkK6EEioBGam266aRatrfvysty48sorp9GjR2fv8+GHH5479urMfOjQoXkpksQLvL54V7ABnmmWK/fee+80c+bMeWb5eIqvuuqqjhkfonq55ZbLsbFlRsjFUjAe5Z6u7bbbLm255ZZpqaWWyiL6nnvuSS+99FKOD+R+8dRw8h1ecpZHq3a+d7Gz7y12xB2DXLEj5rmfVjtL3MXDQAJCsdNhlm2mKONi59Qw7HSmndlJuiIUhuVz7ITdYGeyUbXjnS/Z3dRrsZNJXLZN4vtjp154HXb+rtj5tyR58Tm8rti5P+x0KlU73wc798vnYefz+f6UD9+72LlfyovyLHYu7MTX8nfV96E8qA9eT7liK/ZyZDH1U+yUNx1eq536oV0h/qjnYqeesXPRHil77LQLXst7MVksdv7Pe3dlX5BtCntrm3rjjTc6bVOlrQ1Um8JOnRO3yXNf2khv2xRlg1d18cUXTz/84Q+zYNxrr70W+Wv33XdP66yzTvrGN76R+9zW3++xxx7pF7/4RV7F23DDDXt8P15Pn0c+i+U7MNcaa6yR/vEf/zFttNFGafz48fk55Nnl2Sv9CM9MV/1UWRHg2S7PA1c5SIVnstpP0be09lOl/+Kq2ks/1Vn/1V0/Rd/ZVT/VmZ144N70XwPdT2Gv9keMPd31X61jX3VM7Kmfwk4/V16P8+/KK6/MDj++Z09jYhmzsPP9+zImUiesONEfKKDbXEDTGAifoDHxcPKAPP/883nwxAu8xBJL5MGQh5CwCoR2dfsxPM94l3moeYj4nCKgzz///LT66qvPJ8xpMOwKwmBSwjTosOjAWrnjjjvS/vvv3+OF13yfffbJgxPiHE8Pn8vDzMNP50JHQAPmPoud71K109hp9HQudCjFzsPRmb085Dx0dGrFXh5y7HRkxV4ech6uqr0IXzod7HQw2MvDz8NLZ1fs5eFvtRexw798f+zUaXn4+Tt+LvYiiPmcqr10CtxXsfN+pXPBzudh5/OxUz58v6qd8sJOeWDn4vsxOaNDqb4PduqDeqG8sXFRrtRfEeJVO+2O9lS1Uz+0ZezUc7FTz9i56Pwp+2LntbxX1c4gWOz8v9h5zYJsU8XOQNZVm6raF0Sb4meeY2I3SxvpbZuiDEge/PjHP55WW221PMGmL1nUr2OOOSZtvfXWadlll0277rrrfL+nL0VYr7TSSmmHHXbo8f1YFeR96Pss34G5GDsIPWLVFKdQceTw7JV+pKt+Cnvpp4qd54GLMZb341mt9lOl/6r2U6X/4mrtv3hta//Vm36q2Lvrp7DzXfvaf/W2nyr2rvqpYi/9UbX/qvZTPfVfrf1UGRP5fWf9F79nLPrNb36TdQPfs3VM5O+qY2IZs6pjYuvYR7lUx77SRoqAZgKsgG5zAQ00AJZa8QJTqYRxnHnmmTm5hYSK2267Lb8OUY03qZxORkNCvNKRA43te9/7XoeAJv7xZz/7WW5ErSDKl19++fzQAh6XAw44oF/fk8+hA9xmm20M4QgOHYqn3MWG55ln3BCOgQMPF31oV9tlsdqHkO5tCEfx6knsEA7qs6kt0qSedqCOih4xhEN6JaDpgBHMiM5zzz23w+uEuGEGu+KKK+YwihLucfHFF2fxi+gmXg/xTLhE+X1VQJ922mnZA9VZMgaeZeKlyx6mCOj99tuvX9/TJML2oXiIJXYd1U2kMolwfkoSITsV4Swgafvaa6/NFxMOVuUIIdhggw2yJ6wnEM6850Alu8mCSSKE/iTkyoKHZ6mECSqgpdcCmphjRO+999473+9Ycvr2t7+dB8MyS6NjJ+6O2Ejim1meZYkFeP+qgL7mmmvykiSxX1V4PcmJ/K5scTUQAtpt7NoHlrVYOpO4AwrhSeXZ7iuIwr/7u7/LYQtuY/e3Cf5TTz2VxTPhZiQLUj5ceJ3pSwndOOuss3q15Rn9McvoJuMOHIx1X/jCFwZ0GzvqiaX+Bb2NrNQHEVvCQBTQMp+ARth21ikTyM9BK6effvo8y7VsW0f8MolAd955Z4edZV1intmh4zvf+U4+9bDA+1f3gea1bF2HV5gg/QLimfhnvDGl8SigFy1oD8TASUwY9Dn4oe6+qBxEQQgYS+Ee2f63SQnxqMRKssJHfCgxpdWLFTkmlr3xVtLf4eSou1e3zA+rr8SUP/vsswN6kAqhOeQWSUyIe0bMNjUmKaDbCITql7/85U5FJQ1n1KhRees3BDPCdpNNNunISv6Hf/iHvLl8gY6d0A22nFtllVXyThsF3p9dMPi8wuTJk9PBBx+cvc3rr79+ThZE4OKdJsi+QPY5wlwBvWiAOLOOYgvo/pxEiGjG82yYzoKjnERoLsHAwZiEV38g2y3vVXbhkLgCGlHrSYQyH3goOGWnu6U+hC6VevPNN2ePM6EdLDmNGzduni3oivghTozDAKoimPfnc1o9IiwF49EmvoylMbyPrY0GId7fGboCun0oO6RITPC+lcx5iQl9KB4zQ2RiQygIZy2wM4PEnYziMGhqNUcBvYiCSCbZBZHKMm20h0AB3T6DSme7s4h1JH0T0dZRfPqTkCvNOAyarCMF9CIIoRs//vGPc/wzS4fRjmJWQLcPeJ/7elS7NDugEBrgDhqxJzjETddN9JRmYIJTDhiRuBMc8sGaWnFTQC+CMKCyW8cLL7wQ8v4U0O0DSTq92WlAFt6g77JzbOjv2NWDQzIkLgiku+++e55EeokFMdAjRoxobExSQIsCWmpDQg3HoEpcAc0OD62niEqs/o64TZMI4wtohBJOA4kroNl+t6kxSQEtCmipDUvPJJdKTAjhIHm47kmE0owwY4XA/dTjT0ZJ0neiE1s7MMFhBxYFtCigFdChMUHNOhLraFGa7JhEGNthQBx0U8+SAloU0FIbvJtNzfal75TT00z0jC2e2afbRM/49YR3s3U7WImlHdi6l4OMFNCigFZAh4YYaJMIYwtoYqBNIozd3xEDbRJhbBBII0eONAY6MMRADxs2zCRCUUAroOPjLhzxBbS7cMTv79yFoz0ENKf9ugtHbAHNaZEKaFFAK6DDw56oJqjFhZhATuUyQS0uhAaQmOY+0PEno+zu0FR4gPQd4p/Zq7upkDUFtCigpTYm1bRHHZmgZh3JwIxNdYSSNOcwoI48iVAU0Aro8Lz88ssuPQcGUTZ9+nQTPYOLZzybruTEBlE2ceLEnPApMfnoo4/S448/3thWgwpoUUBLbTxIJb6A9iCV+P2dB6m0x0THg1Ri40Eq4oCigG4bnn/++ezhlLgC+plnnkmvvvqqhRG4vyPRk1h1iS2gx4wZkw9TkbgCmp1SmhqTFNCigJbakKzx3nvvWRBBISbw7bffTnPmzLEwAk9yCLH54IMPLIzg9cRE1FCb2JMcVtuaSppWQIsCWmpD1rNJNfHryETP2JOcJhOfpD4ffvhhfp4k7rOEF7qpMUkBLQpoqQ37bXoyV1zwmrGtk+EBcWHgnTJlSl4pkLgwwXn00Ufd9z4wJBE+/PDDjYWsKaBFAS21Ib7WOootoDmkwyTC2P0duzuYRBh/ojNixIicOC0xwfs8ZMiQxsYkBbQooKU2L7zwQt7KTuIKaHYN+POf/2xhBO7vmIhyKJHEFtD33XdfXi2QmBBiQ6JnU2OSAloU0FIbkjXmzp1rQQSFmEDqCM+MxJ3kvPPOO3nwl9jPEqcQmjQdF8JsmIg2lTStgBYFtPRrxk99SdxB38Sn+HXUZOKT1K8njlt3ohN7MkodNTUmKaBFAS21IUHtT3/6kwUReEBh31rja+PC5Oa5557ztMjg4N0cO3Zs7vMkJkxu7r///sZyPhTQooCW2vz+97+3joILaE658/jh2P3dE0884SQnOAik4cOH53h1iQkrOYhakwhFAa2ADs+LL77oDg/BBbQe6NjogW4P9EDHRw+0KKAV0G0DCYTGBMavI+PU40JsLUlP1lH8eiLZ0xMjYzsMOCmyqTFJAb0AvQos9dxwww3pnHPOSb/61a/yvzfddFPeVqp66hQPJhXAMl6TEGz/u9/9LtzG8Aro9hJn7vAQX5y14ySHe6ZPvPXWWwf1ISMlOU0BHb+eZs2aVXvXIbb8vOuuu3Q4LGABTV/R1JikgF4AsBR3xRVXpH333TcdcMABaffdd08777xz2m233dI+++yT/73ooos6Tgej0v/pn/4pHXjggY3eJ3GRX/rSl9L111+vgJbag4LxtbEHlHbdB5oTLnfcccf093//92nSpEmDto6Ks4Ut0voj7mbMmJGuvvrqdP7556dLLrlknovxBvtDDz3ktpM16e8+0BdeeGH62te+ZqjOAp50uw90m1fgGWeckcUzpxa1FirLP7fddlvaYIMN0v7779+xvdQvfvGLdMIJJzR6r+ye8P3vfz/fjwJa6mASYXwB3a5JhNOnT899wFJLLTWoT38rSYT9meQwjtx8883p85//fFpjjTWyM2bPPffMF2MRE5H/8l/+S9p11109irofAnrYsGG1kwhxqq244ooe2b4AQV/h5TeJsE0h/mb55ZfPs/7uGD9+fLr00ktz54n3YK211soV8eCDD6ZTTjklHXHEEenEE09MTz/99Hx/ywz4mmuuSccdd1x+HYL93nvvnacCSXa45ZZbcgIRM19ed/TRR6e7776743WcF9+dgCaxpXqmPMfNXnzxxemYY47J73f22Wenxx9/fJ6/ofGOGjUqDwjc/2WXXZaXvfrKlltumQdPO/vYUD94CiUuL730Ult6vRD922+/ffrKV74y6LdKHIj6od+l3+xKPJx55pnp5JNPTq+99poPRU1IIHz33Xdr/S0THAR0nfFQej+RfOSRRxpbcVNADzDE3hx55JFp4403TrfffnuvC3XDDTdMX/ziF3NlHH744emggw7KNi6ySst7swS31157pb333jt/Dq/Dq7DNNtukq666Kgt4OPTQQ9PHPvax/DrELq/bbrvt0uqrr55nwkBmfmcCmpPLHn744bxcxcBFh4EwxouBZ+Owww7L78fgttNOO+XfFU/62muvnZZeeukc883rENGEqjz//PN59s7FVkBdXXjteb+f/OQnaauttkpPPfVUPvmJOE68aZQn8YIkc3BhZwLSameZstj5+1Y791u1M3Ptzs5Ep9gpD+qi2CmvnuysTGD/6KOPemXn53IIBj/XtZcJGvdV7HxOV3a+f3d2yqOUTTmFkPdqtVPu1Be/L3bKrys7OQHd2annYqeesXO12nltd/bWtlO3TXVm72ubqtrrtKli76lN8fy99dZbA9bWOms73bW1vrap0mfi6dtkk03Spz71qbTffvulU089dVBeOEyOOuqovAJZ9z3oZ3E4LLfccrmsTj/99OxYKRfCmb55tdVWyyufg7UsF/TFmIYDqc7f0pZXWGGFDodDb/uv0k/1tv/qaz/V1JjY27GvP/0UNsqXCWnpj3o7Jvamnyr2cholWoVVHgX0AMJgRae1yiqrpM033zx3XiTCEMdH5TIDrRY2lbPeeutlMYsHusBSz7LLLptOOumk/DNe3XXXXTe/d+ssdsiQIWmllVbKXmI4/vjj85Idopr3LyBK6UiBgbVVQBNHN3LkyDyLK7FyTATWXHPNdO21185z3zzQJEayZFiE+xZbbJF+8IMfdHjO+Wwe8ssvvzzfOxfhK11dTDzWWWedtOSSS+ayQ8TjiULs89k8DJQhngA8a9h5fxo93vJix8tS7EwCip3vXIRa1U78YUm44vOKnQexJPkUO15X6hg7DxLxVsVOnXVmp77KscqUcbFTbth5MKt2fsbO71nK5l74l7/vzs7nVO3cN3bui/fFzucUO9+jai/isdVOeVFulAc2Lr4f5cln8/qqnXqivvh9sVN+ndmpBzpBOirqrWqns8NOPZc6oZ6xc1XttAteix0PRNXOZ/IZ1bbDa7prU9i7alNVe902VbVX2xR105s2VexdtSnstAEmoawmlTZS2hr30pu21tqmuI/WNlVta/1tUyUBiFU0BN9iiy3m5TUoLgQ0W39CZ/0U/Rf9VNVe+qnW/qs6Jvann8Je+qMFOSbSn9QZE3vbTyFsWX159NFHc95HmRj0dkzsTT9V7CUkDgFNjpsCeoChUbOkhjeZGQpe4GOPPTZ7bQnXwNtQwiOoNDzDvLYKlbbqqqum0047Lf9M47vzzjvzg1QaNbGB7KSBV4FYwQkTJnR4oPmc1krldRtttFGHgEbsIr5h9OjR6corr8yDbRViKBHVRdRzHwh1dhQhVpn3KHFdvDce8s7CTu655558EW7S1YVg5rNWXnnlLPYR4jT4MutFtNOgeWi4ip3vSZn0ZC+z4c7sZQmIz+vOTgdRMql7a6fOSqfZG3vJyOf3/FzXXlYGuK9i53P6aqe8yuy8vDd2vIR0SsVbUF5PPVVf352deiieZuqtasfWW3vp6MogUbV31na6slfbWuQ2VexdtSlez6DDgMLzV+q2v22tszZSp621tqmqHRgEN9100/SZz3wmr7ZdcMEFg/I699xzs2cTL2Xd9yCcbpdddkn//M//nMuKpEHC7bj4/3nnnZf7ZpwThPIN1rJckBdlyAoxqwV1/n7rrbfOIRwlvKCzfqp4mhdWP7Ug+6/ejn11x0T+ReSih9BFZaez/o6J1X6qai8hHOgdBfQChMJmZke8MKJzjz32yA8Sy26lkhHQxDRXoeLxYrMcV2BWiBAn1o2HmeWkX//613lnj6qAPuSQQ7JXuxV2AcHLW94L8XvWWWdljzPvyW4hnWVps9sC4SB0Aohw7hXvMyEmvEfxiPMzO4/0F2Og2wMEtEmEsWHlqx1jiBelGGi8Wv3d3gzHAyuAXe0SgSOG1UwP1akPoY1126Ix0AseNBMOwaZ0gzHQCwFmSghfQi7KpuwIaGzdCWg6WQQwccckIBIvjGDmgUTIfPe7380x0kVAEy7RnYAuISIljAPvMKEfdLRlhgXjxo1LO+ywQxbQbHmHZ51lYYQ24R38fdmCCQFNDF5/y8ddONoDlrgckOOC54TBpB2TCGlb5HYM9l04GHjp5/ojrPCekTTOLhw/+9nPspOGPpsLzzQOiS984Qs5X4YVI+k7OLsIo6y7RZq7cDQjoB977DGTCNsVBDExyux20R0IT0RzXwQ0SXbLLLNMRwxVFSrwG9/4Rha7vRXQiF4ENNscvfHGG9lGaAadLp9VPNF8Pp1yZ5uT44VGQJcBWgG9aMHAXT0USKyjgQIPNCte//AP/9DpbkSDaZJDHbF835/3ICQQRwh7QePoqF7XXXdd3rmJVVBP0uufQKsjlIDdsL7+9a/nGFtZcM9SybNRQLchVB4hFiTWsRNF6/6rdJR4jkksZEmnGsLRmYBGuBYBTYIhMW50hCXuh0ojLprsa2IFSxJhbwR0SSIkEL56/3ii8fwQ1gEkAP74xz/OG5QXiAXCC/7lL385i/CSRKiAXrTAm1J3WydpZkBhcltdUWonZwT5F0zmSRAarCCccWZ4wEn8emI8r+tBZiWIMbTE+MrAgx5i5aqpMUkBvQCgsyfWmeRBls6IRS67TxBjTOwzCXMl5o0H80c/+lEWva0CmqxdwiqA4HU8DIhLEgRJCCHJhphkBO8nP/nJnDAEhFvgvW6F5TzEPbD0/tWvfjXdeOON87wGTzNJDwcffHAW5Hin2deazysXO2SQ9Mh9cLpSmVVzIAzx2AroRQMSTl0Sjj3oc9hNdT93iQX9HXHq5WRaiSvOSLRnS1aJCdoFMdvUmKSAXoCQbMCuEoRr4G1mKztCO1pjqPASEcvcGprB4Ec8D7HPBTzWdLZkmvKeBMyTNILIJf65xNFxgArxWp0JHrw6gIAnKaKzGFY8VnxOiSXCG4RHunwXGgzfjxk5YSNlVo3g7m8Ho4BuH0wijC+gyVfwuPXYApp+01yC+AKa1ZDBHI8/GAQ0otaTCGWRHlAU0O0zSSzx8xIPJuf9WXaWZoQZy86DOUxlMIDzytWc+NoBh0FTqzkKaFFAS78Glf4kP4l1JKnjhE6JjUnT8R0GTdaRAloU0FIbZvruaxp7QCE0QO9m7AkOJ8yV44ElJkxwCLM0Vj32BIczK5pacVNAiwJaasNpcR52E3vQZwu4wX4QSbv3dyw7cwSzxAWBxBkIrSf1ShyIgSZO3YNURAGtgA4PCTXVJFeJJ6BJBv7jH/9oYQTu70jsNokwvoBGKOE0kLgCeujQoY2NSQpoUUBLbRj0PRggLoRwEB5gCEdcCOFghYBtSiX2ZJTwAFcKYmsHVgiaOnlVAS0KaOnX4G/yk3Uk1tGiACLJJMLYDoP+nuqpgBYFtDQCWzpxiprEhIGE8A23sYstnjkbwBM949cT+967jV1s7UDOR1NbqyqgRQEttSEG2iTC2AKaGGiTCGP3d8RAGxoQGwTSyJEjjYEODDHQw4YNMwZaFNAK6Pi4C0d8Ae0uHPH7O3fhaA8BzUnC7sIRW0CPGDHCXThEAa2Ajg/hGyaoxYWYQJYz3WM4LoQGIJ7nzJljYQSfjE6fPr2xBDXpO8Q/432ePXu2AloU0Aro2JhU0x51ZIKadSQDMzbVEUrSnMOAOvIkQlFAK6DDQ/KTS89xQZSxnKnXLLZ4pp/zRM/YIMqeeOKJ3OdJTD766KM0YcKExvZUV0CLAlpq40Eq8QU08bUepBK7v5s4caIHqbTBRMeDVGLjQSrigKKAbhuef/75NGPGDAsisIB26634/R2Jnq+//rqFEVxAjxkzJk2ePNnCCCygOW69qTFJAS0KaKkNyRomqMWFmEBCA0xQiz3J4TTPDz74wMIIXk+c6tlUgprUm+Q0eaqnAloU0NKvujKpxjqS/k1ymkx8kvr1hIeTupK4dcREtKn+TgEtCmipDbFmeGUkJnjNXnzxRcMDAsPA+8ILL2QvtMSFCc4jjzxizkdgPvzww/TQQw81FrKmgBYFtNSG+FrrKLaANokwfn9nEmF7THQ4pIPEaYkJKwSI2qbGJAW0KKClNnjO3NYptoDm5LQ///nPFkbg/g5RxoE3EltA33///WnKlCkWRlDwQJPo2dSYpIAWBbTUhgRCk5/iQkwgdYRnRuJOct599908+EvsZ4n91N9//30LIyiE2XA67ty5cxXQooBWQMef8ZtUE3vQRzxzxK3EriMTPePXE+LZiU7sySgOAw5UUUCLAloBHRoS1IyvjT2gsG+t8bVxYXJDmI2nRcYGgTR27Njc50lMmNzcd9996ZVXXlFAiwJaAR2b3//+99ZRcAH95JNPNjagSL3+jiOijVOPL6CHDx+eE6clJqzk3HXXXSYRSn3Gjx+frr766nTBBRd0XBdeeGG66KKL0pVXXpnuueee+bZM4m/Y/qWvcEAD3q1q42Gj+f4kxCig24epU6fmjeslroAm0fO1115ry/snvv7tt98e1CEofDdO9NQDHRviaxkjexqTeOYQchzmYVhOs+CBfuCBBxpbFVVAD0I22mij9MUvfjFtvfXWHRdidNttt0277LJL/v/RRx+d97PkYQdes9566/X5s+hQ9ttvvzzIFRDvJ510kgJ6EQCB01S8mdSvo3aMU2cifs0116QDDzxwUIcJEVtL0lNvJwm8HscFTgomr6wuVC92IGAfXJPdBr6eSPbsKSGXOjnzzDPToYce6srPQnAYNJmQq4AehGy44YbpsMMO6/L3EyZMSLvuumsWvmSswm677Za22mqrWg3o29/+9jxHBR9++OFpnXXWUUAvAlDv7vAQe9Bv18SnadOm5X7g05/+dA4VGsx1ROJTbyc5TIiuu+66tN122+V+HGcIfS7XEUcckf+l77z55pt9AAa4nmbNmjXPWNfV+PqVr3wl/d3f/V0OzZFmBTTOvKZ2hlJAD0I23njjLI67gzCO5ZZbLievdCWgWfa988470xlnnJGOO+64dPrpp+cGQ2cPjz76aB7gllhiiewl4jVcK620UvrmN7+Z/8/f9jWcg6WyzTbbTAHdBrgPdPwB5dlnn23L+NoZM2bkVbOlllpqUB9egeeZuNre9pOIuL333jutvPLK6YQTTki//e1v0y233JKv2267LV/f+c530h577OEDMIAgkEhQo8/rDg7FWWaZZdJnP/vZfIiRNAeOgtGjR7sPtCxYAf3ggw+mFVdcsVMBzUybTGM8GzvttFM66KCDcoeNt2PzzTdPZ599dl5SZVP5NddcM33uc59LO+ywQ34N1/LLL5+++tWv5v/jCe/rDgBFQDN4MohKXDyJsD3qqB0FNEvhO+64Y/bmDfY4e7ztvV0loH/GmXH55ZfnvrIzdt555x7HAOk748aN6/GYaEIjf/CDHyigF9Ikh0TPpnSDAnoQQggHy3jdiee99torHXPMMR2xy1UBjYdjm222yQ2j9dSlp59+Ov385z/PS4hAY0UwV5dMjj322LTJJpvM83c33nhj7tR7unbfffc8aCLAEdHM+HkYEOEMFgwydGCINjoqvOTYCSNoteN9474YfIsdL09ndkJZSmwhk4NiJ7Gn2IlnK3aSMMvyeNVOeWIngYRZMHYGR8q0M/s777zTEVvH92y182/VzuuwEx86ffr0bOdf3rcsMfI67gU794ed+yp23o/v05Wd8uH7YePifikv7JRH1Y53k/Kqvp7yoD6oF8q72Hkd9UdH8/rrr3eUGXbiqLFTb8VO/bCsjYeuaqeesXHRLlrt/A2Csdj5P+/NZ3Rmb21Tpa31t00VO/Gt1TbVVVvrqU2x8tObNkXbKG2KNjBq1Kj02GOPdbSdrtoU9tKmsLe2qdLWumpT3bW10qaq9q7aVAkJIr/iZz/7WfrHf/zHtP322+eJ/GC89t9//9z30gf35vX0yz/60Y+yBxqnRmev+da3vpW+//3vD9oyWxjXAQcckNZff/08Nnb3On6PU4mL8RK66qeq9pkzZ/bYT/Ga3vZTrXb63IHop8qY2FU/hb30R70ZE7sa+1rtXfVfpZ/CzurADTfckCc6ZYyrjok99VPYW/spyqWzfoo6YccPVnoU0IMIHmBmwPvuu+88Fx0AMXKI1OOPP36exJyqgKZBEj9XPMc8tOy2wNLIueeem770pS9l7wewbEhHzWsKhxxyyHwJibwfn9vThbAn0XHppZfOAhovN421COXSidCIaeR0Cl3ZS2dBJ1LsVbFTtZfOgoeFzqXYi6gpnUixVzuLzuyIHTqXImSrYqdqL51F6VyKvXQW/Fu1l84CkcTDXR5yPq8qrLmXamfB5xc771cV0FV76SxKJ8LF/Rax02ovCRtVexHK5VSoqp3BoSqssVPeRUBTb8VO/RQBXbVTz1UB3WovA1OxtwroYq9Oyqptp7u21tc2VQamapuqTsqqbacqoPvTpoqALm2K1SR+V9pOV22qDEzF3tqmWgegOm2qau+qTRUB/fDDD6dVVlklC2hWwljNGowXzg7C3Y466qhevZ6+nDA5yobBu7PXkJdCiN5gLbOFVU8nnnhidhB19zome5///OfnEdD0Kf3tp1rtPfVTPEdV+0D3U92NiaU/qgrl1v6rtZ9qHRNb+6mqgO6q/+JnRDSfWxXQ1X6nq/6L79+XMVEBPUghdviHP/xhR0xyuXj42cqOgak1EaI1BpoHE5HMe+255545nOPUU0/NHQQxz2yH1xcB3RdorIZwtAd0Xj0l1cjChQGjHXfhWJRCOPpCb0I4mHAYwjHw9CZh2hCOhQsTAnfhkNqwjV13u3B0RlVAM+Ailrfccsv87x133JH3Viwex5/85Cfp/PPPX2AC2iTC9oH9a53kxIXJKDHQPcVtRmRRSiLEU4nnsDeUJEK80ITh3XrrrTlEjuumm27KFyEcJhEOLAikMWPG5JM9u8MkwoU7wSFkzRhoqU1vkgi7E9AsyyCKye5uheULfsfBLEBoBj9XEwUPPvjgfglot7FrHzyJML6AbteTCOlrSFpmKXwwb2PX15MIWYK//vrrs3eesDdE9JFHHpkvwkD4l4kHzg0ZWAHdm5MI2caOEMTFF188i2lpVkB7EqEsVAFNbBXxdcRJVw9IoWPYdNNN08c//vF8WArQSX/ve9+bZ8aHgGZ3jrqnMCmg24cSny4xYbm/xDO2G/Q95513Xtpiiy3ysvhgFmb0c3iWe1unhE1Rp6ws4PBovVgRNLRqYGFlFEHc02SUPpF4aWKhB3O7jQhx4uiUvu78pYCWDlZfffWcnd0XEKtkGBcByz7RbE231lpr5ZAQPEF4O2gsJPUQSw0s4fM6duZYd9110+OPP56PBUfEr7baajkMpK/eLwV0ew3+XcVhSpw6KieOthPcc0n0aceDYPoyySGMox3raFEUaD0JJX7P5I9JjKe0Nv8slUR1BbTUAgHb1yVPYrUQv1WI9br99tvzcbrE1bEVFpmoxEPj1SqDHP8nlOPaa6/t2NmDz2erOzzUZMcqoAcntAfi4iXugEJSTTn8SGJOFNghgWx/iV1PeJfp8ySus6Ds5KGAlkUSBXT7wEE8dFgSd9BnMtuOSYSLUn83adKkXicRysITZ2zlyqqrxIQYaMRsU2OSAloU0FIbTyKML6BZXaru+S7x+jtia5uK25T6AnrEiBGDekeYwSCghwwZYhKhKKAV0PFhf15CBCQmhHAgnqvJwBJPmBEa0NSys9SDuNp23RJyUdIObAlJSJQCWhTQCujwg4rJT9aRWEeLAiR7mjQd22HQZEKuAloU0FIbtrDTuxkXBhL2F9a7GVs849U00TP+szRlyhS37Qw+wWHzg6YSPRXQooCW2jz77LMdO7JIzEGfJU2Pwo7d3xGnrjCLDQKJU+5InJaYEAPNYTdNjUkKaFFAS21IqPGwgNgCmh0eTCKM3d9xWqRJhPEFNEIJp4HEFdBDhw5tbExSQIsCWmrDoG8IR1yICTSEIzaGcLTPZNQQjtgQwsE2g4ZwiAJaAd0Wg7/JT9aRWEeLikAziTC2w8AkQlFAK6DbAmJrm9oySPoOA8krr7ziKkFgGHhnzJjhKkEbTHI4lMh8gtjagXyCpg4lUkCLAlpqYwx0fAFtDHT8/o4YaEMD4k90Ro4caQx0YIiBHjZsmDHQooBWQMfHo7zjC2i9ZvH7OyY5Cuj4Avruu+/2KO/gAprTIt2FQxTQCujwvPnmmy49B4aYQE6KNEEtLoQGsOQ8Z84cCyP4ZJRQm6YS1KTvEP+MeG5qTFJAiwJaakOnYVJN/DoyQc06koEZm+oIJWnOYfDRRx81NiYpoEUBLbXBI+P+tXFBlBEPiBda4ornqVOnplmzZlkYgUGUPf7447nPk5ggnsePH5+37lRAiwJaAR0akwjjC2iy0k0ijN3fTZw40YloG0x0EEr0eRITYqCHDBliEqEooBXQ8SGhRo9MbAHNgD9z5kwLI3B/R6JnU1tvSX0Bfc8996TJkydbGIEFNMetNzUmKaBFAS21mT17dnr//fctiKAQE0gdzZ0718IIPMlhn+4PPvjAwgheT57qGX+Sg7OgqaRpBbQooKVfdWVSjXUk/ZvkNJn4JPXrCQ8nz5PErSMmouzGoYAWBbQCOjTEmr366qsWRFDwmk2ZMsXwgMAw2BMW4PZosWGC88gjj5jzEZgPP/wwjR07trF97xXQooCW2jzzzDPWUXABTRIhx3lL3P7OJML4IJCGDx9uEmFgWCFA1DY1JimgRQEttcG7qTiLLaA5LbKpbZ2k7+CBRpS51WB8Af3AAw+kF1980cIICh5oEj2bGpMU0KKAltqQQGjyU1yICSShhoFF4k5y/vrXv+Y4aIn9LBFmY9J0XAiz4XTcppKmFdCigJbasGTmwB970GeCY+JT/DpqKvFJ6tcTEx36PHEyqoAWBbT0C5YzPaQj9oDCXt3G18YF4fzss88awhEcBNKDDz5oCEdgWGm79957DeFoN1577bV04403pksuuSRddNFFHdfFF1+cLrvssvTb3/42vfDCCxaUAnpQwQEQ1lFsAf3kk0+GilPn+eawA4XI38rjiSeeME69DQQ0SYQkTg8UHPiB+KIf5VmV/sHqwF133WUSYbtx5513psUWWyxtsMEGaeutt84XApBrp512yteOO+6YH8A5c+ZYYAroQcHUqVMb2zJI6gloJu5M8KPAQRTf+ta30tlnn20Fpf/0QLNKQOxmb1//9NNPp2uvvTY7bK6++up01VVX5av8/4orrsgTJxk4iK99+OGHB3RM+uUvf5kWX3zxPN4ZGtJ/8ECzSuA2dm3GrbfempZbbrkuT8DhNLBf//rXabPNNkvDhg2zwBTQg2bGbwx0/DqKFAP97rvvph/+8Id5dU76HgNN+R188MHpm9/8ZlpjjTXSXnvtlXbZZZd87b777vn6xCc+kfbcc08Ld4DraaBjoI8++ujsePvpT39qMvYAOQyMgW5DbrvttrTssst2O/OhgPFQH3XUUfPYqfARI0ak0047LZ188sk53GPWrFnz/T1xcmeeeWY64YQT0kknnZRDRFj6qYJ3m7/n97zujDPO6PL92N7qmmuuSaecckp+7QUXXJAmTJgwz2vuvvvuNHr06Pn+lgYzbty47DVhOZbDNOhgqt+VLc74+zpHn2655ZZZQE+bNs3GFRjam56T2JCRHklA42RAQF933XVWTk0YJ84666wuvdbbbLNN2n///S2oAWagnyPGZwT0qquu6k45A8Tbb7/dWFkqoBsU0LDJJpvkWWfhjTfeyD8jGPEY7L333mnbbbdNBx10UI6PKnC6Dl7Z9dZbL3sceB0eB15bBiIq8PTTT89eie233z6/jsrl/3SmLBOWAXXMmDHZU8Fr9ttvv/wvYSeEmSC4iyjaaKON8j23stZaa+XP54QzPpP7rcbwsXzIe7KUSINmGRkxXQR5Vxf3xWRi5ZVXTltttVWaNGlS3jaIe0ags4yGaMMLw8Sj2PnuVTuz+WLn73uy832x4wXqjZ0HFDsdKoKgJzsz4u7s/NudHRv/8vd9sXPf2LkvbHXtlFc5yrbYuJjU0U753OrrqafiWSt2yq87O96DVjs2Luq5lA313Fd7d22nt/Zq2+lNW6vbprD3pk31pq1hGz9+fJ7MFg9ntY30p63VaVOULf0EAprVuHPOOWeRv1iZPPzww7MjozevP/XUU9Oaa66ZNtxww+z4OO+889L5558/z7X88sunlVZayfIdwIuQo3322Sc7wAbqPRlHEdCMd+UkSvqdav+1oPupYu9tP9X0mNjbfop/mVASA824xDgwEGNi69hXxqYioNE5Cuh+UkI4uopvZtDAY4BARSQCnlm8yJtvvnkWlgUSSvAg4G1GYAMd5Re/+MV5jhGlYdx+++1ZvBdP9te+9rV0wAEHzPPZiFdi5YqARqjy4OJxrt4vjYSEx5///OcdOytst912aYcddpjv+3DPCHCYOXNm2mOPPfLf8lCTsMT9Et9VGhW/W3fddfOFF76ra+ONN07rrLNOWnLJJfNn3Hffffn92EWA96Jx83nE3lIW2HlQaNx4wYudmM9iZ1JT7JRnEVhVOxnwfH/K4/+z997BWlXX/7+JiYmJ3RhbbBGNFXtFjQ0bowhjR0EdFUUsqNg7NlTALnZFxTK0oYiggiDNWL4aKRMFk+jEWGMBBv/bv3nt36z72Rye55Zz7z13nee+3zNn7r3rnuc85+y9z1rvvfZaa/N9JueFRM4LY3K84ig7q7G7aNGiOjmThUpyVgBsCRDCaXJCe5CjPFI5fyPn/5988km8F37y+frkfE8q576Rc19cFznfY3KeI5Ub2czKaS/ajfawa/N8M2bMiOSM+7HzkdNP9BftjYyD9qskpx8Yyygw+i2VoxSR08/WJ/Qzco5UzrjgXOS8b6mc7+Q70rHDOfWNKeTVxlQqzzumUnk6puibxowpk1cbU5zP3+RnMAG3d93GGvfSmLGWHVNcNzum0rFW35iibVn52mWXXSJx0KFDx0rxfbDVVvRUqr9MT2X1V2oTm6OnkJs+ak2biD7JYxMbq6f43o8++iiGhlGJw4h1Y21iY2yfyS0pG7IODxKBbiaIa15rrbUiQWaWmh4XXnhh9ND27NkzEmVbBoIoQ2SnT5++wvUYCBBJBgJ45pln4ix10KBB0QBVCslgYEB48STzPbwMlZYyyCJ+8cUX60g355msR48eMcGHgd4QgYY0W9wRMz684dwfxPnKK6+M1zZA3seOHRsPQj6qHdw3bUlMWEMeaI7UA22z4frklWbhqTydVXM0NAtv7Gy7oVl4fR5o/jZ56hWsJLfZs8mzs2rk6WzbZtUNydNZuF0bOZUUUNLp/WQ90NaWWQ90Vp56jk2e9SjXJ0890OkYqeSBrk+ejrW2GFMt7YFmK28Uf9YD3dixlh1TDY21+sYUbQgJwAPNyha6or0fOFZYhcQD3Zjzr7766rD//vuHzp07h/79+0cPNt7R9MCZs+uuu6p9W7ifsOVXXHFFi12T1eJKHmgPeqpsNtE80DgIceqYB7q5NjHrgTYbZARaHugWwMiRI8M666wTwyFQaulBnNPw4cNXqJdLvDFe5a5du8ZOgJByEMoBCf7FL35Rl3DIy/X444/HF26vvfaKP62qh8FqvhKugfIkrooQDF54SE4KSDNLURBkPNacg4Lo0qVLJNA2w2oMgU7DWPhe7r+5tYEVA12emMA8ikMoDmYAFANdWzHQEDAjXYqBLicUA93yoB2ZVCgGuoQhHE3Z5nPWrFnhz3/+cySweB9I/LMD5fjkk08uV1yfGSGzq/vuuy9cfvnlkdwSF0396RRUrnj66aejZ4JrEysHsbc61CQeQn4h4IR2MAiIk2RmxfW32mqrulCRagQa0p8l0EwSdt9993hdZoDNIWWqwlEOEIakrW39wpY8i9ratjFQFY7lgeODFcXGJuPyzlGFA0cHK5isclr1DZwXOGN++9vfrqCfhea/S4RT5EmKrwbsOAQap5iqcDQfEGdWuKpVQxOBdorGJhGmIGwCTwHkNQuUKcQ4jXmuRDQhyHij65txQZy33nrr8MQTT8S/iUfGgFXK4MYrtOWWW9Z5fgnLoIZ19nuJV7YySSgWQjgg6XwH1UTwfuTdWUsEujxgxSNNdhX8kTP0THYFqq0nXZRgUx3o/9N31HUmIbsxYKmZ0DZqPpND89BDDy13kLiNjidEUGg5QJDIXyK8sqVAqCMEulOnTqpm1AKgDQkTJdZZBLrGCTTxTHiKiQUkGdBAXCkEFIJqnlySgMi+tkRAA14G4oUttonEQEI9Uo8TMdMbbrhhLFkHhg0bFjp27Lhc+AdxRXi8MWx/+tOf6kIwCCXBy2HXQ3mjtIn3xgsCOBevB3Ha/J9ZOqEr/fr1y+WdFIEuD7QToX8C7XEnQirtaGfW/2sP7URYDgLd0jsRQsaxu2zQUlTYQa0TaO1EWELwEmywwQZNNlQsZw4cODDG/EKkOSCPlDViENj2nhgb4pQ5j/9zHokkeJ8h4YAXkDCK0047LcYycw4x0GT4QnDJcgV4hgkDwYtMeAfnQZRJdDzooIPC2muvXef5JrGPa+y9997xPJIMWXYidrtPnz5xuYSQExJbrGIIwCONd5xSPU31RItAlwckm3ra5U5YHkys8cY0dpc7oW2IGfqWUBvBL7Cv3iajwvLAEUhoLBVKRKBLBDzPEydOzBXHRKdTDozwCZbgWIKotJxHBigxymzhynl4lPlcduaK1xqPOOewrSvx2dkBxUxtypQp0VvNeRBvyCrKgWWqNIbo//2//1f3nczuIM2EnUCSWY7lHrLJLBhulo1JlGxqPJIIdLmMvzwn/vvIJuKCz0kOK3fqI/9Q0rT/dwk+pSRCoV0rKRHocgDPZksm1Qgtb1BYGSoqqUZoOiDOOEyq7SEg+Oknreb4dxYUuZojAi2IQAu5QXx9UQkbQj6jT5y6pyRCYUV9R1JgY5MIhbYjZ+xTkM1DEvyAlXXyK4oqfysCLYhAC7lBQo36yDeBZiOV5tZlF1pX382ZM6ewuE0hP4GGnBHSKPgl0CNGjKi3epkItCACLbgAns285QqF1gchHJDnSjuXCn6IGcm4JJQLfkFcLeSZHCDBL3dgxS0taCACLYhAC26NipKf1EeC+qg9gGRPJU37dhgUmZArAi2IQAu5wbJzte2EhbYHhgSPmUqk+SbPVHGiypLg+12ibrNCbXxPcMjLKcomiUALItBCblDKsKiEDSGf0WeXu6Zs8CQUr++IU1c9dd+AILEvAgRN8AlioNnsRkmEggi0CLR7EBNYVMKGkI9AU+FBBNq3vmODDhFo/wSaPRpwGgh+CfSoUaOURCiIQItA+wdG/5tvvlFDOAUxgSw5K0HNLwjhIMxGtbr9T0bnz5+vcoOOQQgHuzYXZZNEoAURaKFZxl/JT+ojQX3UXgiakgh9OwyURCiIQItAlwKEBhRVMkhoOjAklEhToqdfYHjZjEg7evqf5CifwD93IByqqFUCEWhBBFrIDcVA+yfQxEBrIxX/Rl8x0P4nOhAlxUD7BTHQI0eOVAy0IAItAu0f2srbP4HWVt7+9R2THBFo/wRaW3n7J9DsFlmUTRKBFkSghdwgNEAJan5BTOBXX30VfvrpJzWGUxAaQBjU4sWL1RjOJ6OEQylp2vckp8hwKBFoQQRaaJbCUlKN+khoHopMfBLy4+eff85FlITiHAb0UVH6TgRaEIEWcoPZ/ueff66GcApIGe/Ql19+qcZwPMFZsGBB+Pbbb9UYjgEpmzlzZli4cKEaw/EEZ/r06YXZJBFoQQRayI33339fSYTOCTS73CmJ0Le+mzNnjraILsFEh/haEqcFnyAGesSIEUoiFESgRaD946OPPpJHxjmBxuCzUYfgV9+R6KlykP4J9Kuvvho36hD8EmgSPYuySSLQggi0kBskayhBzS+ICaSPli5dqsZwPMkhfAPjL/h+l7Srp/9JDuEbRdkkEWhBBFpoVl+RACX4hRKf/BOzIhOfhPz9xEQUnSf47aMlS5YUZpNEoAURaCE36B/VGPYLvJvz5s1TjWHHwNgTCqXdIn2DCc6bb74pm+QYy5YtC6+//nphu0WKQAsi0EJukESoPvJNoNnl7tNPP1VjONZ3s2fPVhKhc0CQRo8erSRCxyAMClJblE0SgRZEoIXcwLspcuabQLNzmsiZX+CBZntolRr0T6Bfe+21MH/+fDWGU+CBJtGzKJskAi2IQAu5QbKGkp/8gphA+gjDIvid5Pz4448xDlrw/S6xC6F2jPQLwmwIhSoqaVoEugRgyejZZ58NDz30UN3x8MMPh6FDh4Ynn3wyzopryXshAl0eQJ5l+H0b/VpLfGLMUVmkVhIji058EvL30w8//JDbYcAkiZUgJYu27mSUKilF2SQR6BLg5JNPDmussUYklXYcffTRoWvXruGEE06IRLNfv35xaakWjIoIdHlACIc26fBtUGothAOHwXnnnRd/1sLEoKVCOCBmrDSw4gBZ42f6OxMpvgsiKDQdzQ3hGDduXBy39IfQOlAIh7ACjjvuuHDqqadW/T87jZ1xxhmxIxctWiQCLRQGNoBQH/km0LWWRDhkyJCw0korhWuvvbYmyIglETZn+2H6+d133w2XX355uPjii2PbXH311fG45pprwhVXXBHJ27Bhw2IYgpCPQI8aNSomTufBvffeG7baaitVW2lFMEl8+eWXlUQo/B/wMnPUh1mzZoXtt98+TJ06dTk55VyeeuqpMGDAgHDXXXeFmTNnLreEhDeC7UnfeuutaGhvv/32MHz48LikaP9HMfPyc41HHnkkfPzxx3Wf5/ebbrpphePWW28NgwYNigqnqUXNuT887CLQ/rFgwYLCSgYJ+YhVrZWxe+CBB8Jqq60W9VEtbOKDV5hVgq+++ir3NViyfvrpp8Pmm28eevbsGe64446ogznQ6RBq7MNpp52mJLicwC5hX/NuE/3ggw+GHXfcUROYVoTK2Am5CDSewB122GE5Aj1jxoyoMI8//vioVPm9W7du4f77769LKoIg77bbbmG77baLypbz8GJ899130fgSY33sscfGMBL+d8opp4STTjopTJo0KX6e+Gy84+nRq1ev6EHeddddw8033xzjFZtq9CHQ3LfCA3wDw62NBfyT6FoCRGT11VcPgwcPVucmmDBhQtTR1Yg4eh99rIosbYNnnnkmdOzYMcZRC61LoosCBPqss84SgfYMQjggv9XA8t/5558f+vbtWzfzmjt3bujTp09UqOlsDE8ysdMjR46skx188MHxxSYOzzwizLaJJYJw41G2wUGAPtc988wzo2e6Gvj+F198sS6Y//nnnw9nn312gwfLjFx70003DYcffngcoO+8806c9XMPZEDjUeOZ8ZjjAUeOJ4rvNPknn3wSn4ElXjYpMPnChQujHCWWylnitgSEDz/8sE5O2yFnQkH7ICdkhs1DmHywBS/yOXPmRPlnn31Wl63N5MLkGC3kLN+xBGjyL774IsqJfzQ5z/vf//43yvnJ5MjkGEfkfI72NznXRY6nkb+R83/uj/tnedjkXM8mSNwv98Gz8v08P3KeL5XTXrQb7YGMg+fjuWjjVE570E/0CyFFJqddLVmKfuBekON9s0Q3+s3k9A/KkDFEP5ucfkbOwbgwOeOCc0nywTNufYjHjWvzHfxuclY3uBfuKR1T6VirNqZSeVPHFJNC5EwsTW5jyrZ1bokxxVihr6dNmxZXqBhjlcaUyVtjTCFv6piifZHTTtkxBe6+++7w61//OnTq1ClccMEF4dJLLy31cdlll8VQCxwXea9x0UUXhS5dusQQAZwYlf6/zz77hD322CM6OMreZm3VT9ddd1246qqrcn3+kEMOif3D+874Rk+hg0x/mZ7K6i9+R09l9Vd9NpHrZ22i6amsTURHm55CF9enpyrZxKyeQj9U01OpHL1ieqqaTaymp1K56SnkfH7KlCnxXrk/23491VOmv7J6iudsSE+ZnOegnwgXgWOJQDsGhJIXD2ORHihFlC7/5+90ae62226LxNtCMbKeCLzK5jncf//9Y9xcCv6H1xuPRSWPFkoYpV8JeKcHDhwYX3zDfffdFzp37tzgccQRR4RDDz00rLfeepFAv/DCC/FlQEGgRFAWvOTTp0+P4Sh8BwMXpcBLbnIUE3IGP4Pd5KZceFlSOeTIlAIvjclNufDSQR5MjnIxpYCcEBjkvGSmFHhpTW7KBSXAS4gcUmPKBVLDi4mc5zXlwk9efFYTkBux5nOp3JQL38PfyPk/pMuUgsn5HlMiPAf3YXJTIpA/7hs594typd1oD+QcPB//R5Gn59MeKG/6i/ZGxoGSov+Q8xmT096MU8gv/WZyU1IQZfrZ2pJ+NgLNuDA544JrYGgwHNZXGAvGM9/B7yavNqYsGZdnqDamMBwm51loG9qo0piiTSuNKcYabWJyI9z0WaUxxVhLx5RN4uobU4yBxx9/PIZS2dhhTNHXeccU95EdU+lYy44pI9YNjSnkPB/tSztj8LNjChCKBoGGDKL7evfuXeoDD9YxxxwTevTo0axroDe32GKL0L179xX+zzLz7rvvHnbeeeeo18veZm1x4ODB2YRTKc/n99tvv9ChQ4c4nhn36KnG6C9+t4l+qqdMf2X1VGoTK+mpSjaxkp7i/WuKnkptYjU9ZXL0g9nE1Pal+gtCnOopI9bV9BRydoqE++B44/7qs4no1Up6qpJNpN1S/cVzWLw1zk0R6JISaAguS3d0fgpmyRtvvHH0TJ977rl1LzF/Y3h4kc07zIvN+VkCDbHmXD5jn+dafPe6664bTj/99BXulfgjiPXEiROXk0OEMJgcvMDVDsgMLyDk+cQTT1QIh3OgiBWn7hsY0VqKga7FEA7ITXOXni2EA0KiEI7WASGSeeNrFcLR+oAAk9NVFG9QCEcNhHBUwvXXXx/+8pe/1C0N9u/fPx78ToLJ2LFj4+yMAQeBJks7S6DxCLPsBLm2z3NwLqEg2RAOZnmEYKAomgPuC4+Mkgj9Ay9rc6oHCK1vUHiHqpGqMqIWkwhZ9WhOchnOEJLFcbSgnwmfe+655+JBUjjJ33vttVck2HguhaYDL6R5ZvNO/JRE2LrgPSBkDa9zUQRaSYTO0ZgkwiwguHRspRAOlDWhEXR4fQT6nHPOifGGlYCHmZqYBpbGib3Dy5H1hjcVKmNXHtBXtbKhRS33US1t3nDPPfeElSWrmuAAAIAASURBVFdeOcaj1kIZOxwGze0jPgtxIAzEYpxZoeRgjwDyVnBK4LXXluH5wUpq3g1vsI3bbrutCHQrv0vN6SMRaBHoCOIKSXqgekZKQlnegJjeeOONdQq7EoFmIBKTRBgFXmzbfYkZHkoYZfzSSy9FGfG+xFlSKL4lyJQIdHnAZEkbA/g2KMS719L2w8QdsjqG8aqFXTAtnrQ52w8bcSBOFN2Pl5Sf6e945SzuXMjXT7RhXgcRKwQHHnhgsx1MQnXAPwixKcomiUCXAEcddVQ8mgoC/4lbpuoGiQ8QUvNCWGk5lAJxWcQ1V1LKGCvIO0mHHFyHvwkBwXihmInR3myzzeK103M5CD1pasyYCHR5QFJL3iVNoRijT2IQiTy1Asgmq2i1EL5h+o5wOMiv4JucvfLKK1Hn5QGhbiSnacv21gOTSLgJoYUi0EIEnmCOPGC5bsSIEbEKBjFYJEGkYR2QZKpm1Le7EjFz1INm6ZSfZPzadrAk/JHh/+ijj8YlKs5Jj6FDhzZ5yUoEujzQToT+CXSt7URYa7CdCJXc559Ajx49OiZOC34JNKRWOxEK7dqgiECXAxAzec78gokuKwTaPtg3MaOUmJb2fYPQF8ovqjKUX7AqbmVgRaAFEWgRaPfGXzGV/vuo1nYjrLVJjvqoPLZJSdO+36Uik6ZFoAURaCE3CBFq6lbtQrEGhRUC1Z71C4w9HrNaSvSsRTDBYaVAVUz8gvhyOENRqzki0IIItJAbxMMXlbAh5DP6xKnn3fxBKEbfsbNZLW12U4uAII0fPz7qPMEniIGm0hgTHRFoQQRaBNo1SD5lFzXBL4FW3KZ/fccWw0oi9E+gIWdKIvRNoCmaUJRNEoEWRKCF3KAuKnXABZ8ghAPvM7WgBb/EjGRcajQLviejH3zwgXZedc4dcOoUFWYjAi2IQAu5Qfymkp/UR4L6qL1MdpQ07dthQBx0Ue+SCLQgAi3kBt4YlUjzCwwJm6ioRJpv8kyIjRI9/b9LbKIiD7Rv7sAqQVGroiLQggi0kBsoq6ISNoR8Rp9d7pRE6FvfEaeuJELfgCCNGzdOSYSOQQw0m90oiVAQgRaBFoEWRKBFoAUnBJptokWgfRNodkYWgRZEoEWg3YMaw0pQ8wtiAiFmSlDzC0I4CAv48ccf1RjOJ6MLFiwI//3vf9UYTkH887x588I333wjAi2IQItA+zf+Sn5SHwnNg3YiLA9BUxKhb4dBkX0kAi2IQAu5QfITXmjBJyBlCxcuVKKnc/LMkrN29PQ/EWXDG9VU980dqKleVDiUCLQgAi3kBpsKaCMV3wRaRt+/vnv77be1kUoJJjoQJfI+BJ8gBnrkyJHaSEUQgRaB9g9t5e2fQLOVN6XsBL/6jkmOVnL8E+gJEybEUnaCXwINmS3KJolACyLQQm4QGqAENb8gJpCaqD/99JMawykIDWDntCVLlqgxnE9G2TGyqAQ1Id8kZ9GiRYXZJBFoQQRaaJbCUlKNbyjxqRx9pCRC//j5559zESWhOIdBkX0kAi2IQAu5wVKZdubyC0gZ75BKb/mehM6fP1+eTedgEjpjxgyFrDmf4EybNi189tlnItCCCLQItG+8//77SiJ0TqDZpENJhL71HZUDlETof6IzZsyYmDgt+AQx0CNGjFASoSACLQLtHx999FGMORP8EmiqBhTlkRHy6TsSPbVK4J9Av/rqq2Hu3LlqDMcEevz48bF0pwi0IAItAu0aJGssXrxYDeEUxARSX3jp0qVqDMeTnO+++y4af8H3u0SllB9++EGN4RSE2bCSU1TStAi0IAIt5AYxZyRACb77SIlPvonZsmXL1Ecl6CcqpfA+CX77CIdOUTZJBFoQgRZyg/7517/+pYZwCrybLDkXtTOX0HRg7KktTLlBwS/wbk6dOlU2yTGYiL722muF2SQRaEEEWsgNkgjVR74JNLvcUb9W8KvvZs+erSRC54AgjR49WkmEjkEYFKS2KJskAi2IQAu5MW/ePFV4cE6g8W6KnPkFHmgSPdlMRfBNoF9//fVYclDwCTzQkyZNKsxhIALdBgaNygUvvPBCGDp0aHjkkUfC2LFjK261a7uI/fjjj3UyEhheeeWVmt72VQS6PCDeTMlP/vuojHGb6AG2ih83blxMhKxlm0DSE88r+AX2+Ntvv21wx0j+T1lC7HQtj1uPIMyGeupF2SQR6AKBh+GBBx4Ip5xySujevXskicccc0w44YQTYieMHDlyuYoGeCauuOKK8OKLL9bJ8FSst956cSlJBFpoa1DdgVm/4NfolzXxiQ16Tj311PC73/0uvPPOOzXfR81NfKIM3sSJE6MdwaCnB/WLkbMaoSS4/P1E1aGGKtpgo/faa6+w2mqrxdAcodjJKJOWomySCHRBoFMvvfTScPTRR4fHH398uZeQGq233HJLOPTQQ8P999+/3La7e+yxR7j11lvr/sZ7veWWW4bJkyeLQAttDkI4FF/r26DgxS3jbpHs+IYOWH/99Ws67hTizPM1J4QDm/HSSy+FjTfeOBxwwAHh7LPPDqeddlo8zjjjjOik2WijjULv3r2V9JsTECQS1NB59QHSjI1effXV4yZGQnGAODOJVAhHDQHvwnPPPRe6desWpkyZUvW8wYMHR4OBtwXCfd9994U//elP4aCDDgo333xzePnllyOB3nbbbcOjjz4aJkyYEMk1/yMUJFXAM2fOjF5qCoo/+eSTYcCAAWHIkCHh3XffjR4IlAAhJHyWa7D9JTPsFFwPz8Wdd94Zz+Mn4SZpjcWPP/44hqOw8w/3x/dwsBtQc2rPHnvssbEtuL7gF0oi9A/0SRlJE0bwxBNPjMSv1kkf+rO5XjP0PeT5jTfeqCMTHJBrQg/OPffccMkll9R0+F9r480336wYbpkCfYiNXnPNNUWgCwbcBu5RFG8QgS4AJB2cdNJJ4emnn643fooluGuuuSZcfvnlMfa5f//+4Q9/+EPYcccdY9jHPffcExYsWBC22mqrsNtuu4WzzjornH766dHI7LPPPlFBmqfpwgsvDKuuumr0OJxzzjlxKRTlCjHt169flPN5rnvYYYdFkv7888/Hz0KkUehXXXVVvG8GCOcdf/zx0YN+11131e1sxsRgpZVWiuf16dMnfg8ThX333TeSblsuRKmQgMGBgq92MMFgBrn33nvHMBc8M8QzYQi4Lzxq/E2oC4fJMRLV5BB5k3M/1eTmZWhITh9avGJT5Xib+NvktmzbUnK+J5XbS53Kua9K8mrn85P2ot1oD5NxHSZikBvOtzZDTj+l55s8ex2LoeZ8Dvqt0nVSebXzkdsYqSavNEaaKs+OtbxjKj2/tcYUMgg03lzrW+TpdVpiTOWRVxoLNkYAnnNWotZYY42oC9F/tXgMGjQoElv0Zd5roJN79eoVdt1113DllVfGUMGHHnooHg8++GA8B93NKidhgbXalq154ODCs499ru887Osf//jHSKBxWNlkpiF9VE2vFamnsudn9VRzbGJW7zRGfzVFT/GTDYnYiRCeZHqkuTYx1VPp+UagzzzzTBHo1gQJBTvvvHOsIdkQUIQHHnhg3d/7779/9Pyms9tNNtkkdO7cOcazGRg0xEZDUMHVV18dX2C8wdbZZOIfddRRYe211w4PP/xwfPFswB9xxBGhS5cu8W8GIYQYco4Ryz4L5PiJJ56oG0DEep1//vnL1TG9/vrrwxZbbBE9H+COO+6Iyp2DsJRqB8R5l112ifd+5JFHRq8229zy3EYIqGuLh52lMuTcP15xvPMmZwLAwCcBk2cwOUQCOcmYqZztqC1+ihg2k1NhwnYKg8wjpw0gjchJWMALa3K8E7xsX3/9dZTPmjUrypnYWFIoStXk1OdFjrc/lTOZsp2vIEDI8WZwHnI+x98m57rI6WP+5t75Sftzn0x4KGeGnOvxPMi5X74POd/P8yPn+VI57UW70R7IOHg+vheli7cwlVsxe1ZATE77mcKjH7h35LQ3YxTFRb+ZnP7h2igu+tnk9LN511CU1leMC87lM0xaTQ7J59pG+E3OOfWNKeTVxhTvXkNjimevNKZoq/rGFH1WaUzZWGvqmELvcC0bO4wtG1OMicaOKZNzH5XGlI215owp3nVLmmaFbc8994wTdB06ynastdZadaFHWf1leiqrv0xPpfrL9BS6M6unTH9V01OpvKl6ymxiqqdSm8j7nuqvanoKPWF6ivfb5OiVSrbP9FdWT5lN5P+pTTQ9hZzz4EDck+kj9KTZxFRPcV+mj2zVv5KeIu7d9JTJeT5sBPykZ8+eItCtiRkzZsSYKDq1IeCN2H333etmTxDKG2+8se7/vBAdOnSIyxQpGPh8h4WIXHTRRaFTp04reLzPO++86IUw8mwgTg7vNGDAPPbYY3VeZgY6SyLEXTML32CDDWKsNnj22WfD1ltvvcKSCZ/ffvvtI5G0NiDMhNAT/lftID4cr0nHjh0joec7eZEhkrQJpIkXAiWBQkjl3K/JedlsZp7KeVmRo6R44U1uLyHtlcq5f9vdiBfI5CgJ5BD3VM7LiRzlhZx2QUGhhEwOgTI5Ly1ylFoqpw8saYXnNznn2fbMJucn10XO93Ceybk/yx5P5TxPVs738/y0D8/N85jcvMGpnOejPfkO2g+ZyW3pmP+bHMWE4UBO/5ic9rbd8rJyDApy+tnk9CeGgwOlSdsjZ1xwLp9hzJqc35HzHVl5a44pk2fHlI01+oA2yY61amPK5E0ZU/Q1xgPC35Qxhbw1xlQqrzSmkFsGPQYSXcUEHc/ftddeW5MHq46s3l122WW5r4HXmRW77bbbLq444sC44YYb6g4cKjhmcH6w+lirbdna/YS3sW/fvvWexznrrrtuJNDmgU71V6qnKumvanoKeTU9lZVX0lOp/moJPZW1iZX0VNYmpnrK9FfW9pn+yuop01/16SlkhKMyQWiq/uL5bQLQkE3k+YxA42gUgW5FMGMhDIOObYwHmlALI7jVCDRhDtk4x5RAX3DBBdH4ZIEhwgudBbMoQi8MDCQILaEbtmyFcoCA48GG5IJhw4bFeK/sTmd4uCHQeRNjuJfjjjsuDmTBL/CIoHwEv8DrjvEsGzBSrIS1hxhoiE6aPJ4HlPtDb0JoKoEQEXS4dqXMDzyoDe0YSfsrBrptwDtEHeiG4tQVA12yGGiyoJ955pl6Y6CZ4eA5gKQaqhFoQjYaItCHHHJIRQJNaER9BJqZJaEfxMwRe/jUU0/F5VRmXsz+8JBD9I1Ab7PNNnXe6pYg0KrCUS6Doj7yizLvRIi3h0k0K161XIXDdiJsTqUUroF9WWeddaKnGf1PjgsHuTHkphCXS1UOJWbnAwRp1KhRcfm+PtCX2GgR6OLBqhZeYe1EWEOANA8fPjzWfLYY5UogLIJEPSPBzKaoJ3nTTTcVSqDx/DCD5p6zwBDzP0JNRKAFSE4ZS6S1JwKNR6yMu9yxskFY2W9+85uargNNKBJOFpaO84IVQ95Fkgdvv/32qJ/Tgzwa5JRhS/caEBoP7DFhmA2tijJh/fOf/xzjoBsTtim0HAhzmT59emE2SQS6IFgd6K5du8ayculOOXT2wIEDY8gFMcZpNiiJdcReFUmgWeIjeYfvTXdSIoCeSQAGjRJ4ItACxj+P4hCK7aPmhge0leOBsmF4VptDLr0D8ovOK2MftTcQb9zQhjfE3FL+lUT7hsI9hJZ/l+BWRdkkEegCQYgGscMso1F6zuJ8ifMjiY8dB9Ntu/Ee4TVgSQ7Se/fdd8flI4rls5SUgmUjEheI/wEkMkC+syCmeb/99ltBTgKKxUyjzBkQhJ1Q7QMvEJ5x7pF7X2WVVeo80MRJs8SajVGk5jT3mafmqAh0eUAiRjpmBX8GBfIpr6NfWIJSc+rmC8X0E7G1VllK8AdILCvoJCaKQNco8CLjVYFk3nvvvbGiRrUkGTJPSQ7hXOKQ8QjzN5m5WSJDIX1LFiL2qtJuhRBtK7SfgioZ2TJ7kHWqYuAVh/jj3eb6eL9ZcgQsszJ4srHdLBuz6UqezQFEoMsDqjuwdCz4Nfq8x0Ul1QhNB/qOag3a4MQ/OcMGp+VjBV/A+wzvKMomiUALLg2KCHQ5oJ0I/RPosiYRtid9h2Mj6xQR/BFonFS1nNBaCwQaUqskQkEEWgTaPVguk+fMLwjhYJXI6rELPokZlTGInRX8ghh1co1qvaRimUESoW3GIgItiECLQLs3/kp+8m/4sxsnCf7eI/WRf5Q1Ibc9OQyKTMgVgRZEoIXcoMqKPGe+DQremKKSaoR8ExzCN9ghTfALKwlZxk2J2tMEh+3Ri0r0FIEWRKCF3GDLVCUR+jb6bHajZWff+o6kb+0Q6BsQJBLo0XmCTxADTQnBojYLEoEWRKCF3CCJsNrWwYIPAg05I1Zd8KvviNtUEqF/Ag1R+uCDD9QYjgk0Vc2Kskki0IIItJAbbKCjzQL8ghAOStgpzMY3MWOCQ8lSwfdkFO+zdl71zR2oklLUzqsi0IIItJAbSlBTHwnqo/YCJRH6dxjQR0W9SyLQggi0kBt4Y+SB9gsMCfHP2j3NN3mmTrcSPf2/S/JA++cOhBXKAy2IQItAuwfxgEUlbAj5jD673CmJ0Le+UxKhf0CQ2OVOSYR+QQz0qFGjlEQoiECLQItACyLQItCCFwI9btw4EWjnBJrdIkWgBRFoEWj3oCaqEtT8QnWg/UN1oMszGcUeFRUeIDQdxD/Pnz9fdaAFEWgR6HIYfyU/qY+E5kE7EZaHoCmJ0LfDoMg+EoEWRKCF3CD56YsvvlBDOAWkjI1ulOjpmzyz5KyVHP8TUUJt0HmCT/z8889h9uzZhYVDiUALItBCblBzUxup+CbQ77zzjjZSca7v3n77bW2kUoKJjjZS8Q1ioEeOHKmNVAQRaBFo/9BW3v4JNGWd2ExF8KvvSPTUSo5/Aj1hwoTw0UcfqTEcE2gqpRRlk0SgBRFoITe++eYbJag5BjGBX3/9dVi8eLEawykIDSDEZsmSJWoM55NR1VT3P8khxKaoXT1FoAURaCE3SNjIoziEYvtIiU++Jznqo3Jg2bJlsa8Ev+8SfVSUTRKBFkSghdwg+Uk7c/kFXrMFCxbEcoOCT2B4582bF1dzBL9ggvPWW2+p7r1jkET45ptvhs8++0wEWhCBFoH2DeJrlUTom0BTOUBJhL713Zw5c5REWIKJzpgxY2LitOATxECPGDFCSYSCCLQItH+QULNo0SI1hGMCTdWAojwyQj59x0RUqwT+CfSkSZPC3Llz1RhOQfgGiZ5F2SQRaEEEWsgNEgiVoOYXxASSULN06VI1huNJzv/+979o/AXf7xKTHCVN+wVhNtSALsomiUALItBCbhBzRn8JfqHEJ//ErMjEJyF/P0HM0HmC38noTz/9VJhNEoEWRKCF3CBBjdJOgl+DwpJzUTtzCU0HkxvqqWu3SN/AuzllypSo8wS/zoLXXnutsJwPEWjHICCeXcReeuml8NRTT4Xnn38+ZgFXWkJCCaOA886Op0+fHt544w0RaKFJIHZTfeSbQLPLXVm3H0afEYJSy95Z9B3bDyuJ0DcYg6NHj14uiRBSzfhU+I0fzgSpLcomiUA7BEtFZJHefPPN4cQTT4xk8tBDDw1HHXVU/Lt///4xsz6tG0rQ/IUXXph7l6SBAweGG264QQRaaBLmz5+vCg/OCTQ6oYzkDGIybNiwqO9qeSdFnB8ken755ZeN/gy6Hz1JbDthBWzCwsHvHBAJ1ZVueQKNkyn1QPNeXX755dHB9d1336mR2hhMZEj0LMphIALtEH//+9/DKaecEk499dQwfvz45f6Hp+Lcc8+NBHPy5Ml1cgj3pptuGsshlR0i0OUBRlveF/99VMa4TertHn300WGNNdYI7733Xk07TJoStwk5HjVqVLjkkkvicdNNN0XnR3pcdNFFK9gOofn9BElOd4zEVq+99trhiCOOUGiHE4cBfcQ7IgLdDoEX4tZbb40EulrcIor2rLPOChdccEHMCiYGFYW57rrrhnPOOSfceeedMdTDwICigwcNGhSGDBkSZ9HZAZaGcKAgHnnkkXid9LjrrrvCfffdF1544YXlNs8gfg9PEdfnvCeffDJuDJAXeE4wnCLQItBC841+WROfFi5cGI4//viwwQYb1HTtXeujxhJotpLGaP/lL38JPXr0CAMGDKgjzjfeeGM8/vCHP4QzzjhDL0AL9xPVUlICTX7BxhtvHI499ljVwxeBFoFua+BZOOmkk+JuOvUtwRF7evrpp8elI2bBhHj8/ve/DwcccEAkni+++GI8j6UMyHXXrl2jMSIEpFu3buGWW26JysDQvXv3eA3A0mmfPn3idezgsyiJ7bffPn4vS/co/XHjxoXTTjstesu5b85lNs6gIpg/T/Y/igoCzXcqPMA3GAdlja9tL8Az9vXXX5fuvgnbwJGw0UYb1XyiKnqusboS/QhZvv/++6vaCIh17969NfhbGOQTfPHFF3V/4+TaZJNNwgknnCBb5WSS8/rrrxcWsgaBxpkpAu0EeHghwQ1t60pnQYYJ5zCivPXWW8ekw/TlZnkPMpp6pElKJJ760UcfrZtN9+zZMxLr+gDhfu655+oUBZ7ogw8+ON5z6uFiOfKqq64Khx9+eF3CI99JjHZDB0uS559/fth8880jEWdCgffpk08+ic/M/eKV5jlZ1sVLhRwyD1EwOe2BceFeIHkm596R//jjj8vJMdDMXrlfvOcmZwMK5Ewq8DYgZ/LCC2pLesSYvvvuu1FOmyPHS8TExuQoXeT0aypnxQE5BAdPPnKel4RQ5PwkPtLkfB45n0vlfJ/VKeVv5PyfPuP+uS+T8z08D3Keg/vgWZHz/MhZYTA590t70W60BzL+x3NPmzYtthfnI+dATj/RL7S3yWk/YjYhCvQP94Kcz+MxwANHLL/J6R+824wt+tnk9DMyDsaFyRkXXIPPsPxvfYhniO/kO/jd5HwWOfdUaUzxDOmY4t5sTFUaa40dUxDDSmOKNrSawJXGVHas2ZjKjjUbU4wV+vzpp5+OE10bO4ypdKwx9poypriP7JhKx1reMWVy2hdgCPfee++w2mqrxZW16667riaPq6++OjolcHQ05vxLL7007LvvvuGvf/1r6Nu3b8Vz8E7vtNNONdtmbXFcc8010UEEYTIZ9nf11VeP7c07xjuU6qlK+ivVU6n+QjchR0+l+ovfTU9l9Vclm2h6qik2sbF6Cnmqp5Cb3qlmE6vpKfSK6SnTR/XZxGp6KtVrhLDedtttMdmT+0bO91eziameqmYTTU+l+ovno/9efvnlyJ1EoJ3gjjvuCLvttlujliB4mXv16hV/Z4BsueWW0egY2NISElspDIL4uM6dO9f9ryECzUvMveEZN9KNhxlCDXj5GHgMOEgv99axY8c4KMHgwYOjwuc48MADqx6HHHJInEAQjnLYYYfFyiMzZsyIAxYlwsvPSzB16tQYdsILz8BlkDO4TY6CQM73M+BNzvPyMvAS8UKZnOdDzkuOojA5SoqXipeUxE3kTEZQUvbS4pWgXZCjjOwl52U2OWTKyAhx7CaHPCDnZTY5z2vKiJ+zZs2KRBW5KSM+N3PmzDq5KSOUHn8j5/8oHe6f+zI51+N5kKNUuQ/kfD/Kj3bg+VI57YWc9qBd+B/PTZtwLgdyzkdOf9BftDcyDtrVlqpR7CanHyxOl34zOf3Ge4Ciop9pG76DfkbOwbgwOeOCczE0KGrrQ8Yk38l38LvJ+Sxy7ikdUxiFhsZUKudZKo0pjB1y2rTSmErHmo0p5PRZpTGVHWsNjSnGCmPg2WefDWPHjq0bO9kxZQS9sWOK+6g0pmyspWMKOc/ZmDGFnHfGdAY7iu2yyy5h1VVXDcccc0wkmbV4oMPxYOI1bsz5rPTtsMMOYeedd456ttI55MN06NChZtusrfqJlVocVyZjVfZ3v/tdbG/IFO8Q4zirp9Appqew1aansvoLHZjVU+iySnrKbCJ6imtmbSI2uZKe4v1K9ZTZRPRUY2wikwHTU+h/0zu89w3pqdQmoldMT6X6C6JqNrGSnuL/qdz0FHqNe8ShB4E2BwDfX0lPob+aoqd4bpPzfPQffc4KvAi0E0A08S40tNsRAwOla8t0lQg05HadddaJs+SLL744ejg4+vXrF0M6mDnzojZEoHmRCPnAY52N02NQXXHFFVGZcN0rr7wyzsz32GOP6AFhUAKUAi9oQwfKAPIJ8UdRaVnMNxgP2qTD/7JmGdGeQjia2p/EOT/wwAMK4WhjWAiHbJUfFJnvoRAOZ2BGc9xxx8WZD7OkasC7BWklaQ/grcsSaEIsNtxww6hIWeojNMIOiO5jjz1WR9SrEWgI8vXXXx+uvfbaFZLF8EYx+2JWThk8PF0UmocEQ7bxkjSlNFNqIPA4KYnQPxg/aVKN4I9slXUr7/aSRNjUrbxxSmC0O3XqFIk0K37YDQ4MOsdWW21VtzoptNy7lN3KW0mEvsCEEo+2tvJup6Dzqf9MUh4vazWFiyeZRD+rdsHSy5///OdIYA10KmS8kvcGby8K1zzElQg0Sx0QbbzXlRLFiN3bb7/9Kip+PNYkHObZXUtl7MoDlhEhOoJfcgb5ZGm5bLAydmuuuWZNl7FjBYfnq6bvs2DC+uCDD8a2YRUS/YyDhIPKTBxdunSJDhKh5QBBmjhx4nJ7LfA74YYqY+cDhMsQi16UTRKBdggMHp4XvAypRxkQ03TZZZfF+OAxY8bUyYlRIg6LIuIGyCueYTzEaRIh5+K9JrTDPMRZAg2JxbNBlY9q5fQI1ideO609jaeLEnjcy4477piruLwIdHlgSTGCXwJd1p0I0V+UaIOc1PIYs50I09Kg9QFPqOWcQBTwfDLZsIO/ieNsKAxQaDqBxiZigw20Pwn5VEVp7ARIaD1YXLJ2ImznwLNMJQti2YgDJMbKfof44mlO45FRpmeeeWasisFykpWxw/uMhwJyjLeCBBTin9k9Kd3dKy1jxyzu9ttvj1U9SOqDbPP96UHAP8oDxcHnIPxcG8/5eeedF8kzJDpP+SwR6PKAMaAtiH0TaAhVnlAqD/cOKSGJqowhKI0FHmi8l7YaKPgE4QEkmzE5MVgiMyvH9YVcCsWA+GdLRBSBbufg5SSr9N57743eXhIMWZ6oRErxSpDEwLId5Df1OBNfh7cabzT/Gzly5AqhFXyP7WwIgSUDnjqjbJ7Cd2cPjJpdm0FELDbyxx9/PBoDvOhUAclT0FwEulzGP4/iEIrtI23r7BfobnSe+sg/CFdU0rTvd4k+KsomiUAL7iACXR5QDk9Lxb4NChNuq60s+AOeSxwaSsb13084qRrao0FoO0BiWSGwUpgi0IIItOAWlEGkjq/g1+gTs5mGawn+9B15KekOd4JPcsbKrK2+Cv7AijdktiibJAItiEALuQE5Ux/5JtBlTSJsT/qOJELlEvgn0GzQUcslFWuBQENqlUQoiECLQLsHS5rKPvcLQjhY0tSys29ihseMfBLBL4hRp1ysNvXxzR1wGBS1miMCLYhAC80yKso+Vx8JzSfR6iP/UEKuf4dBkX0kAi2IQAu5gfdZ5bd8GxRCA4pKqhHyTXAou6VET99ggkOFKa24+Z7gUAK4qBU3EWhBBFrIjQ8++CBu3iD4Nfpadvav7/72t79V3bBK8AEI0vjx42PitOATxEBTsrcomyQCLYhAC7lBQg0bdQh+CTQVHohVF/zqO+I2lUTon0BDlHAaCH4JNPtcFGWTRKAFEWghN1h6zrPbpFAMCOH47LPPwnfffafGcEzMWCFQPXX/k1F2HdRExzd3YIKT3ShOBFoQgRbcQQlq6iNBfdSeJjtKIvTtMCAOuqh3SQRaEIEWcgPvZlGzfaHpsN3TlOjpmzxTp1uJnv77Ce8mOk/wyx3ee++98OWXX4pACyLQItC+QQy0kgh9E2hioJVE6FvfEQOtJELfgCCNHTtWMdCOQQz0qFGjlEQoiECLQPuHqnD4J9CqwuFf36kKRzkI9Lhx41SFwzmBZrdIEWhBBFoE2j2oiaoENb8gJpBduZSg5heEBpCYpjrQ/iejVHcoKjxAaDqIf6ZWd1EhayLQggi0kBtKqilHHylBTX0ktIxtykOUhOIcBvSRdiIURKBFoN1j0aJFWnp2DEjZJ598okRP5+QZz6ZWcnwDUjZnzpyY8Cn4xM8//xxmzZpVWKlBEWhBBFrIDW2k4p9AayMV//pOG6mUY6KjjVR8QxupCDIoItClwd///vfo4RT8Euj3338//Pvf/1ZjONZ3JHoSqy74JtCvvPJK3ExF8EugqZRSlE0SgRZEoIXcIFnjxx9/VEM4BTGB33zzTVi8eLEaw/EkhxCbpUuXqjGc9xMTUYXa+J7ksNpWVNK0CLQgAi3kBlnPSqrx30dK9PQ9ySky8UnIj2XLlsX3SfD7LuGFLsomiUALItBCblBvUztz+QVeM8o6KTzALzC88+bNiysFgl8wwZk+fbrq3jsGSYRTp04tLGRNBFoQgRZyg/ha9ZFvAs0mHUoi9K3vqO6gJEL/E50xY8bExGnBJ/A+jxgxojCbJAItiEALuTF37txYyk7wS6CpGvD555+rMRzrOyaibEok+CbQkyZNiqsFgk8QYkOiZ1E2SQRaEIEWcoNkjSVLlqghnIKYQPoIz4zgd5Lzv//9Lxp/wfe7xC6ESpr2C8JsmIgWlTQtAi2IQAvNmvHTX4Jfo6/EJ/99VGTik5C/n9huXRMd35NR+qgomyQC3Yr417/+Fd57773YoQ2B4Hdq6rbVphQsIRIrKQItNAUkqDHOBb8Ghbq1ZYyvRQ+wXD558uTCylK1BZjcfPjhh9ot0jnwbr7xxhtR5xnwRjM+ecfkSGh7MLmhP4rK+RCBbkXcfvvtoUOHDuGhhx5qsHGfffbZsOOOO4bzzz+/Te71uOOOC4cddpgItNAkMEFUH/km0OxyV8bth4nb7tmzZ1httdXiboq1CvTd7NmzGz3JgcgR4/naa6+FcePGhYkTJ65wsJmEdghtWWDDR48eHZ1NBiY+a6yxRjjppJO0WZEDsJIDqVUSYQ3g2muvDSuvvHJsYBJ5Ks1QMXDsmnP66aeHX/7yl+HUU09tk3vFUHXr1k0EWmgS5s+frwoPzgl0WT3Q6EV0wPrrr1/TlQ+a6oHG63nNNdeEjh07hoMOOijajh49esTjtNNOi8cf/vCH0K9fP70ALYhKHmiSqDfaaKNwzDHHyFY5gDzQNYT+/fuH3XffPbz44ovh0ksvrbjUTbD75ZdfHu65555wwAEHhBNOOGEFMvnWW2+F+++/PwwePDiWaCGRIQXeCMrr4GV6+eWXw3333RfDQQzUrUTOd9x9993hsccei1vHNkSg+e6ZM2eGBx54IAwaNCh+dyUlTx1grsm1OR599NEVrt9UHHvssdF4quamb7B7mmIC/Xtlyhhfiz478cQTI0HRJO3/QCzuFVdcES644IIYdoeeJpGXg74mHPCII44I5557rhqrFdo+xX/+85+wySabRNtZ1PbRQv0g3Esx0DWAiy66KL5YeOmOP/74OHtNGxnvEDNYQieYNaEQIY4GtkkeOHBgvAbEmqN79+7h7LPPjh5tw7Bhw8Iqq6wSLr744nhwPkt4EBvIN+efcsop8SBUo0uXLuHkk0+OhNi2j80SaJQxpNmILN/Nz/POO285cs6z9erVK+y7777x3rg+B+dDvG0go1ymTZsWD4rRVzu439dffz3ss88+8Xp4nswooLxoM57LDAa/I8c7kMrtfOR8viG53Wc1Of1mctqsmtySteqT83dWzs9UbuOkuXLb3aza+TxHpfMryW3HNJPxfHjD7DlSI04/cT7t3RLybJ8j50jPt7FQbYw0Vl5trKVjpzFjraExlcrTMZWVVxtT6RisNKZMzqSXKg/Wt609BvOOKetzOx89c/TRR4c111wzruYNHTq0Zg+cDo888kijzsVJgc1AN2MfnnjiiRWOXXbZJerQWm6ztjhwFNFX9vcNN9wQ1l577WiriNdHZ5RNTyGvpKeqydvKJjakp/iJQ5LQL7Zbp12aYhMbo6dMblWNINBnnnmmCHRrEegjjzwyzohQaiy7pcs/lFu58cYbw3XXXRe+/vrrGP/ctWvXuqUIPMaHHHJI/Gy6ZMTLyvLcwoULowzvMkbm+uuvrxsE/HzzzTejouU7uH66FAW57dSpU12cXEqgGSjPP/98vHfit9Pvhhzj/TBv+pNPPhljwCC96fX5PB5z806i6Hfbbbfokd9zzz2rHih9zltrrbXi9zNAiTnjPhnwvCAoqlmzZsXNB5AzcEnU5P5Mjuea+4DgYYhNTpshp09SOd4uKyfFcqrJ8Xwh54Vk0oKcmFLi3ZCzexgk3+R443nZaG/kxDbiJWIJHTlkhrhhk7NDnJVHSuWMDeT8H28+cuJA+TxyPB/8bXK+Dznfw9/cOz+ZhHGfKBWui5zrmYLhOUzO9/P8yOlfnsfktBftRnsg4zP23LQ110fOgZx+or9ob5PTfigf5EyouHfktLcpYK5lcvqH8YMip59NTj8j52DZ1PqKccG5KDfeM5MzyTPlx+8m55z6xhTyamOKsIiGxhQrQ7Tl999/X3FM0dbpmKLNkdNnlcaUjTUbI7R5pTHF2LAxyBhggk2sLJ9HztiyMcX5jD0ba/WNKZNznbxjKpVnxxQH77olXVPPFZ2w0kor6dDh+thiiy3CSy+9FN8B01PoCNNTWf2FnkKe6il0UH16Ct2Z1VOmvyrpqaxNROdW0lPor0p6KrWJpqcasolZPYXc9BT6hPe7KTaxmp6qZBP5PyvmOP5YkUdPc5+pTeRz1Wyi6ams/qJdTE+ZTeT5sBFwL7iTCHQrEWgIsIU5sKz23HPP1f0fgkvYBj8BMxkj0HT6fvvtF8MxbCZoYPAfeuihdcSaBMStt956OXIOGBTMknnJIBUYVs4ZP3586Nu3b9hss83iS54l0AzQ7L2mS1Z4hZ566qn496uvvhp23XXXcMstt8RrMQgrgWe899574/MQjlLtgNgPGTIk7LDDDuGoo46K1+fFpz1sRs0A5zlQICbn+TDQJuc+eRlQRqmcZzMvAS+EyY2wooxSub2cyCFEJjdywUtaSY6SSuVGXpCjsEyOEkLOS5rKaUfk/OT5kaMYOQ85n+Nvk3Nd5CgH/oZY8pP7M6Vmcq7H85hS4/uQ8/3IaR+eO5XTXqmcg+ebMWNGVOrpdZCbJ5F2RcaBQqb/UDT0A/ducsY4chujyOkHDArjl342Of2JjAMlaHLGBTKulcp597g2cn43Oecgb80xVUluhoC25tmzY63amMrK6ev6xhRy/saws/plYyTvmDJ5tTGFwW7OmDK5eXcYW+jP3//+9zGu95JLLqnJg1VDVgTPOeecRp3PKuAee+wR7QOfueyyy2K4YHqQvL799tvXbJu1xYHTCttHnpLJWH0lyXXTTTeNCYa8G6meqqS/TE/xv6z+yqunsnLeq6z+Mj2F/qqmp1J91JCe4n1vjJ6qZvtMf2Vtn+mvrJ4ym8j/U3mq1+BGOO7Y8IbnqaSnUv1leqc+m1hJT/F8RqAZAyLQrUSgSfKwcA0UHd5mBjKD4M477wxnnXVWXUwzySBGoOmgLbfcMoZZVIppxDPD5y2EY9ttt40GPgsGya233hrOOOOMeD9XXXVVXA7t3LlzjN2yXZVSAs0Ly3dzL9wzioMDhUGYyW9+85u4jAgYtBB4rodCh3jzTHiOmwPuBW+3edkFn0AxoewFv8A4oAfKBow81Q2Iga71Uok2OWtsHC46/Lbbbot2pBIIGezdu7cGfwsDj2v6LlkMNLH6itNvezChIBS0EhdSDHSJCTRgxgQxhPBSgojwCjrbGj4l0Mz48CqPGjVqhesyE80S6G222WYFIsMyUJ8+fWKGMGEceI2ZmTGT4vvxUlh2e0qgGXzbbbddvJcLL7wwhpbYAZHme9OMY2bTeLUp22dhKIcffnh4+OGHcyWYqQpHeYC3RJt0+O+jMiYRQvyZRG+wwQY1XYXDYvwb20c4LdCzW221VVylw4ONnudgZRGdjdcez5jQsv2UxgYDQiQ23njjaPNkq9oeTELxJCuJsAYJNEDJkcyHoqPsULoNckqg8VLj1SUEIxvCQajEwQcfHB5//PF6CTQhHoRCVPLeUBmEuC1LRkwJNB5xDBdLUpXAYCFWqj4CTEgHda3zbA4gAl0esPxW1LapQj6jD+GyZOEygVU49CEJ0rVcB9riSRvrbEA/koyNw4IVTX7ijbaDFcebbropTJkyRS9AC79L2GV0ngH7ueqqq8aJjCpGtT3wQBPCoq28a5RAE3BPohxZ0sQFp2VxUgINaSbjl5AIize2GS/LcxBxI5fVCPTw4cNjHBwVOVIlQFgIcuqrWtx0NomQgcG9QOANxAaRqEgS49SpU+vIPAmC2bJ1AwYMiDHWxFeJQNcuiDlTmI1vcob3toxhNsRYUp0IHVTLu/SxgoP+zKMrheIAQWKTGssbAsTxUj0FeWN2HBZaF4S3kjBdlE0SgW5FEAtMgl1WWVLFgv9ll77x+qaEm5kuRBQii7ea5AXIM/HMKWGFaEOGs55mQjHISIWEQ0ZJVCEZh9g4ys6xzGcl6SDFJCYa8FjxWUg18V18lvvj85Sas3tnmZXn4b44h4P7ZZJw88031yUEiUDXJrQToX8CXdadCNsLbCdCck8E3wSakMp0J0LBH4EmsU87EdYA8DYTG5wF3qBKRdfxSBOjnB0QeHshs3fccUfMqGcZKYVtlJKGg6SfnzBhQkz6Y3mPsnSQHj5jZXcA34G3J6swyISnKgafJSSk0sDke/Fy23ewpIiiybtsLAJdHjDTL+Mud+0FrDjxrteyB7cWiBl6Dm+m4BeEBzDRIbRI8AlW7uEsRU1GRaAFdxCBLg9YibDa44L6SMg3yaGPGluFQ2hbglbGhNz29C41JSFXBFoQgRbaDJR0SpNqBH8GBe+z4jP9AuJM4nalFUTBVz8RClXGkpDtBZBYVkWLskki0IIItJAbVGOpFI4k+DH6hGyx0YLgV99RZSQbmif4I2eEQ1rekOAPhKxCZouySSLQggi0kBsk1KiPfBNotqVVEqFvfcf2wMol8E+gKe1ayzXJa4FAQ2qVRCiIQItAuweVX1R+yy8I4dCys39ixrIz9boFvyCPQKs5/rkDDoOiVnNEoAURaKFZRkXJT+ojofkkWn3kH0rI9e8wKLKPRKAFEWghN5jpq/yWb4NCaIC8m74nOJQ2/fHHH9UYjsEEZ/78+YpVdz7BYbO5olbcRKAFEWghN9jKVlvY+jb6bLqU3WRJ8KXvWHZm4yvBLyBI7HJH4rTgE8RAE6delE0SgRZEoIXcIKHmH//4hxrCMYGmwsM///lPNYZjfcdukUoi9E+gIUo4DQS/BHrkyJGF2SQRaEEEWsgNjP7XX3+thnAKQjgID1AIh18QwsEKwQ8//KDGcD4ZJTxAKwW+uQMrBEXtvCoCLYhAC80y/kp+Uh8J6qP2AEiSkgh9OwyK3NVTBFoQgRZyg5JO7KIm+ASGhPANlbHzTZ4XLVqkHT1L0E/UvVcZO9/cgZyPokqrikALItBCbhADrSRC3wSaGGglEfrWd8RAKzTANyBIY8eOVQy0YxADPWrUKMVACyLQItD+oSoc/gm0qnD413eqwlEOAj1+/HhV4XBOoMeMGaMqHIIItAi0fxC+oQQ1vyAmkOVM1Rj2C0IDIM+LFy9WYzifjH7yySeFJagJTQfxz3ifv/vuOxFoQQRaBNo3lFRTjj5Sgpr6SGgZ25SHKAnFOQzoI+1EKIhAi0C7B8lPWnr2C0gZy5nymvkmz+g57ejpG5Cy2bNnR50n+MTPP/8cZs6cWVhNdRFoQQRayA1tpOKfQBNfq41UfOu7OXPmaCOVEkx0tJGKb2gjFUEGRQS6NPj73/8eFi5cqIZwTKBVesu/viPR84svvlBjOCfQr7zySvjoo4/UGI4JNNutF2WTRKAFEWghN0jWUIKaXxATSGiAEtR8T3LYzXPp0qVqDOf9xK6eRSWoCfkmOUXu6ikCLYhAC83qKyXVqI+E5k1yikx8EvL3Ex5O+krw20dMRIvSdyLQggi0kBvEmuGVEXwCr9n8+fMVHuAYGN65c+dGL7TgF0xwpk2bppwPx1i2bFmYMmVKYSFrItCCCLSQG8TXqo98E2glEfrXd0oiLMdEh006SJwWfIIVAkhtUTZJBFoQgRZyA8+Zyjr5JtDsnPb555+rMRzrO0gZG94Ivgn05MmTw7x589QYToEHmkTPomySCHQjDBDeAXYgKuNsjASitEA/hOe9994TgRZaBCQQKvnJL4gJpI/QBe0RJHx53ykT/fz9999H4y/4fpeop/7TTz+1yXfzve31PW4sCLNhd9wlS5aIQHshczvuuGO44oorSnfvxAJdfvnly2WknnbaaeGvf/2rCLTQYjN+JdX4NvoYXba4bY8YOHBguOeee0rRR22d6An54H1mQpwekBEbQ+15t0QjsW0x0UHH3nXXXWHw4MFaTWpgMorDgA1VRKCdkLm99torXH/99aW792eeeSb85S9/WW4wnXnmmaFLly4i0EKLgAQ1xdf6NijUrW2v8bXokRNPPNH1PUJMCbNp690iX3/99egouuWWW8Ktt94af3Lcdttt4aqrrooHMcDt1QsKQXrjjTeizisatPkuu+wStt566zB16lQptipgcjNp0qTw6aefikB7IXN77713kwg0ivDVV18NjzzySLjvvvvCY489FrN3zVNHSAjy7DF06NDw9NNPx/+nypXtQ7nWAw88EDsqm60NgZkwYUKsf4iCgzg/+eST0XBssMEGURlyfWau/fr1CwcffHAM5Xjuueei/MEHHwzvvPNORcX+9ttvh0cffbTuu7/55psVzsM4c9/3339/PPi9OYkWDMSjjz5aBLoEIBxIfeSbQPMOF2VQvKFbt27h1FNPdW9j0PFt7Vk877zzwtprrx2uvvrqcM0118SfHNi+k046KWy11VahV69e7bZaCHZp9OjRMXG6LQj0PvvsE3baaacwffp0KbZ62unll19WEmEZCTRLYB9//HFUOscff3w44YQTIhE88sgjwzHHHBOJNMpn+PDhUZ4exx57bNhjjz3i8cQTT8TrEbvHkk337t3j/zm6du0aFV26G9KwYcPCb3/723DppZeGCy64IJx88smhZ8+eYeeddw6rr756OOyww+J3sGvczTffHNZbb734f5Qi8k6dOoXOnTvHLTDTgQi55ju5d76X37l+mkTBQGUA7bnnntGzbedybUh/nqUUlsq4L9qwvRr+soCSTkzcBL9gVy5yIdoj0EXoJ++gzGBbh0f07ds3HHfccVUnYjharrvuunYbDgSwoW31Lu2///7RC01VHaE6d3jrrbcKK9sJgT7rrLNEoFuCQFMPF/JKmARLcikmTpwYrzNixIiqn2cJDU+yEVi8vniL8QAbuC5GAbJs5JIZ15prrhm9Bqlyg6h37NhxuRjViy++OHoZ7r777rpzWfaAZLPcac/84osvhiOOOCKS6FR54NFhKc9q/+LpXmONNcJrr71Wdx7XxQtO/KEF848aNSr079+/wYNrX3LJJWHLLbeM38/A5Ht5VgYoMXkkdOIF+OCDD6L3nYkL38PkxeSQOuTswAbJMzn1ITEGxLJB/k3O81j8VCrHu85LSRz5ggULopw++M9//hPlTHJY0sPjjpwXFznJS0w0TE5ig+0Kl8pZrUCOZ59VAeQ8L38jZ8LFZMnkfN6SWVI534ec7+Fv5Pyf5CTkZPibnO/heZBzv9wHz4qc56cdeD6Tc7+0F3LaA5nJbQc1vGcmpz2smD3tbXLaL5VzL8hpb4uxpN9MTr8xAWM80s8mp5+RczAuTM644FzGM1nY1ocQSK7Nd/C7yTmn0pjimowd5K0xpmir+sYUfVZpTGXHGn1aaaxlx9TMmTPjVtH0VX1jrbFjivvIjql0rDV3TNG+tHN2TPGOI6ddGxpT9A8ycj523XXXcOedd8YYUo8H93bDDTfElcK2vAdCFbfZZpuK/0cvH3744TF/BlvouT1bs41wjt10002Ffy9hNJtvvnkMyYQP8F6hE01/pXoqtYmV9BTvV6qPTF5JTyFP9VRqE3nfkefVU6lNNH2EvCE9VZ9N5POEuLCibnqqmk3M6imeM6unkKd6yuQ8H3YGAo0zUgS6BQg0DTxo0KA6ckmHMpgJ34AMb7TRRjG8oRKef/75GMJh5VcY1Mw4SYDJxpzRgXiMIa/g2Wefjctr2fI6eIC33377OIAM55xzTiTlWc/wGWecET3M5g056qijome70iQBLzME2SYGeLpvv/32+DJV20ITRcASVEPHfvvtF9sbks8zcg9vvvlmHLiQIF5ywgaYbJAkyYuBnO+FJJicgc+A5iVixm5y2gjlwsucyrl35LykhNCYHAVkW+2yzIqcFxTCZS/nrFmz6uT0n5ELiIvJGQfIeTlnzJgR5TwX/YycsZPKjWTR3izZEXvHODKSxedSuSkvG2/I+T9jkPvnvrgucmboPA9yCCVynpXvRxnRDjwf921y2gs57YGMg+fjPo04mpz2oD/oFxSNyWlXzuWdoh+4F+SEGKDUGZMoOJPTPxgHxj/9bH1CPyPjYFyYnHGBUsNw8I6YHMXPtfkOfjc553Av3FM6pmysZccU92ZjCgXd2DFFm1YaU+lYszGFnD6rNqZSOUTfDEG1MUVfE9ZFXCBjCTl9hpx25nwziI0dU4z57JhKx1o6pvgenrMpY4r2pZ2rjSnataExRf8gO/vss6MuMb0CSfR0cE+s3uHo2G233drkHvlObM0f//jHsNZaa9XpYvv/vvvuG3X8n/70p7DhhhvGCQkyb21ZRD9hTwmjSNuntQ/amu+mb37zm9+EU045Jb5X1Wyf6SmIYiU9lbWJ6GjTU+hik/P+VbKJkHXTU6lN5L2vZBNTPWU2Ef3QkE3M6imziVk9ZTYRBwff99JLL8UQWiPuDdnESnoqtYmmp3hu0188H3YG5yUhYiLQLUCgbakLconiJtzB4sh69OgRvcTEHVdaBrj22muXi0PGqHTo0KGixxriwAvFzNRCOLbddts4kBoi0NxXpSRCZlF4lwEDFQ8wMcjcO4klHFdeeWX0fK+66qrRgw0YXEwKILt4Jwi9IMSEWLEUkBdIGwcDtdrBS89z4BEnhlsJar6B8lWYjW9gCNtr3CrhbxxMvCEI9emetji4J4gFBpt3CX3aFvfAJAQiQLghRABiZqs8/A15IPzv/PPPj/eJnvbWlq3dRthRVlIhT0X2E23NJBebv+6664aHH35YSq2eEA6IclFJ0wrhaEECzUtF1jKhB8ST4XXmhYMMQ0ophwepNeAtw4NLyAczpBQoLDJu+XwWfC5LoFl6y26pXI1AoyTrI9AQ2O222y56ofFYM0DsgBwPGDBgOW83bQRhvvHGG+M5XB8C/Pjjj+cq+cNLgJdbSYT+oSRC31ASYbeo27wbfZwnqZ5uC6DrWckcP358DCXkJwc2CocJK5fod+xce8XYsWOXyz8qCpAzPNGsUvA+C5XBiqWSCEtKoImxgcjSmFmw7IhyIpHQXgiWGfCyssSaLfzNcsQhhxwSSXC2zi7k9aCDDqq7VjUCTUgIBDqtnNEYAs3SB14b7qsSUKiESFQDpBlvBcuSeUozqYxdecDkMDvuBF8EGt3TXne5Y0WMvBTPwNtr+QRtCZLXcXz06dMnepr5yXHhhRfG5EIcQ0OGDGmTjUQ8gGV8lvpxbhUNVp0JncGpRgiBUBmsmBBmQZiHCLQTAk0c0h133NHgucxM8TIzW089r8wYSfyjUgaJfUaoWYqpVtORmRQEOBuLzOeocHHuuefW1aOsRqC5Pi9c6tkwD3F9BJpBSBIhfxtJByxjQYyJlWaZxMg8SjVbtg5P/GabbZbLcItAl0thtees/LL0UVtv0tFWIImwd+/eru8RDzT2oq37iNhYJsTodGxLeqCHcepwTnvdTIV+wi63xcZRvMOE2FBGsC3qUJfJYYAzsiibJALdAGgUEiiIR4ZkVjpeeOGFeC4zc+KfreQc/yM5D9IKgf7FL34RCTQKijjkHXbYISp3zkmvB/lkIKCsCIsgnIEXh/PwWHNOuoxDVu7666+/QjkxAvYhongO+Bzkm+9jKSgLyDIebwODkBARnoP4bb6Ta/A78Xo2QJmNX3bZZbFkn90/xJckC7z2eYrui0CXB8TntVePVFmMPkvuRW1t6w0kP5Fg5d3o45zQNs3+3yVia9tia3jGCKu+JLjJYVEdVr2nKJskAt2Il4bGwQNNDcxKB6EYKYhnhnzyPz7H/1lSoNIGLwDZn9TUpHIFJDN7PWKHbZbPjHfy5MmxxBFkGm9ztuA+xJhKHCTqpeBFw3jwWb6HhDwMSqUQE77DSuiln4csc5/cFx7tSqEbDFaSHSH+nEdJJjzY2fsRga49kAlO9rXgl5xReaSoJU2h6TA9XVTtWiEfIEivvPJKm8RAC40Dk9Bx48YVZpNEoAV3EIEuD5RE6J9At+ckwrLoOw87EQoNE+i22olQaDyBVhKhIAItAl0KsJqSLZ8o+AEraIRZ5UnmFYojZui59rpbZFlAeAAruJqM+gWx4oSuFlnGTgRaEIEWcht/DIvgu4/aa+JXWSY5hHGoj8pB0NprQm5Z3iX6qCibJAItiEALuUHpLRIJBb8GhSo8bCQi+ATEmWpF7TXRs0z9xIpbe92UqCzOAvLMikr0FIEWRKCF3GDbaxSW4NfoE6euJELf+o6NVJRE6J+ckWhP4rTgE8RAQ2aLskki0IIItJAbJNSoj3wT6L/97W+xAo/gV98RW1tU3KaQn0CzuVh2zwPBF4GmIpiSCAURaBFo96D2eFtvQSxUByEckOd0N1LBHzEjNKAt6gsLjQdxtSoJ6Z87UBKyqJ1XRaAFEWihWUZFyU/qI0F91B5AsqeSpn07DIpMyBWBFkSghdyghJ28m36BIaG+sLybvskzXk0levp/l9hFWGU7fU9w2OimqERPEWhBBFrIjQ8++CDWGRb8Gn2WNAm1EfzqO+LURcx8A4LELnckTgs+QQw0m90UZZNEoAURaCE3SKj5xz/+oYZwTKCp8KAkQt/6jt0ilUTon0BDlHAaCH4J9MiRIwuzSSLQggi0kBsYfYVw+AUxgQrh8A2FcJRnMqoQDt8ghIMygwrhEESgRaBLYfyV/KQ+EtRH7YWgKYnQt8NASYSCCLQIdClAbG1RJYOEpgND8umnn2qVwDEwvAsXLtQqQQkmOWxKpHwC39yBfIKiNiUSgRZEoIXcUAy0fwJNDLSMvm99Rwy0QgP8T3TGjh2rGGjHIAZ61KhRioEWRKBFoP1DVTj8E2h5zfzrOyY5ItD+CfT48eO1lbdzAs1ukarCIYhAi0C7x1dffaWlZ8cgJpCdIpWg5heEBrDkvHjxYjWG88kooTZFJagJTQfxz5Dn7777TgRaEIEWgfYNlIaSavz3kRLU1EdCy9imPERJKM5h8PPPPxdmk0SgBRFoITfwyKh+rV9AyogHxAst+CXPCxYsCN9++60awzEgZbNmzYo6T/AJyPNbb70VS3eKQAsi0CLQrqEkQv8Emqx0baTiW9/NmTNHE9ESTHQgSug8wSeIgR4xYoSSCAURaBFo/yChRh4Z3wQag//ZZ5+pMRzrOxI9iyq9JeQn0BMnTgwfffSRGsMxgWa79aJskgi0IAIt5AbJGj/99JMawimICaSPlixZosZwPMmhTvfSpUvVGM77Sbt6+p/k4CwoKmlaBFoQgRaa1VdKqlEfCc2b5BSZ+CTk7yc8nLxPgt8+YiJKNQ4RaEEEWgTaNYg1+/e//62GcAq8ZvPmzVN4gGNg7AkLUHk032CCM23aNOV8OMayZcvCG2+8UVjdexFoQQRayI33339ffeScQJNEyHbegl99pyRC/4AgjR49WkmEjsEKAaS2KJskAt0Ogcdw9uzZTV7m+OGHH8KECRNa3ZslAl0e4N0UOfNNoD/88MPCyjq1JGxThOnTp9d0nD3PCSlTqUH/BPq1114L8+fPb5DEsaIwc+ZMbWBUMPBAk+hZlE0SgW6HuOuuu0KHDh2avFsPma0nn3xyrIUpAi0AiI2Sn/yCmECMOIalbMAje/rpp4c11lgjvPvuuzU9ycE5QRx0Y0AoAU4Q6t1C6KZOnRqmTJkSD/sd+aJFi/QCtPC7RJhNQ5M5KhPtt99+Ye21144rC0Jx4N1gd9yikqZFoNsh7r333tCxY0e32cQi0OUB3pbGGn6hbYw+E5wyJj598sknUQesv/76Nb1s3tTEJyZE1113Xdhpp53CgQceGHr27BkdGxw9evSIx3rrrRcuvfRSvQAt3E9MdNB59YHV3S233DKsvvrqMXxK8DsZFYEWchFolG9KoFEKvPjPPPNMePDBB8PQoUNjPcU0seX777+PIRz/+c9/6mQE67/yyivxJ0snDz30UDwmTZrUrEF87LHHRuPJEq7gFyxnapMO35g7d24pkwhZhj3hhBPChhtuGMl0LYPVvYaImQG9etlll4Vzzz03hrdAqCmDx4FOh0B07tw59O7dW4O/hcHqa0M11Xnftt1227DmmmuKQBcMHAWTJ09WEqHQ+gQaQgwgyQ8//HA0VieeeGI4+uijQ5cuXcJhhx0Wrr/++rqsY7xAeDZIpDA8//zz4Ve/+lVcaj3rrLPiZw855JCwzz77hEGDBtV5viBZEPSGjrfffjsahU6dOoXu3buHDz74IC4/YzTwADDD5Hc8NhzV5Hyvyfl8Vs5ST1YOsnLzCqVyDJ3JeWkqyes7n79Nbi9dQ3I7GpLzPel1rDRWS8hpN+Qm4/neeeeduA1xev/IaXfOp12tLbPyauencmRW5ivtc86vNhYqnd+UsdOYMVVJ3lJjqqnyamOH81nK5H1iosN9N2dMtcZYS8dUOhYA8fVdu3YN66yzTtRPFp7w+uuvxxAFO8i6ryS3sIbmyPk9j5x7aqwcZwNOixdeeKHi+dlnRf+edNJJ4YwzzgjDhw8Pb775ZqwOQUgHfc3f6E/0t91j9jrVrp9X3tg+KbP81VdfDQMGDAiPPfbYCu1g7cxxzz33hA022CCGHqEfbdKTjvGW1lOVbFxz9VRL28T65C1h+7gfwlLhJPAGnrWl9VRqm4xAn3nmmSLQ7ZFAL168OP597bXXhqOOOiqMGTNmufMIn4AQ4+2wmTWx0+PHj687h20zf/e738VZWJpFfvXVV8dlrG+//Tb+Tdz1nnvuGQ/IdbWD2LE99tgjrLXWWvGeuD7EHU80AxRCABkgtozZvcmJS8PgmhyPFQMfOfdtcuICkeOlIdHD5BB8FA6TCmLYTM5MFjmeHZKxkKMU8UIg5/l4WU1OshYvG96gVI7X3mLoeB6T//e//41y4raoaGFyEoqQ8392KWNiQRwo5yHHo2hyfnJd5HwP55kchWIbAJic7+F5kPMcfJ/JeX7kxFianPulvWg32oN24X88H7/jPeP6dj5yxhb9Qnsj46Bd6T8UEZ8xOf1gCpt+S+U2eaKfaRvk9DNyDiZ3JmdccC5KjrFrcgi+kTR+NznnIK82pniG5owpPKgNjSmT03a0OXL6rNKYyo413rdKY4qxYXLGAAaFVSLGJGBs0dfZMZUda9XGFPeRHVPpWGvMmEKeHVM21izGlBWtvfbaK6y00krxWGWVVeJk/Re/+EWdjGPllVeuKEfWXDm/55FzT02Rp/dh8l//+tfx/ErP+stf/nK5c9Pz0+tzbqXr8PmWlKf3Y/dZhLzSWGiqvCljKv1/pbGT9iUeaAs9yuov9FQl/WUOh1R/mZ5C3lQ9lcrRuchZsUj1FPrL9FQlm5jqqVR/8b5nbWIlPWX6K6unzCZmbZ/ZxKyeqmYTTU9xHVYI4Ddjx46Nz8991mcTK+mprP5K9ZTJeW5kL7/8cgyhEoFuhwTaDNUjjzwSZ86AwY9hZqBAXnfeeefo6ahGoJ999tmw9dZbr5CZzCx9u+22qwsBYSYPib777rujZ7raMXjw4DBw4MD4WQg0hh8lw6BmwEKOeLFRDJAhXoJKcp7BPHAQGZPzMvGSIEdxmNxIB8ooldvLTFuhgExupANlVEnOy4giM7m95MhRfCanvZGjpFI5L7ntIsfzI0eRcp4pKZPzk5fciDvn0R/IuT9TXqmc5zGlw/ch5/t5ftoHZZXKaS/ak/ZAzsHzcR8o9vR8W47mfNoVmckxGiga+od7R057Y1AqyTEoGA/62eT0M3IOxkUq51yuBVkzOb9z7Wry7NipNtaaOqZM3tgxZQai2piij9MxRV83NKboa4wW766NncaMKeTZMWVjrdqYMnlTxhRyG1Mmt6RUvKoHHHBAnKATznX22WeHc845pyaPPn36xJCMxpyLwUZ/42gg3pnPnXfeefGnHVtssUXUy7XaXm119O3bN7Z1fed069YtOoA4LPm1kp7K6i8IWn16Ct3JOQ3pKbOJvEfV9FfW9jVFT5m8mp5CXsn2oU9SPWX6K2v7svqrIT2F/jM5n6fN0Xdm46rpKeSmd5Dz/PXpr1RP8Xz0IQS6V69eItDtkUCnMdAYqwsvvDAq8quuuipceeWV4aKLLorxhxguW1LNEuhhw4bFeK80Lhqw5Lr99tvnLs2EEjruuOMK29NeyAeUcWNjN4W2QbrMWSZg/AlV2GijjRRnnwAjz6rhbbfdVrWSEuF4ioFueTRmt0jImmKg2w7wmqKSphUDXcOA8L744osrlLAyAm01KomjO+aYY8Ipp5wSPcTPPfdcjEfmc2R2Y8TqI9DbbLPNCokVzSHQqsJRHjDTV7ksv8BzwnJqQ4lPHoGXh0k08aS1XIUDTxZLxXi4GksQcHRA0nA04Ozo169fPAi369+/f4y/xVMttBwgSMSro/PqA7YTOykC3TbOAgodFGWTRKBrGIRmEAqR9Q5TYYPYQlsqPfjgg8Mll1xSkcgeeeSRkViLQAuVQEyZ+sg3gSZmr4yb3WAEmdgT+2zJWLUI9B2kq7Gb3XA+SWw33HBDJMs33nhj/N0OEr9ZRYTsCS1LoEeNGhUnO/WB923zzTePcdBspiIUBzgNYRXaiVBoNsgaPvzww2OcsoEld2KMidWyDidREC9zmgSIMsezQRwX54pAC5VAjFgZvZvtiUBb3GLZQAwj3iRWzGp5lz480OhWS/IUfILwjRkzZjRYUpHYWuwiOT1Z55XQuiB+nCo0RdkkEegaBvFxhHBAjkk2odQcZPjOO++MWbUGEghJFMTbbOXoKM2CDAJtIRx8hpJSzMINjz76aNzoIFt3cciQITF2MU/9WRHo8oC+KmN8rfpI8AIrZ9aY+FqhbfuprJsStbc+auymRCLQQoPGk8Lit956a7jmmmti+EalGTSZpffff388hyVBvNaQYsrB4Mk2Qv70008vtxyMd4vZdnZ7U8g218izzbMIdHlAPGZDW9sKbWtQeG+L2tpWaDqsHKaScf2/S6zMet3BV/j/VwnwPlt+lwi00C5Jvwh0OcBESZVSfJMzYjYphSX41XeU3irjbpHtCRAkyqpSK1nwCSahOP2K2rlUBFoQgRZyQ0mE/gl0WZMI25O+a0oSodB2BJpdIBtKIhTalkAriVAQgRaBLgWolKBEGb9g2RlvDJsDCH6JGRs5VKvpLPgA4QGajPoGuQTsRpgWRBCBFkSgBbfGX8lP/vsIT7Tgd5JD0pP6qBy2SQm5vt+lIhNyRaAFEWghN/BsKqnGt0GhhF1RSTVC0wFxJv6ZLYMF3/2k1Rz/zoIiV3NEoAURaCE3Pvzww8ISNoR8Rp84dSUR+tZ3bBSjJEL/5Iw9ENISsIIvEAM9ZsyYuD+BCLQgAi0C7Rok1KiPfBNothP+5z//qcZwrO/mzJlTWNymkJ9AQ85qeVv5WiDQI0aMiF5oEWhBBFrkzDXwbNbyLnFlByEckGfqDAt+iRnJuN9//70awzGIq4U8a+dV39yBFbeidl4VgRZEoIVmGRUlP6mPBPVRewDJnkqa9u0wKDIhVwRaEIEWcoNl56+//loN4RQYEjxmKpHmmzyz6+sPP/ygxnD+LrGJikJtfE9wyMspyiaJQAsi0EJufPDBB4UlbAj5jD673EHQBL/6jjh11VP3DQjSuHHjIkETfIIYaDa7URKhIAItAu0exAQWlbAh5CPQVHgQgfat79igQwTaP4Fmm2icBoJfAj1q1CglEQoi0CLQ/oHR/+abb9QQTkFMIEvOSlDzC0I4CLNRrW7/k9H58+er3KBjEMIxd+7cwmySCLQgAi00y/gr+Ul9JKiP2gtBUxKhb4eBkggFEWgR6FKA0ICiSgYJTQeGhBJpSvT0CwwvmxFpR0//kxzlE/jnDoRDFbVKIAItiEALuaEYaP8EmhhobaTi3+grBtr/RAeipBhovyAGeuTIkYqBFkSgRaD9Q1t5+yfQ2srbv75jkiMC7Z9Aaytv/wQaMluUTRKBFkSghdwgNEAJan5BTOBXX30VfvrpJzWGUxAaQBjU4sWL1RjOJ6MKh/I/ySkyHEoEWhCBFpqlsJRU4xtKfCpHHymJ0D9+/vnnXERJKM5hQB8Vpe9EoAURaCE3mO1//vnnagingJTxDn355ZdqDMeT0AULFoRvv/1WjeEYkLKZM2eGhQsXqjEcT3CmT59emE0SgRZEoIXceP/995VE6JxAs8udkgh967s5c+Zoi+gSTHTGjBkTE6cFnyAGesSIEUoiFESgRaD946OPPpJHxjmBxuCzUYfgV9+R6KlykP4J9Kuvvho36hD8EmgSPYuySSLQggi0kBskayhBzS+ICaSPli5dqsZwPMkhfAPjL/h+l7Srp/9JDuEbRdkkEWhBBFpoVl+RACX4hRKf/BOzIhOfhPz9xEQUnSf47aMlS5YUZpNEoB0bPYrrv/LKK7Fz6juInxOBFtoC9I9qDPsF3s158+bVVI1h9ANGslaqVmDsCYVSeTTfYILz5ptvNmiTIHGQKWy4KqsUi2XLloXXX3+9sN0iRaCdgqSfjTbaKGy55ZZh3333rffo37+/CLTQJiCJUH3km0AzEf/0009r5pnIsr/66qvDjBkzamL1A303e/bsZicRGnGDRBAOkj2snCHnCU0HbTt69OgGkwjZRnro0KHh1ltvVWJowWCcQ2qLskki0E5BFulWW20VO6a9QQS6PMC7WUvkrBYJNDun1ZIhv+eee8KvfvWrcP3114cff/yx9M8DsWV76OaUGqSfSW4bOHBguOmmm8Jdd90Vf+fg99tvvz1cd911kQAWtclELRLo1157LcyfP7/e82bNmhU23XTTsMoqq9Tc6rB3MHkk0bMomyQC7RQff/xx2HrrrWMHNQYkNrzxxhvhu+++q6hceaktEx8PBEoAZfrUU0+FJ554IpbnSZfi+cy0adPi0iIk9vnnn4/n8TOb0Y/if/nll+P/OV566aVmZSozEI8++mgR6BKAZA0lP/kF7zp9hGGpFTzwwAPh97//fRgwYEBNJLCia5kIsOSfF3z2mWeeCZtsskno1q1buPLKK8Nll10Wj8svvzz07ds3rmaedtppsea0kO9d+uabbxrcMRLSjPNrjTXWiCUkheLACguhUEUlTYtAOwUeaAj0xIkTG3U+nsCDDz44DB8+fDlCw4CCLHft2jWMGzcuGlJ+9uzZMxx33HHhyCOPDIcddlg46KCDwoUXXhjeeeedOhK7yy67hB133DEq4WOPPTZ07tw5dOzYMX72ww8/jOexkcZ5550Xdt1113DIIYfEax111FHhlFNOieQ8r1E45phjwvHHHy/vpnPQv80x/ELro9YSCB988MGw+uqrh0GDBqlzE1C+69RTT6262oDn/sYbb1RJw2ZOdhoCE5Rtt902rLnmmiLQbQDyI4oKU4JAn3XWWSLQ3gBx7NChQ+jVq1cYPHhw1QMvMcATM2zYsHD22WdHb7MB7zBLekOGDAlfffVV9A5DhO+7777lsomJ24IIQ6pt8O23337Ro4Gn2gAZ33zzzePSIIAkoygmTZq0HKl6/PHHYwwYgxmMHTs2LiE2dHCvV111VZzBQ+4xCkwOSApggDI5WLRoUVyWxsuN15xJAjNOaj+aHCOBnO9P5ZS4QQniRYD8mxyjg5x2xPtvctqF9sBDxKTG5NRsRY7nP5XT3ibHe25y2t5KiqVyPBrIWTlA8SLneSlrhZyftDkrAcg5zzwhqZzrImf2zd/I+f8PP/wQ5dyXyfkensfk3IfJeX7ageczOfdLeyGnPZBzIGfCRfum59Me9Af9Rbsi46Bd6T8rNWRy+oGJHUvZ9JvJuS5jiXFKP1ubIUfGwbgwOeOCa/AZcghMzrtksaH8bvJqYwp5a44pEvpsTKVyG1P0WUuNKfp81KhRYcqUKXWrU4wp+jrvmOI+smMqO9byjCmT0760M+2UHVMA4vzb3/42dO/ePf6OLrv//vtLe9x7770xppswi7zXwBacfvrpYaeddoo5MZX+jz499NBD43eVub3asp8uvvjiaKeqncNYpP032GCDsNZaa4V33303jtlqeiqVo5uQo6dS/cXv9ekv3otKNjGPnkrlvH+2OlLJJjZXT6FXsrYv1V9ZPWU2sZqe4v/Epz/yyCNh8uTJdTaO72+MnuL8rJ5CXk1P0X8QaDiaCLQz8NKw5LbHHntE72+1AwJrwMDjAX7ooYfqSDDLSchIvAHs0vPkk0/G3xkYDC4GFXFDLP3tvffedbPsvfbaKy7/peAl3m233cKdd94Z/54wYUL0SvM3L1m1JdU77rgj7L777vHgmaodfCfXR/lA9J9++ulo/HkxIEwMckgbhJ1sW2IHUTq8tCRLmZyXkQHNy0UbmJwXAOXCy0bijslpA1v+YQJicl4U2oN2YhtXk/OstDEvG8lMvLDIUUDIedneeuutOjkKzuqI0hfICbmhn5Gj3JgMIed5UYLI+UnmN/KpU6fGzyPnc/xtciNlKNhUjpLg/lGkXBc538PzIOd+uQ9i+5CjnGgHFCP3jZz7pb2Q0x7IOXg+PkubpufTHigp+ov/IeOg/eg/5Cgh7gU5/cBYZGzRbyan3zAOEFz62dqSfkbOwbgwOeOCa2A4SG60vsKIoez4Dn43OefUN6Z4hmpjKpXzLJXGFEobOW2ajimUMm3PWEvHFG2InD5rypii7yuNKcYKYwDD/9xzz9WNHcZUOtYYe00ZU4z57JhijNpYy44pnrMxYwo5z0f72vbW2TEFIIMrrbRSPLbZZpuos1gBK+OBrmOlD4fBDjvsEPVjU6/BZ3beeeewxRZbRL1Jm6BH7f/oVf6/4YYbRmK33XbbRRnfXdZ2K/qgjemnzTbbLK4M036VziOpn3MYm6ySoGN4h1L9hVc61VMmRzchR0+xsU5WT2FbU/1lNpH3gmuanNVh3p+sTTQ9BWFN9ZTZRPRUKuf9M5tYTU8hz+op9EM1PWVy9AN6xfSU6SPkTAyQw2dSPcXfyPl/JZuIXoPHMEEknMkIOt9v+qsxegrbnspNT6X6i+eg/whdZdVHBLrkIRzm+b3hhhvCpZdeGgcBxIB4wd69ey9X1gXDh6eXuDgGGwdhGnxfp06d6sg3Svjmm29e7jt4iVEURqB56R577LFIdvFu4MG+5JJLYvm9FNwLLxYHA7jawWDlReF6J554okI4SjBOVcbONzAUvFe1Ala3fv3rX4cDDzwwEhMIRH06xfPBRBYCgGFnwoURb+o1+AyTHyo/EKrHZMM8kxzYBfr/2muvjWF6kAn0dlnbrC0O2hgCyGospJH2rHQe9pFVXiYyq622Wp0HWigGcBdIL84GhXC0Y1gSITOcpsRn8TmWNjEyvOgs2zFjsjhVlCuJJMQpQ7ZZ7mBmiRFiCRGvhBX0h0ATM1cfgTavNEqDxJUePXrEWGy83oSU5ImP5SUgBlpJhP6Bd1gbC/jvo1ra7Ialcrx7d999d83E3zf3HUJnP/vsszFnBd2MBw2Pm3kBIX44JUh4YtIr5IOFptUHvMeKgW4bwIHgMkXpBSUR1hCBNuBlOPfcc2OZpy5duixXtuiCCy4Ihx9+eEWFfcUVV8SlqqYS6EpKhs8Rj5dncwCVsSsPGA/aJtq3RwaDUkuVUkiGW3nllWMsai2UsbM+ao7RR2fjKEFvknyNnscGcJx//vnRyOOxp3JJLW2qU3Q/sWLQUOUXHFcbb7xxLLWoMnbFgveAlQDLvRKBbqewEA5iepoKXlqW8ogNpCpHukUsoRrEaaWljCBAjz76aIzd4n9pCEc1Ak1tUQDBJSue+KoUt912W6yFSciGCHTtgn4nxkzw65EhVrKWKi9QSnOfffaJcd21UJ6P1QG8lnl0ZUruiJ3lXeSdJF7fknHtwKZAAGtpNaJIQJCwxw2VaMVmUakKjz9hOUJxwFFA4QHCVEWg2zEYAOuss0444IADYgxzfQcENquQyRbOep8BxvSiiy6KoR18lsob55xzTozjgUCz9GQEGgKfTSLE40OyCjHUpizweJ988snxOlyToHpiqQnpyOOdFIEuDzD86iPfBLrWdiIkZphnsuohZYftREgyp+CbQFPRhqS+hvqTmHSItlbnigXtzaq9diJs58DTi1eYxA/K4tR3WFWNFMx8qy0fsYTHtSG4hG2Qpc/5JLIQR2dGCQ8Py1FZ5UCGKwbMwPIjnm67V65J/HPe5VUR6PKABDUZft8EmneoOd5NoXWBw4MqQCT2CX7BSi72sCjvptB0EAZFEmFRK24i0II7iECXq69qbaOOWuyjNIxL8AUcFuqjcqDWEnJr8V0qso9EoAURaCE3WEavhUSuWjYolNxqaPthoe3AKgHeZy33++8nPJu2IZHgD5BYSvYWZZNEoAURaCE3SFbSkqZvo0/Mpmp1+9Z31AsuqnatkJ+csb8BOk/wCbzP7HpMaKEItCACLQLtGkoi9E+gay2JsBb1HUmEJEcKvgk09bRJxBf8EmhIrZIIBRHo/6+98w6Ss7j2NuBrE67BNrZJBgMmg8k551zES85Q5GiyyTmYnHPOUEKohITIGZEMFqBwbYQDvtjXxoBJBf/1V0/f6v1ejWZXu7Ozr85on6fqrd3pnZ3Q/fbpX58+p1sBHR6EmZ6zuBDCwQpBK/uxS33CjH3/DQ2IDTHqHIzCDhsSE5IImYzWtde5AloU0NKvwd/kp/hthCda4k5ybKPOGZtMmo7dl+pMyFVAiwJaWoZTnxr3GpdYAworBGw1KTFhsMdjZqJnbJjgsFKAzZOYsPsGmqGu1RwFtCigpWXeeeed2hI2pLVBnzh1MtMlrr178803PWI7OAgkTrnD5klMiIEeNmxYnugooEUBrYAODTs8cESwxBXQxm3Gt3ccemUSYXwBjTgziTC2gB4yZEhtY5ICWhTQ0jLsi/qPf/zDiggKIRx4n9kLWuIKM5JxP/vsMysj+GR0zJgxnrwaXDvg1KkrzEYBLQpoaRniN01+so3ENhoMEGNr0nRshwFtVFdfUkCLAlpaBm+MW6TFhYGEQ1TcIi22eCbExkTP+H2JQ1T0QMfWDqwS1LUqqoAWBbS0DMaqroQNaW3Q55Q7kwhj2zvi1E0ijA0C6dFHHzWJMDDEQHPYjUmEooBWQCugRQGtgJYgAppjohXQsQX00KFDFdCigFZAx4c9hk1QiwsxgQgzE9TiQggHYQGff/65lRF8MjphwoT097//3coICvHP48aNSx9//LECWhTQCuj4g7/JT7aR9A9PIuwcgWYSYWyHQZ1tpIAWBbS0DMlPeKElJoiyiRMnmugZXDyz5OyJnvEnohx4457qsbUDe6rXFQ6lgBYFtLQMhwp4kEpsAe2gH9/evf766x6k0gETHYQSeR8SE2KgH374YQ9SEQW0Ajo+HuUdX0BzlDdb2Ulce8ckx5Wc+AJ65MiReSs7iSugEbN1jUkKaFFAS8sQGmCCWlyICWRP1C+++MLKCAqhAZyc9tVXX1kZwSejnBhZV4KatDbJ+eCDD2obkxTQooCWfhksk2piY+JTZ7SRSYTx+fbbb1sSSlKfw6DONlJAiwJaWoalMk/miguijD7k1luxJ6Hjx4/XsxkcJqEvv/yyIWvBJzgvvPBC+vDDDxXQooBWQMfm7bffNokwuIDmkA6TCGPbO3YOMIkw/kRn2LBhOXFaYkIM9JAhQ0wiFAW0Ajo+7733Xo45k7gCml0D6vLISGv2jkRPVwniC+jHH388jR071soILKBHjBiRt+5UQIsCWgEdGpI1vvzySysiKMQEsr/w119/bWUEnuR88sknefCX2H2JnVL+/e9/WxlBIcyGlZy6kqYV0B0Mm+8/9dRTufF6ukaNGlX7MbEYmt/+9rdZDCugp12IOSMBSmK3UScmPnFfsesB4Q3T8iQNYfbNN9+YnNYB7cROKfSnnqAtGbfYmtDdb+pvI2xFXWOSArqD2XnnndNss82WVltttR6vTTbZJIvtOrn66qvTL37xi5aWJRXQnQPt8+c//9mKCAreTZac6zqZq53wmffbb7/0ox/9KE/Gp1UY7NlbmO0Ge9umeNmYWJAw9corr+TkNq7yO+X2y/aCd/O5556b4phEWNu6666bfvKTn+QDcqQ+mLzgVKzr3ldAdzBbbbVV2nfffUN+tuuuuy4tueSSeX9TBfS0C0mEtlFsAc0gjie302C3A2zAnHPOOU0nbmHvXn311V4nEbKaeMYZZ6TlllsurbPOOmn33XdPO+20U7522WWXfM0xxxzp+OOPtwO0EQTSI488MsV7kbZcaKGF0qyzzpoTeKU+CINC1NY1JimgO5htttkm7bXXXn36HxKKRo8enWdoDzzwQD72ksMwCniMhw8fnm6//fZ0//33pwkTJmSR9OKLL3YNyMzCGz3aDALPPPNMV0LZ9ddfn5ZaaqmWBHT5bgyedXvOpW+w/ZY7PMRm3LhxHXnKHaIfUTj33HNP81uH8V17GwNNCMGxxx6bDjzwwGyLiZ/GbnNhy//1r3+ljTbaKB100EHe/G0GQTyliQ4rPksssUT6wQ9+oICeCpNRPdDSK/BAH3DAAX36H54/zzzzpPPOOy/tuOOOaYcdduiaUdPZDzvssLTtttumzTffPBvhPffcMy2yyCJpxRVXzM9huZHH55xzziSvyx6mCyywQLrkkkvy4xtuuCEL6LIsyVHCLMMSF8bP7i6y0ZnBr7322mn77bfPR0UzYNAxiG9CwPM7gw1XibGmnOdVy8vzq+V8/u7KgWW6KZWzTFQt53EpL52or+X87E15ORCjXeV8j96UU1/UG+WlbijHG1bqu1penl8tp/6avU61vPH5lPW2vLR5d8/v6R7pxHtqSs8vbU4fJNmzrnutv/dUOVAE4Y8tmn322dMtt9ySwxNeeumlPJknRKFclLVSXi2bmuV8vkcffTQ98cQTk5QRitH4fB6zy8Buu+2W9t9//zyAUy84RQjpwHbyO/Zzs802y89v9jrdvX6r5c3quFPKe3vvPP/883mLtMcee6zb53Nde+21edKHgGa8K8Kut3atmT2akv3qj50q9q43dir6mEiMOjsOMalsl/2q2qlSXuLg6X+EmSmgOxCW6lZeeeV0xRVXdHvde++9kyQ9HHXUUTmmkPLizeDGwIt4+OGHpz322KMrXpLMfZYKWYpaf/31u26uFVZYIV100UWTfBa8HksvvXSOfa4KaG5kQFgTj7366qunNddcs9uLJUmex2fcYostsoccEY0HqnQQvOIsS2OcSjmJA3hDSznb2NAhSOJgIC7leHooR/jhKSjlfH86CkKDGLZSjvCnnJ0MiFOkHKHP4SGU872r5Xgn6GyU87mZlFBOnVKOh4hVgFKO16gct1wtx3NPOT9ZAaCcn/w/5fxftZwJTMkS5zGfnZ/Uf4mZZHJCORMmvg/lfI8yseH9+f6UY4Sq5dQX9UZ9UMbF9ytHEFfLqQ/ag3ahvks59cpzuYdYqeCzU047FENOu1XLMViU086lnHbmvuVihaK0FfcFz+V/2Ae0lLOcV0Qav5dynkP5QN9TZO03u6eq9xp1TZ2XHRnacU9RTlszqCOuuMfKPUU5z+eeKOVTuqdKOZ+j8Z6ivF33VEm8YsuwVVddNU0//fT5mmWWWdJMM82Uvvvd76bvfOc7+fqP//iPNOOMMzYtp6yncn4fqHI+U1/KsbHf+973usr5zM2ez3PKe1InM8wwQ/6d588888z5+fxe6qx8Rv6v2eu0s7yU1Vne23uhXeU//OEPc1t1d09xTTfddPlCQBfnVKP9Knaqmf3CTlXtV7FTjMd9tVPVcmxuMzuF/Sp2qlqOF7evY2IzO1XsF/akWo5dmdKY2Bs7VR0TeR4THT5TsUfYye7GxGKPeJ9ipxrtF/VS7FQp53tT9tBDD+UoAAV0B4J3eL755svhDt1dCOZqBjvLeojhxuXCCy64IMdTN8ZKcrPh7VhjjTVaEtAlPITB8Nxzz82e7/PPP7/bi89x9tlnp8UXXzwL6JEjR2ajwc3LDcvnxhBwA9PZSznGpVrOYE054giDUsqL8KVOquVFjGB0MEylvHRyjA7GrpSXTk7nqpYX4UtnxPBheBBbpfPTqRFxpbyIFOq5Wk59FmPE96ccY8jzijHicSnn/Yox4jGfhZ98vmKMSjmvx/cpYor3o5z35/tTP3w/yko59UV9Uh+lnO+HEaO+qs+nPmiPsqVQtZz2w9DQDnx2yvn/4sGg3Uo57VMmeLRzKaedGWi4MPKl7innufwP4rWU83vxHjSW81kG6p7iu5fy6j1V7rWBvqcop83xmhFexeP+3FOlvD/3VLWceqG8ek9RTv0CAyGeVIThlltumSf35cL2lWsgy6tlA1WOfcVbTMhabz4jK4fYVmKg+R8G8L333jtf/M7185//PMfhTo06m1bLiTUnObDci909n9VbkvsR2yX5tWq/GGOLnarar1Lek53iOc3sVLNy+lHVfmGnmtmvvtqp7sbEYqewD8VOUV7sFPakaqeK8G0c+6pjYnd2qlpetWsIYVYAnnzyyWx3mtmpqv0q9ojy8vxGO1XsV+PYR1shoOl3CuhBFMKBMG2EZQh29WjGmWeemb3CrQjoVmOgWbolvKSuDdGlNUwijA9emU48SAXhwCobIWfTepw9A3hv9+pmMD/llFOyw6Gs8DWCyDYGuv0wEZ3SvUhbGgM9dUCfDB061INUZMq0kkSIgGaG3AivgzejGWedddYUBTSzwGWWWaYtAtpdODoH2gePh8QEsdWpSYQMgkyi55prrml6Fw5sKt60ajJ3T2BrDz300PTLX/4yOz1OP/30dOKJJ+br5JNPTqeeemr2fvZ1bJCewXvLqsiUjokmDn3hhRdWQE8F8N4zyTGJUGoV0BhdlqJYHmm8Icn2Jna5GPvll18+XXbZZZM8j2UgBLMCevAZrFYOy5F626gTD7tBQG+99dY53rUkY02LsGxcQpt6A0v/hMSdcMIJOW/l17/+df6dCxHNT0L3SDaU9rYTy/n0p54g32D++efPcdAkeEq9DgPaaEqH3SigJYdwIG7bIaBZij/kkEPSMcccM8mphTfeeGPeh7UkEXKTEJ9c3WOUmCIEOHFfZMsroAcP3CslZlViDvr0z048JprPzXLshRde2JEe9L4M+sSHTkmYydTvS4xnUzrVl+fcdNNNeacq4o6lPlglIIa5rjFJAd3BIDLZLodYt54uRHHZWYOYwpIQ2AjbKJEEwQ2BmN5nn31yLN2CCy6YNtxwwy4jQpIfO2aQVFFEN//HjJsAfrj88svzZ2tl4FNAdw4sPZe9vyWmOCP8oRNjoAcLrA4Qp97Kqa1SHwgkPP/YPIkJjgJWXoyBlilCZyY+mU31e7pOO+20LuM8atSonDnaHSRIXHnllem4447LW9iRRYx3GUFb9kkk2eW+++7LXmiu2267LQvdW2+9tStWkZ94o1uZCSqgOwcGftsotoDu1JMIBwvlJEK9lfEFNCsirNZKTNAm6BtPIpRa4dRBtpBrjIFmk/iDDz447yldDjioY0BRQHcGbHvkwB9bQJP01OpuODLw4IFmm61G2yuxwIFETLM7Q8WF2GcOualrTFJAS4YDSwjX4OjcXXfdNYd6kFTIHqUcy93bDHEF9OAb/FsxHFJvG5XVI4lHOZHONopPpybkDqa+1JeEXAW0tA2WeQnN4NRAtqm77rrr8ilmdSe3KKA7B/b/nlJSjUzdAQXPZvUwJYkFqwQ4KHq7D7RMvXZiy05snsQEEUsYKgnICmgZlCigOwdOoSKMQ+IO+sRsuld3bHtXjjaW2OKMk3GxeRITvM/Dhw+vbUxSQIsCWlrGkwjjC2iTCOPbO5II2UtfYgvoRx55ZJo+1GdaENCIWpMIRQGtgA4Py2V6zuJCCAfbDNaZwyB9F2Z/+MMfuj2WW2JAjDoH+tR1yp30HZIIOcimbNurgBYFtIQe/E1+ij/w17WDjrTej2yj+JiQG99hUGdCrgJaFNDSMmyPpucs9oCCN6aupBppbYJD+AZHEEtcypaQHngTe4IzYcKE2hI9FdCigJaWeeedd0wiDD7oc9iNy86x7d0bb7xR27KztAYCiVPusHkSE2Kghw0blkOiFNCigFZAh4YkQrwyEldAI86IVZe49o64TZMI4wtohNKYMWOsjMACesiQIbWNSQpoUUBLy3z44YfpH//4hxURFEI42MLOMJvYwowJzmeffWZlBJ+M4n325NXY2oFdUuo6eVUBLQpoaRkT1GwjsY0G02THJMLYDgPioOvqSwpoUUBLy+CN0QMdFwYS4p89PS22eK7z9DRpvS/pgY6vHfRAiwJaAd0REA9YV8KGtDboc8qdSYSx7Z1JhPFBIHHKnUmEcSEGeujQoSYRigJaAa2AFgW0AlqiCOhHH31UAR1cQHNapAJaFNAK6PCwJ6oJanFxH+j4uA9050xGGY/qCg+QvkP88/jx490HWhTQCujOGPxNfrKNpH94EmHnCDSTCGM7DOpsIwW0KKClZf74xz+mv/3tb1ZEUBBlHHRjomds8cySsys58SeihNpg8yQm3377bXr11VdrC4dSQIsCWlqGjGcPUoktoN98800PUglu715//XUPUumAiY4HqcSGGOiHH37Yg1REAa2Ajo9HeccX0JwWyWEqEtfekejpSk58AT1y5Mj03nvvWRmBBTQ7pdQ1JimgRQEtLfPxxx+boBYYYgL/+c9/pi+//NLKCAqhAYTYfPXVV1ZG8Mmoe6rHn+QQYlPXqZ4KaFFAS8uQsNGK4ZB628jEp9iTHNuoM/jmm29yW0ncvkQb1TUmKaBFAS0tQ/KTJ3PFBa/ZhAkT8naDEhMG3nHjxuXVHIkLE5yXXnrJfe8DQxLh888/nz788EMFtCigFdCxIb7WJMLYApqdA0wijG3vXnvtNZMIO2CiM2zYsJw4LTEhBnrIkCEmEU6rkCjCNitPPvlkvpgt4SHqz5IDnguSuTDEU4L4oOiiVAHdOZBQ88EHH1gRgQU0uwbU5ZGZWpQwiN7YwIj2jomoqwTxBfQTTzyRxo4d29b7lvZ3D/D2QPgGiZ51jUkK6Jr49NNP88zo6KOPTltssUVaZZVV8rXxxhunAw44IN10000tL4XffvvtacEFF+xVpv0+++yTNtxwQwW0tAWSNUxQiy0saaOvv/56mv6e7777brr44ovTnXfe2XGxxIgnxgcG/4F6fWwqy9uNl+Ktb32JSU47k6ZffvnldOGFF6YHH3zQXJI2QN9nD+i6xiQFdA3gdT755JPT5ptvni699NLJjgKlE2222Wa5ISZOnNjn12fQWHTRRXvlZTrooIPSpptuqoCWtsAgbFJNbAZD4tPVV1+dpptuurT66qt33HcdyMQnVhwvu+yydMEFF6TLL788XXHFFV0XjxFvjEmtjDuDUUAjzLB57eLYY4/N9+2KK644zU9y62yjulaiFNADzBdffJGuv/76LFo50KA7iFNE3F555ZWTzahYJqeh7rvvvvTss89OtkXLXXfdlRZffPHJBDQzsVGjRqX7778/NzDLGnvttVf2gBfxQ1IE8ZHEdfE8PkeBmTaxebz3vffem3+y4X/VgPAeL774Yp4k8JPPyPXKK6+0PJApoDsHwo/Y2kligneRJee6TuaaWlx33XVp+umnT+uss07HCWg+Lx70gTgtkkMl/vM//zOPP0ceeWReAf3Vr36Vf/KYsWCWWWbJtl96hrGY8Reb1y5OOOGELKBXW201BXSbnAVPPfVUbTkfCugB5rnnnks77bRTFpVT6iB0zOom7QjV2267Le2www5pgw02yBfC8sQTT5zEY9BMQCNmjzjiiLT99tunjTbaKK233nppjz32SIssskh+PcATPt988+XPd9JJJ+XB54wzzsg3AoIY7wQidsstt8z/z8X733LLLV0Z4wjrmWeeOYt/wkP4jHiB1lhjjTxxaHW2vt122+XPqWckNky8nOTEhvjaaX2nlBtvvDHNMMMM4cPTerL9AyGgnn766Wz/uwvvw87z98cee8yO0gsQ0O0UZ4y3CGjGy3Z6tgcrTEYfeeSR2nSDAnqAueeee9JKK63U56xQvLA0yiabbJIuuuiivDQBnFiFoD399NO7vEpFQJcsbrwZiNmDDz64y1uNd+PQQw9NM800U9p5551zGQcsIKgRveWGYzN/yvnfXXbZJb3wwguTfC4M7dprr53uvvvu/Ji4bl4Tcc5yYQGRz2vzWoBH+tZbb+3VxWC47LLLpq233rrLu83m9SWWj9fku/L9P/nkkx7LMUrVcmINqUvKqZNSTj2VpdRqOV74Us6Eo7GcrN9q+eeff56/L4NhtZyViFJOHF0pL7Fa1Huzcn7y/SnnZzlsgderlpfBt7Gcz8fn5HNVy/k+pZz3o5z3L+V8v2o59UV9lnIuvh8CmpWN6vMpL7GV1DdlpRwD11hOfZd9cGm3ajlGqbGc9qSci/uiWs5zG8uZ7FHOe/B7Ke/unprSvdbbe6qUN95T1XttIO6pUs69wmOSlbEb5d7p7p5qLO/rPVUt7+091ay83DvUU/XeaXZPFfvCZB8P9GKLLZbzSXprayJc2DscGJdccklbXxdHx+GHH57D+0477bTsjGm8zjzzzPz3Qw45JD+/k+qt7ov7ijGUsbdd7UNYZwnhKA6w7uxUtbw3dqqxnH5T7NdA2qme7Fd3dqq7MbEvdopyNAh6iI0ait3pyX4Vu1MdExvtUbNyvh9jCgJ63333VUAPFDfffHNaaqml+rzHJ51pm222yZ2sEcTutttu2yVii4AuR8Eed9xx6bDDDptsWyQe423YaquturwPDDgsf1ah051zzjlZiAMdjOcyCLPUt8ACC6Srrroq/43PgFBuPN4UY7Pkkkt2ndp07rnnpmWWWWaK1/LLL5+WXnrpNNtss2VvN8dysgRNx+AGpbNwTCfCjZ1H8AZQTudif85STlgBNzidislLKccTgxGhU1XL8dCVToVHtZRTZ6Xz4CUq5XSkkqBVLaeeKMeIjR8/PpdTj3S4Us6er6WcuqaceuJ7Npbzs1rO8yjH0FHnlPOT16Wc9+F57LxAeTGCGIJSzusVI8jnrZbz/akfvh/fh3I+L/VFfVIflHPx/Xg/6rj6fOqD9qBduI8pK+UYL8ppBz475dQ35QwQtFspp31KolMJM6KcdqaMi/uilHNfUIbBQ9SXcvoLr8178Hsp5znN7qlyr/X3nuK7l/LqPVXutb7eU/TD3txT3BvVe4owLLzQ5d7p7p6ivNxTlDfeU+Ve6+6eKuU93VPVcuqF8nJPlXuNeqeeqafqvdPsnqK+eU8EKEKEcAXsB3akN/YmwoWzYOWVV04rrLBCW18Xxw22mjrBRi+33HL5vcp78phy/j7//PPn53dKnU2tdiLUoh31xGvxOnPMMUe+bykru3t0Z6eq5Y12qnFMpP802i/sVDP71Vc7VcbE7uwU5cVOUY6daGaniv3qbuxDM1XLedzMfhU7RTnvR04Z9q6McdUxsWqnGu0Xdory3tgpvh9jykMPPZT23ntvBfRAQYIfxrGvS6h0DjwDxCyT5IEXmotMc8QoApPHVQFdtkFCeOJ5aMaBBx6YExaLgOb/CC9pxogRI9Lxxx+fLzwVeJXxXn//+99PN9xwQ9d7L7HEEpPFWBK+wcShJExWvUnFg9nsYvDHACD0CS0xhCM2GPWB2j1A2gOTkGn9lLtrrrkme6AROEx0GEx7sjORLsYGhAg2v52vy4QLLzPhAWyXinBCDCAU+MljxMaaa66Z7TnP75Q6mxpXEVCIzP6+FmMvwg9HlyEc7YX7u648CEM4BpjHH388xxETOzWlCsaAFcHJbBFhSlwyQpLXKBehFSSBMMtqJqBJDKFjNoPQDJaNqgKaMJMqzFyvvfbavMXebrvtljO4eY+yVynLTQj56ns3JjA2Cui+wCwQL7lJhPHBo1AN3ZFY4Dkp3qRpGewNMdDkaXQieLoQVO1m6NChad555832mjEIIU1eDj95zA4d/P2BBx6ws/QC6q6dJxGWlRPyhkwi7D84cwgzdR/oaQRmm+edd16Ok+lpn2ZEK0KWrGlgwCOEg4ZpBrHBJa66MYSDeDYEdON+ldxcJOaVXTi6E9B4fVlSuuOOOyZ7X/4HYUy83kAJaHfh6Bzeeust2yi4gGbnnGl9ksO2bAiRVVddteN24cDeEbM5EJMcPMzrr79+DvnjvAEcKCR885PHJGvzdwS19AwCiQlJcVy1A3ZE4b4lpKPE+ErrMAkhrKKuMUkBXQN0OBLiELXPPPNMV0JggVieU089NZ111lk5vgZYGkec4n0usc7A8gTiFQ8tW9RVRWyJecZo7rfffvk1S6fkPdn3k5irsgtHdwKa2Rsd+vzzz8+fo4C3kYkAMXMIZAW00D69OcBHpp6AJl6vTK6nVciVWGuttXKIWqcdSIHgxwNdEiLbSckHKDHsJXacq8SQ8veqnZfmEAZFUn07PdDkCuF9RhsYCtee+52VlbrGJAV0TYNY2ecZTwAe4qOOOiodc8wxORSD7eZOOeWU7M2rQpwascd4osv/IIwR1YSGlJgpOiHCuLofLzNldsYga5hZLv/He5c9QQHBzf81JioiuomdwztBCAfvy2vw+dkBhBkzS3/dvTfw97nnnrulgVsB3VkGqxOPTx5sbTStH6SCY4EER+xFo4MiOmVHA0+ii99O7T5IhcS4aiKf9F9roZs8SGUahBhnPCVsg8OMk43sCe8gZqe7Tkk5Z7uz4Tr/Qzwyu2FUoQOSRFO2iyngeSLRkIRCYq04NIWEwbJpPsaA/yu7bTTChuR4sXlf3p84OcI7SDhhybGn9+bQGHb3aGVZSgHdORAm5NJj7EF/MBzl3emD/kAe5S3t60vtPspb2gurBDjtPMpbBi0K6M4Br587pcQWZyzVN4ZYSRxYHWD1sSSBS0wQSIRNNm7ZKnFgJefRRx/1IBVRQCug42MSYXwBPRiSCDvd3g1UEqG0V0C3O4lQ2otJhOKAooDuGJjpNx7YI7EENLv1tJLMK/WAB5p9oMuhUxITwgNGjx5d2xZp0ncIeSVUta7JqAJaFNDSr8Hf5Kf4bTStH6TSyRBbi82zjeIzGBJyO70v0UZ1jUkKaFFAS8uQRW5STewBhe3RyEyXmLBKwAmsJuPGbydOycXmSUwQsawQkDitgBYFtAI6NOzC8v7771sRgQd9Yjbdqzu2vWPXoml9r+5pQZyxI1Z3u1bJ1IckQsRsXWOSAloU0NIyiDPbKLaANokwvr0jidBcgvgC+pFHCzADEAAANiZJREFUHsm72khcAY2oNYlQFNAK6PCwpOn2W3EhhIMlTZedYwszPGbsBS1xIUadMxgaDw2TWNoBh0FdqzkKaFFAS78GFU/Qso2k/yLaNoqPCbnxHQZ1tpECWhTQ0jJ4n91+K/aAQmhAXUk10toEh223TPSMDRMctht0xS32BGfcuHG1rbgpoEUBLS0zZsyY9Ic//MGKCDzou+wc39698cYb6aOPPrIyAoNAGjFiRE6clpgQAz1s2LDaxiQFtCigpWVIqOGgDokroNnhgVh1iWvviNs0iTC+gEYo4TSQuAL64Ycfrm1MUkCLAlpahqVn9hmWmBDC8eGHH6ZPPvnEyggszFghcD/1+JPR9957z4lOcO3ABId91RXQooBWQIfGBDXbSGyjwTTZMYkwtsOAOOi6+pICWhTQ0jJ4N+ua7UvfKaenmegZWzyzT7eJnvHbCe8mNk/iaoe33nor/e///q8CWhTQCujYmEQYX0CbRBjf3hEDbRJhbBBIw4cPNwY6MMRADx061CRCUUAroBXQooAeDPbOXTg6Q0A/+uij7sIRXEBzWqQCWhTQCujwsCeqCWpxISaQU7lMUIsLoQEkprkPdPzJKLs71BUeIH2H+Gf26q4rZE0BLQpoaRmTajqjjUxQs42kPWNTK0JJ6nMY0EaeRCgKaAV0eD744AOXngODKHv//fdN9AwunvFsupITG0TZa6+9lhM+JSbffvttGj16dG1bDSqgRQEtLeNBKvEFtAepxLd3HqTSGRMdD1KJjQepiAOKArpjePfdd7OHU+IK6Lfffjv95S9/sTIC2zsSPYlVl9gC+rHHHsuHqUhcAc1OKXWNSQpoUUBLy5Cs8fnnn1sRQSEm8OOPP05ffvmllRF4kkOIzddff21lBG8nJqKG2sSe5LDaVlfStAJaFNDSMmQ9m1QTv41M9Iw9yakz8Ula55tvvsn9SeL2JbzQdY1JCmhRQEvLsN+mJ3PFBa8Z2zoZHhAXBt5x48bllQKJCxOcF1980X3vA0MS4XPPPVdbyNqgFtDMVtjHlk3s//nPf/b79VjKfvnll9NTTz3VEQkh3GzEsEY75lcB3TkQX2sbxRbQ2LfoSYSEL2CL2NUFL99gcxiwu4NJhPEnOsOGDcuJ0wW8nSQVIthciZv60B5DhgypbUwa1AIa0XzCCSekn/70p+mMM87ol5D861//mk466aS06KKLphVXXDF3tOgwqP7iF79Id955pwJaWmLs2LFZ9EhcAc0Aj32KPhGbZ5550rrrrjvoTnrD3vH9ceY0E214PF999dU8EWq8KI/oBJlWBfQTTzyRVwsK1P0cc8yR9tlnn/B9bDDA5JtEz7rGpEEtoPEUb7311umoo45KW221VXrppZdafi0E87zzzps90J0Cx/si+O+++24FtLQEyRpfffWVFREUVtloIzwzkcGr98Mf/jDNP//8/bLDnTrJ+fTTT5t63jn1btNNN00LLbRQ2n333dOOO+7Yde28885plVVWSauttlq66aabvNlr6Eu0RzVpGgfC3HPPnXWEY9XUhzAbJqJ1JU0PWgFNIsCVV16Zb3w6wSabbJJuvvnmySoB48byWuO2KDQUs3+W3fDkHnbYYbkjXX/99enBBx/M4rSAd+CZZ57J5UOHDp2so9Ex8SaMHz8+vxZnud9///15P8Nms1o68QsvvJAbj+fReNVZcRVeb8SIEemBBx7IM7NqLCSfcfHFF0/33HNP0//lvaueDYz8888/n78Hn416azw966233srlbDbPc/jerdzM22yzjQK6Q2b8THgk7qDfCYlPCOjZZ589LbzwwtkbK/8HOz6stdZa6cgjj8y/Y5PJOeAnthy7jpC+6KKLrKwaaNQHjK84zrbddltjo4NMRr/44ovaxqRBK6BZJjzxxBPTxRdfnLcQOuecc9LJJ588mWCjIZZeeun83Co00hJLLJEuv/zy9Pjjj2chOssss6RVV101rbPOOunJJ5/smqH+6le/Sptttllaf/3108Ybb5x22WWXLEJLhdPoa6yxRtf7bLnllvk1llxyybT33nt3bdxekk2OP/74tN1222XPBM/j2nXXXbNQLt7AkvCwxx575PdkaXTDDTfMQh/xXQRyMwHNgEv94FVH1AMTCN538803T+utt17aaKON0k477ZTuuOOOSW5W3mu55ZZL559/fp6U7LXXXtngI8RZVpnShUGiDagrXn/ixIlahcDQVtXJosSDJEIm3ZHBTiKg55prrnTjjTfmfZE5AGYwXDhiEMKMGY1/w6YjoI8++ug8yWByUf153333Zc80dh1Hz2Cps6lxUb/cm8TY8ph7FAcWIRw4exTQMSY4OO3qCqcZtAL6mmuuyUIWoYh3Bg8wneC2226bTEAjik8//fRJyvGqrrDCCuncc8/Nj/EsI6ire0QiBo855pjsTa3G9Z199tk5RKGI7CI86Yj33ntvVxkdEo8M8dlF9O+www7p8MMPn+SkHZZnr7vuuiyk6dSAJ3j//fdPBx54YFd2N0KW977hhhvyY7znjQKauPBnn302Pfroo13eZ27GU045JQt7TswqMPlgYsBzyxZMfNf55puv67tRT9xYt956a9p+++1zHVeXIRsv2oTJAQMpz2c5F08Ln4WJBu3BZ+Szc4Q09d1TOYmS1XK86HjlKGfiVMo/++yzLm9dtZzl71KOCCnlLOOVLXMay4GkqGo5E65SzhJTKS/eeSY+zcr5yfennJ9lgtRYXvaQ5X2q5Xw+Piefq1rO9ynlvB/lvH8p53tXy6kv6rOUc/H9GPyZZFVfh3Lag+dTr5SVcvpaWbIu5dR32WqNdquWc+80ltOelHNxX1TLeW5jOfc/5bwHv5fy7u6pKd1r/b2nquXVe6Tca+26pyjnMf2Twb/cIwN1T1XLe3tPUc77MOgRwjHddNOl7373u/n3WWeddZq/Zptttvxzpplmyg6Y8rj87fvf/376zne+k2acccbJ6oS/8z/f+9738t95bvX/vdrbTtQv9yZtxWPag99nmGGG7OxihZd7eaDsVLW8N3aqsRw7VezXQNqpnuxX1U4V+9Xd2Ed5X+wUf8cJh75BNxT70pP9Kvaor2Mi34+2QkDvu+++g0tAU4F4hQ844IBJyvfcc8+cCFiNF+QmJMasmYAmWRBPKyB8F1tssUm2T8E7jRe12RZSl156afYaF+8t4vfQQw+d5Dk00Oqrr94loPE4IIDpRHQEOgqimLPfWcJDuJb4QcQtgrSn7VwQ+AhobgJgVn3XXXflMI3qki/xdYhawjIaYUaOKKazAYIar3djaAeD+KmnnppOO+20XJfdXXxXVgKIzcbbzY3JyU+8NzconYWJBR4YPPN8B8rpPI3l1B/txGSjlFMfZZkH72kppx5L56mW01lK50EolnI6EuV872o5bU05bcNqAW3GxIeOSDlGr1qOwSrleOFKOYaPcn7y/SkvyUKU83+lnJ+8X4nR43l8FsqLEeT9q+XFCPJ5eT/KeX++P/XD96aMi89LfVGfpZz/oZx7hlUCXqc8n/qgPWgX6rWU4wkte3TiteazU059U849R7tVyzGC9JFqOe1MGRcGs9R9KcfgVcv5fLw278HvpZznNLunyr3WjnuK8sZ7iglpuaeok8Z7rbt7igGwr/cUbY7H7Omnn+66R3pzT1HeeE+Ve627e6qU93RPVcupr2LHHnrooS6RwuoTjoLBcmE/t9hii+x8aPwbTgtCA5dZZpmm/8tK4CKLLJJXLwdTnU2ti1VVnF/VxzPPPHOac8458yoCfbTYKWxEsV/YlEb7xd+qdopV3p7sFOU8p7d2qrEcm1vs10DaKcqLPaK82KnGMRG70mzsK/YLnVO1RzxuZqeK/eLvOBAR0CR7Yl96slOUF3tEeXGKMbb3ZkykrbBbRAkMKgH9yiuv5PCHtddeOwvZSy65JP9ErBITjShoVUBXl7MRghi3yy67LL9HuRDWGEz+VsQ6n6UxTIQOxnufeeaZk4RXsGvGsccem18fwclOIoRnsJsIHkFggsB37AkGfrzmV111Vb7BdttttzypaLwRLrzwwrTAAgtkkV7qi4vvhRH52c9+lm9q4D0POeSQfrcRMWW8tiEcsUF8DrZtxzoN7Ej0QzoYwEoMNLZI/n+oILaQULlmMBliDCCfR+oJEaiCyMRxhaOsmYNJ6gfBW1fOx6AM4cDLTPYy8bnV2SUeaMI1SlhGTwIa4bDSSiv1KKDPOuusLC7xNDfOZBGqhF0ws2HWg4AmxrgnAc3MCA/uBhtskA4++OAsYomlZoaKcGbwIfwCjjjiiBwW0hO8Hp955ZVXTrfffnu69tprs/jFq1yNa0YoE1JBskrj9+DmYUJQRBQC+qCDDupX+7gLR+eAlyP6Dg+DGWwLk31sSWRKEiET9cG2C0dZZm6W+ISTgzGJHBbGpcaLcYQxghC7xlU/aX874UWt7jqEh5IxntUDx6qpD30AT3RdY9KgE9B0ALzMVa9uFby5CMVyljozGQwYoRNVWDYgWe6CCy7oVkAjcHHvNzNsiFfELp4h/t4bAT18+PC01FJLTeIhL/BaCy64YJeARvCzNV91y51GWJLgM/O8ElPN1n54PEg0LLM4dhZhEtDspuRmJX6xDNAK6MFF2XFF4g4onbAPNDaN+Gf2gu6krUDbAXaWZfBmiZ6MQ3iX99tvv2yDGy+cPiQYksguA0uzfaDpW4RwELpYzUuSqYP7QA+woSJrFoOD6GvGyJEj877QJAWWWeeyyy47SXwy3mfCGkgiuOKKK7oV0CxL8lpkSFcHMAYIMqcJsyiV3hsBzWfjPdjmrgpilxCOH/3oRzkeGujohGTwOcvyLTNnYnbI7IayCwde7KrBZl9oNoYv20kRR8VnIyGxGlLBoEcAPV7rMitXQA8uSFa1jWILaBJ/o09ymMwz6SecbLCdyIe9YwXRgzjiC2h0QXWbReJoca6hK4h/lqkL2gyN40mEAwDeZxLrrr766m73JsZji+hEfBYPLB1kzTXXzGKRXTXwUjPzx2PCc4FdJohBbpz5cC4770m4CMKdi4Q8QjHKQMEgRxJIY+wwsykEcxHWeK0JGUFcImZ5LUQ4vxOGMf300+cEwCKW6dR423ldPjfPI8Gv7PTB8iA7f/DZG70ePJ/3xcMIGHg8Hvw/70kMNgKX51QnDQh+6k4BPTjA69JToqpMfQFNok+zRGaJ49jBzhLPLHEpW8O6XV1c0ExorrrGpEEloBGVbNlW9jbuDpZlEJlFQBO6wGPiitlCDgHOMg6xwiQkAokvbI1XQj+q4LXFU83/I3oRttUDShjkiEEmfKJxxnvLLbd0ieIyw8JjjHDFs83OFmwZh7cb7w0ZuNX/xzuNZ4fPjfjmeVWhzGdulrTDgEv2fvVvCGWez/fAs46nunHZkfotHm4F9LQPqyTRD+mwjb5tybhLPZStwmyj+O2EhoieTzDYHQY4Rz1IRQYtCujOgS2B6jo2VVob9FlaLnulSsxBn9VRd7OJ35dwLJUtWyUeZatVj/IWBbQCOjysULjVYGxxxg4X7PUqMWEFh/1riaeVuCCQRo0aNckqrsSCaAHOnKhrTFJAiwJaWsYkwvgCuhOSCAe7vTOJsDMEdGMSocQT0CYRigJaAd0RMNMfbLsmdBIsO5P0VA46kpjCDDtXzYuReBAewESnri3SpO8Qn84uZ3VNRhXQooCWlmH5Ofopd7aRbRR9kkMbeRBKZwg0kz1j96U6E3IV0KKAlpbhIB2TamIPKHifOelOYoJwZjej6gl3ErOdCIXC5klMELGsitY1JimgRQEtLfPOO++k999/34oIPOgTp+5e3bHtHYdSuVd3fHHGYWbNtn2VGBADjZita0xSQIsCWlqGhBrbKLaAfuONN0wiDG7vXnvtNXMJOkBAcwowu9pIXAGNqDWJUBTQCujwcLiO22/FhRAOl53jCzOWnT0KOjbkEbiaE1874DCoazVHAS0KaOnXoGLyk20k/RfRtlF8TMiN7zCos40U0KKAlpZhpu/2W7EHFEID9G7GnuBw0M3nn39uZQSGCc748eONVQ8+wRk7dmxtK24KaFFAS8uMGTMm7zMscQd9Trkj1Ebi2juWnT/66CMrIzAIJE65I3FaYkIMNHHqdY1JCmhRQEvLkFDz+9//3ooILKDZ4eFPf/qTlRHY3nFapEmE8QU0QgmngcQV0A8//HBtY5ICWhTQ0jIM+v/85z+tiKAQwkF4gCEccSGEgxWCf//731ZG8Mko4QGuFMTWDqwQ1HXyqgJaFNDSr8Hf5CfbSGyjwQAiySTC2A6DOk/1VECLAlpahi2dOEVNYsJAQviG29jFFs8ffPCBJ3p2QDux773b2MXWDuR81LW1qgJaFNDSMsRAm0QYW0ATA20SYWx7Rwy0oQGxQSANHz7cGOjAEAM9dOhQY6BFAa2Ajo+7cMQX0O7CEd/euQtHZwjoESNGuAtHcAE9bNgwd+EQBbQCOj6Eb5igFhdiAlnOdI/huBAagHj+8ssvrYzgk9H333+/tgQ16TvEP+N9/uSTTxTQooBWQMfGpJrOaCMT1Gwjac/Y1IpQkvocBrSRJxGKAloBHR6Sn1x6jguijOVMvWaxxTN2zhM9Y4Moe/XVV7PNk5h8++236ZVXXqltT3UFtCigpWU8SCW+gCa+1oNUYtu71157zYNUOmCi40EqsfEgFXFAUUB3DO+++26aOHGiFRFYQLv1Vnx7R6Ln3/72NysjuIB+7LHH0nvvvWdlBBbQHLde15ikgBYFtLQMyRomqMWFmEBCA0xQiz3J4TTPr7/+2soI3k6c6llXgpq0Nsmp81RPBXSLfPXVV9n7RmMNVPIHgx9LEXVtCq6AllbayqQa26gdto4M+sGYkFp34pO03k54OGmrqqimTBsYp42YiNbVHgroFgeke++9N80///xp2223HbB4GwLiV1pppXT66acroCUk3Pt4ZSQmDPDjx48PHx7AdohXXXVVuvPOOwedw4CBd+zYsdkL3RehQNsy6cBeNl68Js+R9sEE54UXXphkvOe+vfjii/Pew67ETX2++eab9Oyzz9YWsqaAbtHY77XXXunAAw9M22yzTbr22msH7L1WXXVVBbSEhfha2yi2gO6EJELuo1lnnTXNN9986aWXXhp09q4vSYQ4Vp577rl0+eWXp0suuSRdd911eQyqXhdddNGgq8c6JjoIZRKnC8RDzzHHHHm80g5OfVgNQNTW1RYK6D7CrJ6EjzXWWCO9+OKL6dhjj037779/nvk0QiA7nY0tpJ5//vn0yCOP5IqeMGFC09dme5zHH388d9KXX345h4esvPLK6ayzzppslsWAw7GiJSu4uqxU3ptyxP6TTz6Znnrqqa7YLV6X/y2fh8/WbJsrBl9uxJEjR+bPNHr06PTFF19M8hz+jwEa7wnH0fI8Luqo1WUUBXTngOfMbZ1iC2hOTvvrX/8a+nNiJ3/0ox+lBRdcMNu+wSag+f699bxjxw844ID085//PG222WbpyCOPTIceemi+DjvssHz98Ic/TAcddJAdoM0CmrF03Lhxk9i/eeaZJzvS3I1o6oM2ItGzrjFJAd1HEIosNWK0/vjHP6aHHnooHXzwwemZZ56Z7LmI6znnnDP9+te/zmJwzTXXTMsuu2zafPPNcyNXO+aQIUOyEN9iiy3S2muvnTbZZJO0++675//Hy1AgIYjHW2+9dVpnnXXSuuuum7bbbrt05ZVXThI4f9RRR2VvzoUXXpg795ZbbpkHUmbMu+yyS/rlL3+ZPw//v+mmm6YjjjhikoELo37XXXelnXbaKT+H9+I1Tj311Py9C/fdd1/2HB1++OHZK8/zEP289i233DKZsO8tfKcddtjBHR6Cw4TK5KfY0D4s9UeGfJLZZ589LbzwwoPyqOS+hFswXpx22mnp0ksvncyhUcBuI7KlveDhrEL42rzzzpu23377fEqhTH0+/vjjvEqjgA4IS22IOyqO2Q6eHcT00UcfPdlzTznllDTLLLPkn5999lkuI04KkYxoBeKq8A7jcf3Nb37T9b9vvvlm2mCDDdJ3vvOdLI6LWLn++uvT+uuvnx588MFJROyGG26Ybrvtti4xc+KJJ2Zhy/PLIAo09mKLLTbJki6C+KSTTup6LqKXrWA23njjdP7553clt7CJPB6PM888M3u2AeE/44wzZlFeDAiDwXHHHZcWXXTRrrg+vNR8Ti7ix3u6EO7LL798niQg6stx0SXmj0kEMZ14bEo5n7laTn2XcjpUtZzPRwerljP5aFZOe1FOW/NdSjltUZJKGsuLoa2Wl10QaAe89qWcZNSeyvnJ96ecn6UdG8uLYed9eMxrlHI+J5+rWs73KeWUcfH+fH/K+d6N5dRntZzvR73xWtXXoZx65/n8vVpO+1FOO5TvSn2XEw27K6edSzntTFl35fwPXrpSzu/dlUe6p0p5u+8p4gEJD+ju3untPVUtb9c9Vb7v008/nb2mc801V15xu+eee6ZoJ6aVC5uII+aBBx7o1fNvuOGGPF7gYLjiiiu67Gr1IncGZ8ZgqcO62onxjrG3lDFm/+QnP8ntwSoCfai39ou/Vct7Y6eq5d3Zqb7ar1btVLMxsZmdqpZX7VRv7Fdv7FS1nP9Hz2Dvin3paUws9ojy8vze2C++H22FDtx3330V0L2BCsPIIWyrCR8IXDpQ40lSiOrVV199si1VDjnkkCxEgb/tuuuu2ZtQRHaBE3V+8YtfpPPOOy8/JoEBLzBB8o2MGjWqqxMXDzRe4MbXxIO8wgor5Abn5mjmmWJSwCThpptumuxvhJ/wN4wJ3H333dlr1Li5PP+75JJLdoWNMCguscQSU7zwjC+++OLp+9//fv6uhIPgnWJJhhuUzsJS2VtvvZW/K52FcjpPYzntRWcgDKSUl11TKOe7lHJERhF8JF2VcuqiCD6W7ko5HZRyjFW1nFP5ytZhLO9RTt3Q6Uo5qwClnDagHMNVLef+opyffP9SzvMop8PjqaOcn7wu5bwPzyPEh/JiTDE2pZzXK8aUz1vKeX++P+V8P75PKae+qE/qg3Iuvh8TI1YJqs+nPmgP2oV6pYyLei0Z0kzg+OylHKPGvUi7lXLaB+OFwa+W086Uc/He1XKei2FnMlfK+Z3X5j0ay5vdU+Vea9c9heGt3lN4rco9VS2f0j1FX+rNPcW9Ucq5B7BZTzzxRNc90t09xb1Y7inKG++pcq/1556qllNflPM+CEgm/NNNN10W0cstt1yv7EWnX9hI7B3hGNjRpZZaaor2EcfEj3/84/TTn/40/w9l5e/8P4+pSyYkyyyzTH6PwVCXdbTT3HPPnTcPoI6pW+r/u9/9bl7tvf/++3MfKvYFG1HsFDal0U412i9ODJ2SneI5vbVTCMdqOTa32K/+2KnuxsRip7APxU5Rjp1oZqeK/Woc+8qY2GinypjI36vlVbuG4/Hqq6/OK/zF7lTHRP6vO/vVnZ2iXigvYx/lfD/aCru19957K6B7AzcUwnTppZfOovaaa67J12677ZbDFpiZVgUpz0VsN0JsGmEcwGBHZyyCtDGehyRCPL5ALDLxVjwmcaS8P78ff/zx2WgSzwyEZGy00UaTvSY3PN7p9dZbLy/zEX6CeK/GZdMBMdIsAeKVLu9DcgrPJVaxhJXgLcbANB7nzP9hzIunmsEfocFFh+3u4nUwGHjU+Xwui8XGJML4MNBE3ymFAekHP/hBnjizksag2JOdmFYu2gUbh6OAHBIG6Z6ez6DPII4ThtBAck0QBIgHLuwsjxlf8FAjNniPwVCXA3nRLgjWm2++OYszxinqG2cWoUdM+sgrkqkLE5OhQ4fWphsM4egDJN2tssoqaauttspxxfzkwlCxXIaQboxDJtxiSgKa2W0zAc1skWTFM844Iz8mgYHlIsI/qu/PtfPOO2cRXTK5EdCI0GZgENh6h5hrPOHMpPfYY48cnlI80IR58N5s01d9H2K9MN4Y7iKgmZk3DtCNArqv8YC8l0mE8WHixaRIYoLnBHHaOMGNBqKwxEAjJAcT2DscG709oAPPH4mCO+64Y/aA0QdpYy5eB28hjhc8Y9Je2DigmpfD+EQMNG1hMvXUB6cjIbF17TqkgO5Dw+D5JUyi2cEpzD4JmWCJsySE9EZAF28BgrMxnIJBD3FbduFgtsv7s4zTbKAkxKOEkfQkoBvhfRCsTAAALwePiYNuBrHQxYgMhIB2F47OgWXFuhI2pPU2ajWZty7wks8000w5aRo7NtgENMvwvU30ZEkZpwrOHPJECBUsu29g97kI0yuhf9K+dmLyUk0kZImfcBocUd3triX1Ogxoo2a7oimgpyJs4YaH98Ybb2yaMU3n4e+EORRPQm8ENEaTZATEK4cIFIgLIjmRJc0SLkEsD0l97HaBiC3gASQsg5CHspVOdwKapDxiIhvjtTHEJbGRm+/WW2/NiYE8t0BMFUkriNuyi4gCenDDPdGYmS6xBn1iHusaUFqFfs4qHitcxCMOtjZCFPd2ksPKJN5OJhqE9Y0YMWKSC8cH5XpE299OjJsl+Q0Yb3GcHXPMMeG3ihwsAhrtVNfOUAroXkLyHTHB3QlCvHAk8iGMS3gDFctuEo0glgmPqHqICKkgmZDdKxDD++23X94+jqSaqieB2B4+ByEbPJc4OMIvyAQlHrV4x3m84oorTvbeeMp5f17j5JNPzu+15557prXWWivHORcIReHvhIrg4eB5CH/CVTDOZUAmWZCN5BuX8S+77LKccNHKCWgK6M7BfaDjDygkxEQf3PHA4oVGkAy2CRlOFGz3YDuBsdNAIJGMi82rOhAI6yiJfjJ1QZfUOXlUQPcSKqi7kIYCnmcEZRGTPJ+kg0aIpb799tsnG+jYSxovNrHJ5557bvYyc9oUp05VYYaFh5hYZJ7Lcxo3cUcosw9zM3juBRdckAUx/89PAu8blxAZyEhuwZPO8wglaYxPxPAjlht3GiGems9Vna0roKc9ED22UWwBTZ+t7t0uscDeYev1YMYX0IyTjHkSE5yR5AV4EqEM6gFFAd0ZMBmLvsPDYBfQhJfp3YwLjguS/6pbo0o8CJ3hePRmOUgSg3LMPRslKKBFAa2ADm+wop9yZxt96/JyYMqhFLZR/HbqhITcwe4w6EtCrgJaFNAy1SDjubvjhCXGoE9oWTndS2IO+iSnmYwbvy+xTSw7Z0lMymFfdY1JCmhRQEvLsGNCdV9UiSfOiNmsa0lT+g7eMhLPW0m4lvpAILH7FFvXSUyYhJJ7VteYpIAWBbS0jEmE8QW0SYTx7Z1JhJ0hoNkAwCTC2ALaJEJRQCugOwK2C4p+yt1ghmVnkp440lniCjPsXOPe/BILwgPYXcrJaFzI93jllVe6TmRWQIsCWkIP/gwsEruNmp2eKnEmOYRx2EadIdBM9ozdl2ijusYkBbQooKVl2HqLREKJO6Bw+BMn3UlMEM5sM2iiZ/x2YsXN7QZjOws41KauRE8FtCigpWXeeeedbLAk7qBPnLpJhLHt3ZtvvmkSYQeIM065G2xHzXcSxEAjZusakxTQooCWliGhxjaKLaDfeOON9Kc//cnKCGzviK2tK25TWhfQnMz7u9/9zsoILKCHDBliEqEooBXQ8eHYekIEJCaEcCCeP/74YysjsDAjNMD9hWNDXK1bQsbXDmwJWdfJqwpoUUBLvwYVk59sI7GNBgMke5o0HdthUGdCrgJaFNDSMmxhp3czLgwk7C+sdzO2eMaraaJn/L40btw4t+0MPsHhoJu6Ej0V0KKAlpYZM2ZM3mdY4g76LGkSaiNx7R1x6gqz2CCQOOWOxGmJCTHQHHZT15ikgBYFtLQMCTW///3vrYjAApodHkwijG3vOC3SJML4AhqhhNNA4grohx9+uLYxSQEtCmhpGQZ9QzjiQkygIRyxMYSjcyajhnDEhhAOthk0hEMU0Arojhj8TX6yjcQ2GiwCzSTC2A4DkwhFAa2A7giIra1ryyDpOwwkf/zjH10lCAwD78SJE10l6IBJDocSmU8QWzuQT1DXoUQKaFFAS8sYAx1fQBMD7aAf294RA21oQPyJzvDhw42BDgwx0EOHDjUGWhTQCuj4uAtHfAGt1yy+vWOSo4COL6BHjBjhUd7BBTSnRboLhyigFdDh+cc//uHSc2CICeSkSBPU4kJoAEvOX375pZURfDJKqE1dCWrSd4h/Rjx/8sknCmhRQCugY4PRMKkmfhuZoGYbSXvGplaEktTnMPj2229rG5MU0KKAlpbBI+P+tXFBlBEPiBda4ornCRMmpH/9619WRmAQZaNHj842T2KCeH7ppZfy1p0KaFFAK6BDYxJhfAFNVroHqcS2d6+99poT0Q6Y6CCUsHkSE2KghwwZYhKhKKAV0PEhoUaPTGwBzYD/4YcfWhmB7R2JnnVtvSWtC+hRo0al9957z8oILKA5br2uMUkBLQpoaRmSNb744gsrIijEBNJGX331lZUReJLDPt1ff/21lRG8nTzVM/4kB2dBXUnTCmhRQEu/2sqkGttI+jfJqTPxSVpvJzyc9CeJ20ZMRNmNQwEtCmgFdGiINfvLX/5iRQQFr9m4ceMMDwgMgz1hAW6PFhsmOC+88II5H4H55ptv0jPPPFPbvvcKaFFAS8u8/fbbtlFwAU0SIcd5S1x7ZxJhfBBIjzzyiEmEgWGFAFFb15ikgBYFtLQM3k3FWWwB/c4779S2rZP0HTzQiDK3GowvoJ966qk0fvx4KyMoeKBJ9KxrTFJAiwJaWoYEQpOf4kJMIAk1DCwSd5Lz73//O8dBS+y+RJiNSdNxIcyG03HrSppWQIsCWlqGJTMH/tiDPhMcE5/it1FdiU/Sejsx0cHmiZNRBbQooKVfsJzpIR2xBxT26ja+Ni4I5zFjxhjCERwE0tNPP20IR2BYaXv88ccN4RAFtAI6PhwAYRvFFtCvv/66cerB7d2rr75qnHoHCGiSCEmclpiwOvDQQw+ZRCgKaAV0fCZMmFDblkHSmoAeO3Zs+uijj6yMoOCBZpWA2E2JC/G1zz33nGNSYPBAk+hZ16qoAloU0NKvGb8x0PHbyBjouBgD3TntZAx0fIeBMdCigFZAdwTuwhF/0HcXjs5oIyei8dvJXThiU3bhqGtMUkCLAlpahvCADz74wIoICh4ZEtQ+/PBDKyMoeJ6Jq/373/9uZQQGgUSCGjZPYsLqwMiRI9PEiRMV0KKAVkDHxiTC+ALaJML49s4kws4Q0EOHDjWJMDB4nk0iFAW0Aroj+MMf/qB3M7iAJtFT72Zc8EBzoufHH39sZQSG8ICXX345vf/++1ZGUAiDev7552sbkxTQooCWfrVVK4ZDbCP5P4itZeBHoEnsdvJQos5oo7oSchXQEnLA32qrrdJOO+2UPZwSF2LOTCKMDcfaOujHHvRJImS1QGLDKgFtJTFhEsqBRO7CIYNaQG+66aZp/fXXT2+++aYVEhAGe5Yyb7755rysKTFhsL/hhhvy3qgSdxJ69913p+HDh6dPP/3UCgk6ySFZ+swzz7QvBYYdUs4777z08MMP1+LYUUBLSAG97rrrpoUWWiiNGDHCCgkIS2R33nlnWm+99dKNN95ohQSF5ME111wznXLKKVZGUNi3do899ki77767CWqB7R1iaeGFF05XXXWVFRIUthlcZZVV0j777FNLHLQCWkIK6HXWWSfNO++8+ehUiQdLZNdcc01aYYUV8k+JCSFQiy++eDryyCOtjKB89tlnaYcddkhbbrllGj16tBUSdEy644470o9//ON00UUXWSFBYQ/oxRZbLG277ba1bK+qgJawAvrnP/95GjZsmBUSVEBff/31uZ0I45CYEGaz9NJLp6OPPtrKCAphNnjMENFsZycxxyTCbOacc850ySWXWCGBBfRSSy2V+1IdW3cqoEUBLS21EQJ69dVXzzG2ooCW1gU04Rvbbbddeu2116wQBbQooEX6J6Dnn3/+nFgj8SDbmdjnlVZaKV177bVWSFBYxkRAH3PMMVZGUEh8YsDfZptt0htvvGGFBLV39957bxbQl156qRUSFHZJQUDvuOOO6c9//vOAvx/Jivvvv78CWmIJ6LXXXjsbK2b9ZNOSaEOsoNfUv7788su8VRCemGWWWSb95je/yW1m3cS56C8Is9/+9rc5BvqQQw7pKrd+4lzswPGnP/0p73vPzkPs8IC9s25i2Ts8m6y0/eQnP0lnn3123oXIuol1ffPNNznngxhotsH93e9+l9tuIN+PVVi222WlXAEtIeBGJKFmuummy2EcK6+8clpxxRVzwprX1L/wOi+//PI5yXPGGWfMP8l8to3iXLQF7YQ35nvf+1766U9/2lVu/cS5sG3LLrtsmm222dKss86aB3/tXUx7x4ro9NNPn+aZZ5602mqr2UbBLsYgHDrYO/rTL3/5y9x2A9FOvCbvN9dcc+Xfn3jiiZb2cVdAy4BA/NLrr7+eXnrppfTcc8+lZ599Nj3zzDP54jHHdXI1/s2r/1dv6pcy2oY2euWVV/LzbKdYbVSeR2Iae3WXNqq2oW00MFdf6pZy2oj4Z/oUj8tzbaM4fenFF1/MITbN7J3tVE87Ve1Xd8+hjehLL7zwwoD3JV7nnXfeyat9raCAFhERERFRQEu7YYPzc845Jy9XLrfccmnnnXdOI0eOzDGAjYwfPz4H5pP8xPIIe9gSz8RpUB999FE64YQT8t9YVtt3333zTNOjitsDsV2XX355XqairdhPc8iQITmWrJEJEyakX//613nJmTY99NBD82wc/vWvf6WzzjorL6nxt1122SU9/vjjOW5M+gfxmI196bHHHmvalwp/+9vf0mGHHZb23nvvrqXGv/zlL+n444+frC9xaIT0j//5n/9JJ554YlfdUu94vJrZKfoWh3NwKBHP/9WvfpVtIEycODH3q2IL+Z1VH5LapD19iZjmqp2iLzXaKeqbfAL6EO1JW7CzzdixY/PfGZeqfWm//fbLHmv7Untg7Cd5kzrvLlSC59BGu+66a24HQiwYn37/+9/nv7MjEbkg1b6Et3pq9iUFtPQKBoi99torZzIzkDC4MGCPGTNmkueRRYshwlCNGjUqZ7cipk899dScuEYnYtsYsl+ffPLJdMQRR+ROUceWNYOBW2+9NZ+Kxk8GgNNPPz0/Zmm5Cslo7F2LQWP5meWsww8/PP3Xf/1X3vnhlltuyaLh/vvvz8tktCnt9u6771rJ/eTKK69s2pfK5KUZV1xxRZphhhnytoMFRHjpS8Twlb5EUpu0DqLp/PPPzyKKySeJgUcddVQ6+OCDsyBudCxcffXVuQ1xKBAecNBBB+ULUUYb8X/8jVNZDzzwwLyjCsJP2tOXsFOlL2Gn6EuNdoo+sfHGG6eLL744/43rggsuyLs98DecDvSloUOHdvUlBJp9qf8wmaR/kCOwwQYbdPs8dt1gDKJ/PP300+mhhx5Ke+65Zz74Bu1wxhlnTNaXjj322NwHFdASGoQVs8Fqp2CrusZ9nhlgSNDAEBXuu+++tPnmm+fZPnulXnbZZV1/Q+RxVLEHELQHBn0MS+Gvf/1r2nDDDbOgbvTI4MH89NNPu8oYOJjdv/nmm1lcV4+Pfu+999Jaa62VjZf0j+23336yvsSuNc22fMQrw16lrAbgYcPLCSTq0q4I68a+5F7E/eOrr75Km2yyyST7BSOMqVt+VkGIsfvGnXfemQ8nol8x2COeOYqYdmUnogIns2I3i1dN+t+XTjrppK7H48aNy3WOwKqCU2DdddfNbUGf4uIAKXZP4X/YgrDal4iNtS/1H/oEtuu6667LqwPrr79+tx5o6hqvM3asOkFikoN22GijjdI999wzWV9i5w4FtISGm5fQiwKDA1myiOMqDAxsu1UVA3jIyKYljIMZKLP9QtmmC++BtGeig4gucMgDdY8h6gmWoR944IHcxqwGbLHFFunkk0+exIPDjhB45KR/0Aea9SXqv1E80xZ42Ji44BVlEgN4SQnTqbZr6UuEcUjr0BcYyKv7BWO7qFtWY6ow2VxooYXySs5uu+2Wn4O3jYkp7cqEtGojWZXjOSV0QPrfl6qTUZwC9CW8l1XoL9Q9kx12SuHCqUNyLuFqq6666iR9idAAnmNf6h/YMFalCamhnZjcdBdywSrpoosuOsmk5Zprrsmim5VuQg2rNpL2XGKJJfIESAEt4Q3VcccdN5mhYumsyn//939nw1P1TONB4+ZnEMKDVh2YGIAU0O31yOA9LhCqMSUBTVwnkxw8OcTa4iGgnaoDE0IOAU1bSv9gQGjWlwiXqfL3v/89hwIQ/kRMLhMa2hJxRrw0Aro6GS19yUG//wKaema5v1FAE+pUhXjmn/3sZ7k9EcWswLHUTAgAj2mjqteMiRCDvgK6fX2pOhklDIC+9OCDD07yPPoP4QB4mYmlRXSde+65OWQADyYT02pfol3tS+2F8JopCeiFF144jR49uquM8KgioIl7rk5GS19SQEtHCLOqoMIIEarR6JGknNl8NYQDY4YAJwyApLZqCAedhcEKT4D0H+L/qiEcxFqyzMWpg81AjN1xxx15pl+Ny2Qje4RbdWKEV86TJfsPYUyNfamxzwAeTMI2FlhggTxQ/PjHP04zzzxz2nrrrfOSND+ry86lL1UHIOk7hHAQL1sN4UBQUbfV5WXAU4lzoOoAoC8hyAjv4HWqIRz0H9qaBF5pT1+qrpQhhqnfxtBC6hvvZjW0g3EJUUbuAeNStS8xHtmX6hXQeJ4b+xi5V9g5tAOr4FWHXelLjE0KaAkNgwmhAWQ4M+MjsJ/ktHJ0LV4blsIQYSxn4pHhbww8PKbzEBd44YUX5kSnsv8iSW4kb0zNOKZpCU7bIkGN+DAMCzN4lpbL0jOnpLGkxpIm3jROYULMEYdLvDSeGv6G9412YecNvGW0Gx6ct99+20ruJ9Rts76EB7n0JdqIgYYJDkkyeKPxlhESwN+IgabvlL6Eh6b0pcZEN+kbrMiceeaZOWGJfoMQ5jFtVmKXCY365JNP8iSHXAG8l9gzVmrYFQIPNP2JSSi7cpDjQYgNdpDkNFZ6pH19ieV8+hKnqtKX3nrrrUnGJdqJ3R2Y3OClpp0Y0wiP4nEZl/A405dOO+00+1KboR8geBsFdOlLtAl9jrqnDWgLHtOf0A70s5L0jq0smxVgGxXQEhpiYMl4XWSRRfJMnmUVZvllWydCBIgpw2Bx8xP4z3O5EHBlGzsGIJalWarhb5xYiJBr5RhNmRwGZoQUy4+00xprrJGXvcoWaSwnEwdYttdi+XnBBRdMSy65ZA69IXGGtmbQwVjRTrwOKwh4b9xusP8wUDT2JXarKXWLGCOJrXErLgZ8vDEFBMMBBxxgXxoA8FhW7RQ5AewMUBKgEMY77LBDtmlMcBjcCddggsPfGPD5GxPO3Xffvet1mLDiaWvl1DNp3pfYtaGnvsS4hP1DKLObCm3EhZOH/6edaO9qXyK5kMmTfal9sCMNKwaNApoVBLbypE/gfcaO0Qa0BaupONdKX0JLVPsSDrqp2ZcU0NInzwyzReJqWebkpi4gphlEyLoFDBbP42oUAjyn/A2PaPV1pP/gQa62U9XAlC3pShwtEx5OYSrtwf+V51fb23aqry8RykFfapys0K6lf9mXBh7qtrv7n103iKFt1p6N7Yb9K23U017fMvB9qdoWPfUl2sm+1P5xqbHO4fbbb0/nnXde12P6WndtFK0vKaClLbCkQoasM/bY4LXEC42RkpgQ+mRfig3Ly40x62Jfkr5DCFqn9iUFtLQNZ+y2k9hGtpHYTjIY2kgBLSIiIiKigBYRERERUUCLiIiIiCigRUREREQU0CIiIiIiCmgREREREVFAi4iIiIgooEVEREREFNAiIiIiIgpoEREREREFtIiIiIiIAlpERERERBTQIiIiIiIKaBERERERBbSIiIiIiAJaREREREQBLSIiIiKigBYREREREQW0iIiIiIgCWkREREREAS0iIiIiooAWEREREVFAi4iIiIgooEVERERERAEtIiIiIqKAFhERERFRQIuIiIiIKKBFRERERBTQIiIiIiIKaBERERERUUCLiIiIiCigRUREREQU0CIiIiIiCmgREREREQW0iIiIiIgCWkREREREFNAiIiIiIgpoEREREREFtIiIiIiIAlpERERERAEtIiIiIqKAFhERERERBbSIiIiIiAJaREREREQBLSIiIiKigBYRERERUUCLiIiIiCigRUREREREAS0iIiIiooAWEREREVFAi4iIiIgooEVEREREFNAiIiIiIgpoERERERFRQIuIiIiIKKBFRERERBTQIiIiIiIKaBERERERBbSIiIiIiAJaREREREQU0CIiIiIiCmgREREREQW0iIiIiIgCWkREREREAS0iIiIiooAWEREREREFtIiIiIiIAlpERERERAEtIiIiIqKAFhERERFRQIuIiIiIKKBFREREREQBLSIiIiKigBYRERERUUCLiIiIiCigRUREREQU0CIiIiIi0yj/D8u8fDFFWX7TAAAAAElFTkSuQmCC</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>